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Abstract 
Introduction: Gestational Diabetes Mellitus (GDM) patients are stratified into 
low-risk and high-risk groups in Canberra, Australia, according to whether their 
glycaemic control reaches the target levels with lifestyle measures only. High-risk 
patients, in whom glycaemic control is unsatisfactory, are referred to a multidisciplinary 
“diabetes in pregnancy” team, while low-risk patients continue regular antenatal care. 
The aims of this study were to test the accuracy of the current stratification system of 
GDM treatment in Canberra, and to access whether low-risk patients have satisfactory 
perinatal outcomes compared to the high-risk patients, considering their less intensive 
antenatal care. 
Methods: A retrospective clinical audit of GDM patients treated between 
01/01/2010 and 30/06/2014 was conducted. Maternal demographic data and 
neonatal/maternal clinical outcomes data were analysed including, for key outcomes, 
comparison with outcomes for the background population in the ACT. 
Results: Low-risk (n=509) compared to high-risk (n=466) GDM mothers were 
younger (31.7±4.8 vs 32.6±5.3 years-old, p=0.009), leaner [body mass index (BMI) 
26.3±6.7 vs 29.3±7.5 kg/m2, p<0.001], and less parous (0.73±1.0 vs 0.98±1.2 times, 
p<0.001), with less past GDM (13.2% vs 23.2%, p<0.001), less family history of diabetes 
(55.4% vs 67.0%, p=0.001), and a lower fasting glucose level in the oral glucose tolerance 
test (OGTT) (4.9±0.5 mmol/l vs 5.0±0.8 mmol/l, p<0.001). There were more South-East 
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Asian women in the low-risk group (19.4% vs 11.9%, p=0.002). Low-risk mothers had 
lower rates of pregnancy-induced hypertension (PIH) (6.1% vs 11.8%, p=0.002; ACT 
5.7%), induced labour (23.2% vs 50.6%, p<0.001) and elective Caesarean-section (CS) 
(14.1% vs 20.4%, p=0.010). Rates of emergency CS were similar in the low- and high-risk 
groups (16.7% vs 19.1%, p=0.328; ACT 14.9%). The rate of preterm delivery (delivery 
before 37 weeks gestation) was higher in the low-risk group, (9.8% vs 6.0%, p=0.014; 
ACT 8.3%), attributed to a higher rate of spontaneous preterm delivery (6.1% vs 2.6%, 
p=0.010). After adjusting for maternal age, BMI, parity, smoking status and alcohol 
consumption during pregnancy, premature delivery was still more likely in the low-risk 
group (odds ratio 1.897, 95% Confidence Interval 1.137-3.164). 
For neonatal outcomes, there were no differences in rates of babies with 
birth weight >4000g (5.5% vs 7.1%, p=0.309; ACT 11.8%), shoulder dystocia (1.6% vs 
1.5%, p=0.930), hypoglycaemia (6.1% vs 7.1%, p=0.532), respiratory disorder (6.3% vs 
6.0%, p=0.857), and hyperbilirubinaemia (8.8% vs 10.7%, p=0.320). There was a trend 
towards a lower rate of customized large for gestational age infants (cLGA) in the low-
risk group, compared to the high-risk group (6.1% vs. 9.4%, p= 0.050). The rate of 
neonatal admission to the intensive care unit (NICU)/special care nursery (SCN) was 
higher in the low-risk group (16.7% vs 10.9%, p=0.010; ACT 14.7%). However, this 
difference might have been attributed to the different NICU/SCN admission criteria 
adopted by the two evaluated hospitals. 
Conclusion: The stratification system is efficient: low-risk compared to high 
risk patients were younger, leaner, and had less past GDM, less family history of diabetes 
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and lower fasting glucose during the OGTT. Adverse pregnancy outcomes were either 
less (PIH, delivery interventions, cLGA) or similar (emergency CS and some neonatal 
complications) in the low compared to high risk group. One exception was a higher rate 
of preterm delivery among low-risk women. Some adverse neonatal outcomes for low-
risk women were also higher than in the general ACT population. The treatment 
pathway of low-risk GDM patients has considerable merit, but requires further 
assessment and optimisation to ensure safety.  
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CHAPTER ONE LITERATURE REVIEW OF GESTATIONAL DIABETES 
MELLITUS (GDM) AND RESEARCH HYPOTHESIS  
1.1 History of GDM 
Reports of Diabetes Mellitus, a disease originally described as “too great 
emptying of urine”, were initially found in Egyptian manuscripts dated 1500 B.C.(1). 
Aretaeus the Cappadocian coined the word ‘diabetes’ after the Greek word for siphon, 
and described it as a condition in which “fluids do not remain in the body, but use the 
body only as a channel through which they may flow out”, in the first century A.D (2). In 
1769, William Cullen, a British clinician, added the adjective mellitus (Latin, ‘sweet like 
honey’) to distinguish this variant of diabetes from others such as diabetes insipidus in 
which the urine was tasteless (3). The modern understanding of diabetes mellitus is that 
it is a group of metabolic diseases characterized by hyperglycaemia resulting from 
defects in insulin secretion, insulin action, or both (4). 
For more than a hundred years, doctors observed that women who developed 
diabetes before pregnancy were more likely to have severe adverse effects on fetal and 
neonatal outcomes (5). In 1824, Bennewitz first described diabetes in pregnancy in 
Germany; in his case, the patient presented intensive thirst, recurrent glycosuria and 
had a baby that weighed almost 5.5 kg (6). 
However, during 1940-1950, it was recognized that patients who developed 
diabetes years after pregnancy also suffered from higher rates of fetal and neonatal 
mortality (7). The term gestational diabetes mellitus (GDM), coined by Elsie Reed in 1957 
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(8), became accepted at that time and was defined as the development of abnormalities 
in carbohydrate metabolism in pregnancy (9-11). Dr O’Sullivan pioneered the diagnosis 
of gestational diabetes by establishing a statistical upper limit for glycaemic normality in 
pregnancy, through 100-g oral glucose tolerance testing (OGTT) in the 1960s (12). In 
1979, the National Diabetes Data Group (NDDG) defined GDM as “glucose intolerance 
that has its onset or recognition during pregnancy, regardless of the severity of the 
disease or whether the condition persists after pregnancy.” “Women with diabetes who 
become pregnant are not included (13). This definition was endorsed by the 
International Workshop – Conference on Gestational Diabetes and became popularly 
used all over the world (14-17). However, there are currently concerns that this 
popularly used definition includes too wide a range of glucose abnormalities, especially 
for those with undetected pre-gestational diabetes.   
To address this issue, the International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) proposed a new definition of GDM, which is “the condition 
associated with degrees of maternal hyperglycaemia less severe than those found in 
overt diabetes but associated with an increased risk of adverse pregnancy outcomes”, 
and divided patients who had hyperglycaemia first detected during pregnancy into two 
subgroups, that is, overt diabetes and GDM (18). This new definition was endorsed in 
the new World Health Organisation (WHO) and Endocrine Society guidelines (19, 20), 
but was refused by the Australasian Diabetes in Pregnancy society (ADIPS). In the latest 
ADIPS guidelines, authors insisted that a definitive diagnosis of non-gestational diabetes 
cannot be made until the postpartum period (21). 
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1.2 GDM pathology 
Pregnancy is characterized as a diabetogenic condition. To meet the energy 
demands of the fetus and to prepare for delivery and lactation, the maternal metabolism 
changes from carbohydrates to lipids (22). Insulin resistance, which starts from the 
second trimester and goes on throughout the whole pregnancy, may contribute to this 
change.  The increased placental secretion of hormones, such as progesterone, cortisol, 
placental lactogen, prolactin, and growth hormone, combined with increased maternal 
adiposity, are responsible for the raised insulin resistance.  To counteract the decrease 
of insulin sensitivity, insulin secretion increases consistently from the first trimester and 
peaks at the third trimester (23-25). It has been shown that insulin secretion increases 
by 200 – 250%, to balance a 50% decrease in insulin-moderated glucose disposal during 
pregnancy, to maintain normal glucose levels (26). 
Gestational diabetes mellitus happens when impaired β-cell cannot produce 
enough insulin to compensate for the increased insulin resistance of pregnant patients. 
There are different pathways leading to GDM, including autoimmune and monogenetic 
abnormalities in β-cell functions and most commonly, the same pathway as type 2 
diabetes.  
                   1.2.1. Auto-immune GDM:   
Auto-immune GDM accounts for a small population of GDM patients (less 
than 10%), and is correlated with the risk of type 1 diabetes in different ethnicities (27). 
Islet antibodies include autoantibodies to islet cell cytoplasm (islet cell autoantibodies 
[ICAs]), to native insulin (insulin autoantibodies [IAAs]), to glutamic acid decarboxylase 
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(GAD65As) and to tyrosine phosphatases (insulinoma-associated antigens [IA-2As and 
IA-2Bs]) (28). The frequency of GAD65A and IA2 positivity is higher than other 
autoantibodies in GDM patients but the antibody titres are lower compared to the type 
1 diabetes patients (28).  
GDM patients with autoantibodies are younger, leaner, have lower 
prevalence of diabetes in first-degree relatives, have lower fasting plasma insulin and 
experience lower weight gain during pregnancy, but need insulin treatment more 
frequently compared to the autoantibody negative GDM patients (29).  Auto-immune 
GDM patients have higher risk of developing type 1 diabetes in the future (30) and share 
some similar characteristics with latent autoimmune diabetes of adulthood (LADA) 
patients (31). 
 
1.2.2. Monogenetic diabetes:  
Monogenetic diabetes is caused by autosomal dominant mutations, with an 
early onset but a mild and relatively uncomplicated course (32). Previous monogenic 
diabetes was termed “maturity-onset diabetes of the young (MODY)”, but currently, the 
term “monogenetic diabetes” is found to be more suitable (33). The more common 
mutations include: mutations in the glucokinase gene (MODY2), which presents as mild 
fasting hyperglycaemia(34) and its prevalence ranges from 0% to 12% among all GDM 
patients (35-37); mutations in the transcription factor HNF-1α (MODY3), which causes 
slow progressive deterioration of insulin secretion (34), and accounts for up to 1% of 
GDM (38, 39); mutations in the transcription factor HNF-4α (MODY 1), which may cause 
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macrosomia and neonatal hypoglycaemia (34), and has a rate of 1% in GDM patients (40). 
There are other rare mutations, for example, mutations in the PDX1 gene (38) and 
mutations in the mitochondrial genome that combine with neurosensory hearing loss 
(41). 
 
                   1.2.3 Other pathological pathways 
However, most GDM cases share the similar pathological pathway as type 2 
diabetes, due to β-cell secretion deficiency on the background of chronic insulin 
resistance (42). 
The cellular mechanisms for chronic insulin resistance are well described in 
the literature. In skeletal muscle, decreased levels of phosphatidylinositol (PI) 3-kinase 
activity is caused by increasing expression of the p85α subunit of PI 3-kinase, the 
negative competitor to forming a PI 3-kinase heterodimer with the p110 subunit (43, 44). 
In addition, lower levels of insulin receptor substrate 1 (IRS-1) tyrosine phosphorylation 
and decreased concentrations of IRS-1 protein (45, 46) contribute to the reduced 
translocation of  glucose transporter type 4 (GLUT4) to the plasma membrane, and result 
in decreased insulin-stimulated glucose uptake (47). In adipose tissue, insulin resistance 
is induced by reduction of the transcription factor peroxisome proliferator-activated 
receptor (PPAR)-γ1 gene and protein (48). The exact cause of chronic insulin resistance 
is still unknown. Potential culprits could be obesity, inflammation in adipose tissue, 
plasma and placenta, and hyperlipidaemia with increased levels of leptin, tumour 
necrosis factor-alpha (TNF-α), interleukin 6(IL-6), interleukin 1 (IL-1), C-reactive protein 
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(CRP), and decreased levels of adiponectin (49-52). 
Not all patients who have insulin resistance develop hyperglycaemia, due to 
compensation via increased insulin secretion. Therefore, β-cell dysfunction plays a 
critical role in the pathology of GDM. Insulin response to oral and intravenous glucose 
are lower in GDM patients compared to normal pregnant women, even after 
adjustments for insulin resistance (53). A mismatch between β-cell function and mass 
(54), as well as failure of the cell to respond adequately to secretagogue stimulation, 
could be a possible mechanisms of β-cell dysfunction (55). Genetic defects may 
predispose patients to β-cell dysfunction.  
Multiple genes interact with environment factors, which can lead to GDM. 
Environmental factors include increased excessive energy intake and decreased physical 
activity (56). Genes related to the development of GDM are mostly associated with the 
regulation of insulin secretion, and include TCF7L2, GCK, KCNJ11, CDKAL1, IGF2BP2, 
MTNR1B, Gly972Arg, and IRS1 (57). 
Other than the well-recognized causes of GDM in the above discussion, other 
hypotheses have also been suggested. For example, the development of GDM could be 
triggered by an antigenic load that is the fetus itself, which is analogous to the 
development of type 2 diabetes in some patients submitted to organ transplantation. 
Human leukocyte antigen-G (HLA-G) expression that responds to the load of fetal 
antigens and the complex interactions between this response and the increased nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-kB) activity that cause 
increased insulin resistance might also explain the development of GDM (58). 
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1.3 Diagnostic criteria of GDM 
1.3.1 Historic diagnostic criteria of GDM 
The diagnosis of GDM is a very complicated issue that has been intensely 
debated for almost 40 years but still has not achieved worldwide consensus. The first 
diagnostic criteria were made available in 1964. These criteria were based on identifying 
women at high-risk for development of diabetes after pregnancy (59). GDM was 
diagnosed by using a 100g OGTT test (12), and this method is still used today with some 
modifications. NDDG started to test plasma or serum instead of whole venous blood. 
This test method also changed from Somogyi-Nelson technology to the new approach 
using glucose oxidase and hexokinase, which is more specific to glucose (60). Another 
common diagnostic strategy, which has almost the same cut-off values of diabetes 
mellitus outside pregnancy, was used by the World Health Organization (WHO). The 
WHO diagnostic criteria were initially defined in 1980 as a fasting plasma glucose level 
≥8 mmol/l or/and a 2-h glucose level (after 75g of glucose load) ≥11 mmol/l in the OGTT. 
However, after lowering the threshold in 1985 and 1999, the criteria changed to a fasting 
glucose of ≥ 6.1 mmol/l or/and a 2-h OGTT glucose of ≥ 7.8 mmol/l, which are widely 
used in developing countries. The WHO criteria were based on the increased risk for 
diabetic patients of developing microvascular complications, especially retinopathy, in 
the future (61).  
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                   1.3.2 Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study, and 
new diagnostic criteria for GDM 
None of the previous diagnostic criteria for GDM were based on the 
prevalence of perinatal adverse outcomes. The Hyperglycaemia and Adverse Pregnancy 
Outcomes (HAPO) is considered a landmark research in this area, and included 23,316 
patients from different ethnic backgrounds. It showed that higher maternal glucose 
levels during an OGTT are associated with an increased risk of complications for both 
mothers and babies. The HAPO study found a strong and continuous association 
between maternal glucose concentrations, even in mild hyperglycaemic levels, with 
adverse birth outcomes, including birth weight > 90th percentile, primary caesarean 
section, clinical neonatal hypoglycaemia, cord-blood serum C peptide > 90th percentile, 
premature delivery, shoulder dystocia, intensive neonatal care admission, neonatal 
hyperbilirubinaemia, and maternal preeclampsia (62) (Chart 1). 
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Chart 1 –Maternal glucose concentration associated with adverse perinatal 
outcomes.
 
Fasting: category 1 = <4.2 mmol/l (75mg/dl), 2 = 4.3- 4.4 mmol/l (75-79 mg/dl), 3 = 4.5- 4.7 mmol/l (80-
84 mg/dl), 4 = 4.8-4.9 mmol/l (85-89 mg/dl), 5 = 5.0-5.2 mmol/l (90-94 mg/dl), 6 = 5.3- 5.5 mmol/l (95-99 mg/dl), 7 = 
≥5.6 mmol/l (100 mg/dl). 
One-hour oral glucose tolerance test (OGTT): category 1 = ≤5.8 mmol/l (105 mg/dl), 2 = 5.9- 7.3 mmol/l 
(106-132 mg/dl), 3 = 7.4- 8.6 mmol/l (133-155 mg/dl), 4 = 8.7- 9.5 mmol/l (156-171 mg/dl), 5 = 9.6- 10.7 mmol/l (172-
193 mg/dl), 6 = 10.8- 11.7 mmol/l (194-211 mg/dl), 7 = ≥ 11.8 mmol/l (212 mg/dl).  
Two-hour OGTT: category 1 = ≤ 5.0 mmol/l (90 mg/dl), 2 = 5.1- 6.0 mmol/l (91-108 mg/dl), 3 = 6.1-6.9 
mmol/l (109-125 mg/dl), 4 = 7.0- 7.7 mmol/l (126-139 mg/dl), 5 = 7.8- 8.7 mmol/l (140-157 mg/dl), 6 = 8.8- 9.8 mmol/l 
(158-177 mg/dl), 7 = ≥ 9.9 mmol/l (178 mg/dl).  
Adopted from Coustan DR. The HAPO study: paving the way. Am J Obstet Gynecol 2010. 
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Based on the results of the HAPO study, the International Association of the 
Diabetes and Pregnancy Study Groups (IADPSG) recommended new criteria for GDM 
diagnosis, with compared to the previous ADIPS diagnostic criteria, a one-step 75-g 
OGTT with a more stringent fasting cut-off value, the addition of a 1h cut-off value, and 
a less stringent 2h cut-off value at 24–28 weeks of gestation in women not previously 
diagnosed with overt diabetes. Moreover, only one abnormal value is sufficient for the 
GDM diagnosis. There are two main issues addressed by the new criteria. Firstly, IADPSG 
advised to screen for hyperglycaemia at the first prenatal clinic visit, in order to detect 
overt diabetes as soon as possible.  Secondly, the cut-off value for the diagnostic OGTT 
test was based on reflecting a 75% (odds ratio 1.75) increased risk in three primary 
adverse outcomes of GDM, including birth weight >90th percentile, baby’s C-
peptide >90th percentile and baby fat>90th percentile (63) (Flowchart 1). 
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Flowchart 1 –IADPSG diagnostic procedures of GDM. 
 
GDM, gestational diabetes; IADPSG, International Association of Diabetes in Pregnancy Study Groups.  
FPG, fasting plasma glucose; RPG, random plasma glucose. HbA1c, Hemoglobin A1c 
OGTT, oral glucose tolerance test. Diagnosis of GDM if 1value ≥ threshold 
 
There is hot debate on whether to implement these new criteria. The 
advantages of the new criteria are quite obvious. Firstly, the IADPSG guideline is the only 
one among all other guidelines in that it is based on pregnancy outcomes, and its 
diagnostic thresholds are specifically selected by using the pathophysiologic condition 
of hyperglycaemia in pregnancy (64).  Secondly, it finally brings uniformity to GDM 
diagnosis and makes the comparisons of outcomes between different studies possible. 
Thirdly, the new guideline, as a one-step procedure, may be easier to implement by 
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health care providers. Finally, the data in the HAPO trial was collected from more than 
23,000 patients with different ethnicities, age, and BMI.  Having adjusted for these 
potential confounders, the new guidelines are most likely to be suitable for the 
worldwide GDM population (65).   
There are also many concerns regarding the IADPSG recommendations. There 
is a lack of evidence that patients diagnosed via the new GDM criteria would receive 
significant clinical benefit, in both maternal and neonatal outcomes (66). Compared to 
the ADA guidelines, using the IADPSG criteria will increase the number of GDM patients 
by 3 times in the United Arab Emirates, which will increase the strain on health systems 
(67). Similarly, the rate of GDM increased from 7.89% to 19.9%, almost twofold after 
using the IADPSG diagnostic criteria instead of the ADA criteria in the Chinese population 
(68). In Canada, there was also an increase in rates of GDM, from 7.9% to 9.4%, when 
using the IADPSG criteria (69). There is a limited number of studies focusing on the cost-
effectiveness of the new screening consensus, and some have reported contradictory 
results (70, 71). Some organizations, for example the WHO (72), Ministry of Health of 
the People’s Republic of China (MOH) (73), and the Endocrine Society have decided to 
follow the IADPSG recommendations while other institutions, such as the American 
College of Obstetricians and Gynaecologists (ACOG) and the National Institutes of Health 
(NIH), have refused to accept the new criteria (74, 75). Interestingly, the American 
Diabetes Association (ADA) initially endorsed the IADPSG criteria in 2011, but in their 
latest published guidelines (2014), it stated that there is no uniform approach for GDM 
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diagnosis, and both the one-step strategy (IADPSG criteria) and two-step strategy (ACOG 
criteria) could be used (76, 77) (Table 1). 
   Table 1 –Recommendations for screening procedures and diagnostic criteria for GDM. 
Organization Screen  
population 
Type of  
test 
Glucose 
load 
Cut-off  
points 
Number 
of criteria 
required 
WHO 1999 
 
Not 
mentioned 
One-
step 
75g Fasting ≥ 6.1 mmol/l 
2h ≥ 7.8 mmol/l 
≥1 
WHO 2013 Not  
mentioned 
 
One- 
step 
75g Fasting 5.1-6.9 mmol/l 
1h ≥10.0 mmol/l 
2h 8.5-11.0 mmol/l   
≥1 
ACOG 2013 Universal  Two- 
step 
50g GCT 
100g 
OGTT 
GCT ≥ 7.8 mmol/l or      
7.5 mmol/l* 
fasting ≥ 5.3 mmol/l  
1h ≥ 10.0 mmol/l  
2h ≥ 8.6 mmol/l 
3h ≥ 7.6 mmol/l 
≥ 2 
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ADA 2014 Universal  Two- or 
one-
step 
50g GCT 
100g 
OGTT 
Or 75g 
OGTT 
GCT ≥ 7.8 mmol/l or 
7.2 mmol/l* 
100g OGTT  
fasting ≥ 5.3 mmol/l  
1h ≥ 10.0 mmol/l  
2h ≥ 8.6 mmol/l 
3h ≥ 7.8 mmol/l 
75g OGTT 
Fasting ≥ 5.1 mmol/l 
1h ≥ 10.0 mmol/l 
2h ≥ 8.5 mmol/l  
 
 
≥ 2 
 
 
 
 
≥ 1 
Endocrine 
Society 2013 
Universal One-
step 
75g Fasting ≥ 5.1 mmol/l 
1h ≥ 10.0 mmol/l 
2h ≥ 8.5 mmol/l 
≥ 1 
NICE 2015 Selective One-
step 
75g Fasting ≥ 5.6 mmol/l 
2h ≥ 7.8 mmol/l  
≥ 1 
WHO, World Health Organization; ACOG, American College of Obstetrician and Gynaecologists; ADA, 
American Diabetes Association; NICE, National Institute for Health and Care Excellence; GCT, Glucose challenge test; 
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OGTT, Oral glucose tolerance test; * ACOG recommended a lower cut-off point of GCT in high ethnic minorities with 
higher prevalence of GDM. 
 
1.3.3 Diagnostic criteria for GDM in Australia 
In Australia, the first diagnostic criteria were developed in 1991 (78). They are 
used nationwide with some modifications, even today. If a patient was suspected to be 
at high risk for GDM, an OGTT test could be performed at any stage of pregnancy. If the 
OGTT results were normal in early pregnancy, these patients would take another 
diagnostic OGTT test between 26 to 30 weeks of gestational age. Besides high-risk 
patients, all pregnant women were given a non-fasting glucose challenge test (GCT) 
between 26 to 28 weeks of gestational age. If the results of the GCT were positive (50g 
glucose load 1h>7.8mmol/l or 75g glucose load 1h> 8.0mmol/l), patients would have a 
diagnostic 75g OGTT test before 30 weeks of gestational age.  Patients would be 
diagnosed with GDM if their fasting glucose level was higher than or equal to 5.5 mmol/l 
or/and 2 hour glucose level higher than or equal to 8.0 mmol/l (79).  
The Australasian Diabetes in Pregnancy Society (ADIPS) recently endorsed the 
IADPSG’s cut-off points for the diagnostic OGTT test. Additionally, the new guidelines 
recommended a 75g OGTT at first opportunity after conception in high-risk patients to 
detect undiagnosed overt diabetes (80). The research in this thesis included patients 
who were diagnosed with GDM from 2010 to 2014 when the previous ADIPS screening 
guidelines were still used (Table 2). 
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 Table 2 –Screening and diagnosis of GDM in this research. 
Indication Timing for 
testing 
Population Glucose load Cut-off points 
Clinical 
suspicion of 
GDM 
Any stage Selective 75g Fasting ≥ 5.5 mmol/l or 
2h ≥ 8.0 mmol/l 
Screening  
(GCT) 
26-28 weeks Universal 50g 
75g 
1h ≥ 7.8 mmol/l (50g) 
1h ≥ 8.0 mmol/l (75g) 
Confirmative 
test 
(OGTT) 
26-30 weeks Women 
who had 
positive 
GCT results 
75g Fasting ≥ 5.5 mmol/l 
2h ≥ 8.0 mmol/l 
GCT, Glucose challenge test; OGTT, Oral glucose tolerance test 
 
1.4 Short term complications of GDM 
It is known that pre-existing diabetes is associated with an array of maternal 
and neonatal adverse outcomes including gestational hypertension, preterm delivery, 
stillbirth, malformation, macrosomia, neonatal hypoglycaemia, neonatal 
hyperbilirubinaemia, neonatal respiratory distress, neonatal polycythaemia, neonatal 
hypocalcaemia and neonatal cardiomyopathy during pregnancy (81, 82). GDM is defined 
as any degree of glucose intolerance with onset of first recognition during pregnancy, 
including a wide spectrum of diseases, from undetected type 1 and type 2 diabetes to 
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mild glucose intolerance that disappears after birth. GDM patients might suffer from the 
same adverse perinatal outcomes as patients with pre-existing diabetes, but the 
incidence and the severity of these complications are significantly lower among GDM 
patients. 
As previously described, the researchers of the HAPO study demonstrated 
that maternal glucose intolerance less severe than overt diabetes was associated with 
increased risk of neonatal birth weight above 90th percentile and cord-blood serum C-
peptide level above the 90th percentile, primary caesarean delivery (CS), clinical 
neonatal hypoglycaemia, premature delivery, shoulder dystocia or birth injury, 
hyperbilirubinaemia, preeclampsia and neonatal intensive care unit (NICU) admission 
(83). 
These adverse perinatal complications of GDM can be divided into short term 
neonatal complications, short-term maternal complications, long-term neonatal 
complications, and long term maternal complications.  
 
1.4.1 Neonatal short term complications 
1.4.1.1 Stillbirth and malformation 
1) Stillbirth 
The HAPO study did not find any association between the risk of stillbirth and 
maternal glucose intolerance less severe than overt diabetes (83). Fadl and collaborators 
also demonstrated similar results in a large cohort study that included 1,260,297 
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patients (10,525 had GDM) and aimed to analyse the maternal and neonatal outcomes 
among GDM patients. They found there was no difference in terms of the risk of stillbirth 
between GDM patients and non-GDM women (Adjusted OR 0.85, 95% CI 0.59-1.23, p= 
0.284) (84). However, the presence of fasting hyperglycaemia (>5.8 mmol/l) might have 
been associated with increased risk of stillbirth during the last 4-8 weeks of gestation, 
which might have been attributed to undetected overt diabetes among GDM patients 
(85).  
                    2) Malformation 
Pre-existing diabetes increases the risk of neonatal malformations due to 
poor maternal glycaemic control in the periconceptual period. Janssen and colleagues 
conducted a population based retrospective study involving 1511 patients with pre-
existing diabetes and 8869 patients with GDM to examine the relationship between 
diabetes in pregnancy and the development of congenital malformations in the United 
States. The authors indicated that there was a slightly higher prevalence of 
malformation among babies of GDM mothers (OR 1.3, 95%CI 1.0-1.6), however the risk 
was significantly higher among infants of mothers with overt diabetes (OR 4.0, 95% CI 
3.1-5.1) (86). Fadl and colleagues in Sweden also found a mild increase in the risk of 
neonatal malformation among GDM patients compared to non-GDM sufferers (Adjusted 
OR 1.19, 95% CI 1.02-1.39) (84).  
Researchers demonstrated that there was an increased risk of a particular 
type of malformation among babies of GDM mothers, as well as babies of patients with 
pre-existing diabetes; these malformations include cardiac malformation, oesophageal 
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atresia and spinal anomalies (87). Interestingly, when analysing the relationship 
between major malformation and maternal blood glucose concentration at entry into 
prenatal care, the authors found that the rate of major malformation was 2.1% when 
the initial fasting plasma glucose (FPG) was < 6.6 mmol/l; 5.9% when FPG was between 
6.6-11.0 mmol/l, and 12.9% when FPG exceeded 11 mmol/l (p< 0.0001) (88). Based on 
the available information, researchers concluded in a large literature review that the risk 
of malformation was slightly higher in pregnancies of women with GDM compared to 
the general population. However, this increased risk was probably associated with the 
presence of undiagnosed pre-existing diabetes among women with GDM (89).  
        
1.4.1.2 Fetal overgrowth 
Macrosomia, a common term for fetal overgrowth, is defined as birth weight 
higher than 4000g (National Institute for Health and Care Excellence) or 4500g 
(American College of Obstetrician and Gynaecologists). Larger for gestational age (LGA) 
is another term to describe fetal overgrowth, which corresponds to a birth weight ≥ 90th 
percentile for gestational age. This criterion can also identify excessive fetal growth in 
premature infants. Recently, more advanced percentile calculations have been made 
available for populations in specific countries, to enable adjustments for maternal height, 
maternal weight, parity, maternal ethnicity, gestational age and gender, and to provide 
more precise results for LGA (the customized LGA) rate (90, 91). The reasons for 
macrosomia could be divided into two categories: non-modifiable factors and modifiable 
factors. Non-modifiable factors include genes, epigenetic regulation, maternal age, 
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maternal height and fetal gender, while modifiable determinants include pre-gestational 
maternal BMI, gestational weight gain, maternal nutritional status, level of physical 
activity, smoking and metabolic parameters (92).  
GDM has been known to be associated with an increased risk of fetal 
overgrowth for some time. According to the Pedersen Hypothesis, fetal hyperglycaemia 
caused by maternal hyperglycaemia, could induce hypertrophy of fetal β islet tissue and 
cause hyper-secretion of insulin. This extra insulin acts as a growth hormone and 
contributes to fetal overgrowth (93). In the HAPO study, the researchers demonstrated 
a strong continuous relationship between maternal hyperglycaemia, even below 
diagnostic glucose level of GDM, with increased rate of birth weight > 90th percentile and 
neonatal cord-blood serum C peptide > 90th percentile. This result supports the Pedersen 
hypothesis (62). Recently, maternal dyslipidaemia, another common metabolic disorder 
found in GDM, is suspected to be related to fetal overgrowth as well (94). 
Fetal overgrowth has both short-term and long-term consequences. The 
babies’ short-term complications include birth trauma (shoulder dystocia, plexus injuries, 
and bone fractures), metabolic disorders (hypoglycaemia, hyperbilirubinaemia), fetal 
hypoxia and NICU admission (95-97). For those mothers who gave birth to overgrown 
babies, the adverse outcomes include prolonged labour, operative deliveries, perineal 
lacerations, uterine atonia, abnormal haemorrhage and a necessity for caesarean 
section deliveries (98, 99). Long-term complications for overgrown babies include 
increased susceptibility to diabetes, overweight, metabolic syndrome, asthma, 
persistent plexus injuries and cancer (especially breast cancer and childhood leukaemia) 
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(100, 101). 
Interestingly, infants of diabetic mothers are more likely to have 
disproportionate overgrowth that refers to excessive weight characterized by a high 
weight/length ratio. Anthropometric and skinfold measurements in newborns of 
mothers with gestational diabetes suggested a disproportionate pattern of growth in 
fetuses of diabetic mothers with increased tendency for deposition of subcutaneous fat 
(102).  Compared to non-diabetic mothers, macrosomic babies born to diabetic mothers 
have a significantly higher rate of shoulder dystocia and Caesarean deliveries (103, 104). 
Previous studies also showed that disproportionate macrosomic babies have a higher 
rate of neonatal hypoglycaemia, hyperbilirubinaemia and acidosis compared to 
proportionate macrosomic babies and babies without macrosomia (105). 
 
                   1.4.1.3 Shoulder Dystocia 
Shoulder dystocia is objectively defined as “a prolonged head to body delivery 
time [i.e., more than 60 seconds], and/or the necessitated use of ancillary obstetric 
manoeuvres.” (106), and can be further categorized as mild and severe, according to the 
kind of manoeuvre applied (107). It results from a size discrepancy between the fetal 
shoulders and the pelvic outlet. The classic maternal risk factors include obesity, 
diabetes, excessive weight gain, high parity and a prior birth complicated by shoulder 
dystocia (108-110). Labour risk factors include prolonged first or second stages of labour 
and instrumental delivery (111-113). Vacuum extractions increase the risk of shoulder 
dystocia more than forceps deliveries (114). The risk of shoulder dystocia also increases 
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along with the increment of birth weight: risk is 5.2% for infants between 4000 to 4250g, 
9.1% for those between 4250 to 4500g, 14.3% for those between 4500 to 4750g and 
21.1% for those between 4750 to 5000g (115). Mansor and collaborators demonstrated 
a similar positive relationship between infants’ birth weight and the rate of shoulder 
dystocia (116). 
Landon and associates found that the shoulder dystocia rate was higher 
among women with mild gestational diabetes compared to women with a normal GCT 
(approximately 4% vs. less than 1%) (117). Large observational studies also indicated 
that the incidence of shoulder dystocia appeared to be doubled across all birth weight 
categories, for babies born to diabetic mothers, both with overt diabetes and GDM. 
These rates are 12.2% for infants 4000-4250g, 16.7% for those 4250-4500g, 27.3% for 
those 4500-4750g, and 34.8% for those 4750-5000g, whereas the incidence rate of 
shoulder dystocia for non-diabetic mothers is 5.2% for infants 4000-4250g, 9.1% for 
those 4250-4500g, 14.3% for those 4500 to 4750, and 21.1% for those 4750-5000g (115). 
This increased rate could be attributed to the higher rate of disproportionate 
overgrowth among babies of GDM patients. Macrosomic infants born to diabetic 
mothers have large shoulders and extremity circumferences, decreased head-to-
shoulder ratio, higher body fat and thicker upper-extremity skin folds compared with 
babies born to non-diabetic mothers (118). Furthermore, among GDM patients, 
maternal fasting hyperglycaemia was associated with increased risk of shoulder dystocia, 
with 1 mmol/l increases in fasting OGTT results leading to a two-fold increase in the rate 
of shoulder dystocia (Relative Risk 2.09, 95% CI 1.03-4.25) (119).   
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Shoulder dystocia increases morbidity and mortality in both mothers and 
babies. Common maternal complications are postpartum haemorrhage and 
unintentional extension of the episiotomy or laceration into the rectum (fourth-degree 
laceration) (120). Other complications include vaginal lacerations, cervical tears, bladder 
atony, and uterine rupture (121). For babies, the most common complication is 
temporary or prominent brachial plexus injuries, including Erbs palsy (C5, C6), Klumpke 
palsy (C8, T1), total brachial plexus palsy (C5-T1) and Horner’s syndrome (C5-T1 and 
facial nerve) (122, 123). Other rare complications include bone fracture (commonly 
clavicle or humerus), and hypoxic-ischemic encephalopathy and even death (123, 124). 
It is still controversial whether GDM patients who had shoulder dystocia will have worse 
outcomes compared to the glucose tolerant women who also suffered from shoulder 
dystocia (125, 126). 
The manoeuvres for shoulder dystocia alleviation include McRoberts’ 
manoeuvre, suprapubic pressure, fetal rotational manoeuvres or posterior arm 
extraction (Woods’ corkscrew manoeuvre and Rubin’s manoeuvre), and “all-four” 
techniques.  There are also other more aggressive techniques, for examples, the 
Zavanelli manoeuvre, symphysiotomy, hysterotomy and deliberate clavicular fracture 
(127, 128). 
 
1.4.1.4 Neonatal hypoglycaemia 
Neonatal hypoglycaemia was first described by Hartmann and Jaudon in 1937 
(129) and has been associated with prominent brain damage for more than 40 years 
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(130). The “numerical” definition of neonatal hypoglycaemia, meaning the blood 
glucose concentration cut-off point below which would create risk of long-term 
neurological and developmental consequences, has been continually debated all over 
the world (131). The most widely accepted cut-off value of hypoglycaemia is a glucose 
level less than 2.6mmol/l, and it was based on an observational research done by Lucas 
et al in 1988 (132). Other published definitions range from a blood glucose 
concentration of less than 1.1 mmol/l in preterm birth and less than 1.7 mmol/l in term 
infants, to a plasma concentration of less than 2.5 mmol/l (133). The reasons why it is 
so difficult to achieve a uniform definition, are that healthy newborn infants also 
experience low glucose levels during the early postnatal period, and that newborn 
infants have the ability to compensate by producing other metabolic fuels and provide 
energy to maintain brain function, for example ketone bodies and lactate. There is also 
a lack of evidence regarding the correlation between the level of glucose concentration, 
and adverse neurologic and developmental outcomes (134).  
Recently, the American Academy of Paediatrics stated that a specific 
concentration of glucose that can discriminate euglycaemia from hypoglycaemia, or 
predict acute or chronic irreversible neurologic damage could not be supported due to 
the lack of sufficient evidence (135). Instead, Hawdon proposed a new diagnostic term 
such that neonatal hypoglycaemia should be accurately defined as a persistently low 
blood glucose level, measured with an accurate device, in a baby at risk of impaired 
metabolic adaptation but with no abnormal clinical signs; or a single low blood glucose 
level in a baby presenting with abnormal clinical signs (136). To make the definition more 
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practicable, a group of experts suggested a new concept of “operational thresholds”- 
the blood glucose thresholds for taking action (137). 
Fetuses do not produce glucose under normal conditions and their energy 
needs are entirely dependent on maternal supply and placental transfer of glucose, 
amino acid, and free fatty acids, ketones and glycerol (138, 139). After birth and 
clamping of the umbilical cord, neonatal glucose levels drop quickly and reach a nadir at 
1-2 hours of age, then rise to levels that are similar to late gestation fetal concentrations 
(about two-thirds of normal maternal values) by 2-4 hours, mostly through 
glycogenolysis and gluconeogenesis. Following that period of rapid change, the neonatal 
glucose levels rise slowly and reach adult levels in 3-4 days of age (140-142). These 
glucose changes are vital for promoting glucose production, stimulation of appetite, 
adaptation to fast/feed cycles and enhancement of oxidative fat metabolism (143). 
These crucial changes in neonatal glucose levels are modified by several factors 
including umbilical concentrations of glucose, plasma insulin concentrations, and the 
onset time and capability of neonatal glucose production (144). 
With the occurrence of GDM, fetuses are exposed to hyperglycaemia and 
develop fetal pancreatic hyperplasia and fetal hyperinsulinaemia, which contribute to 
neonatal hypoglycaemia after birth (62, 145). Furthermore, the liver is stimulated by 
glucagon to generate glucose, and this glucagon response appears to be blunted in 
babies of diabetic mothers (146). In the HAPO study, the authors demonstrated that 
maternal hyperglycaemia, even under the diagnostic criteria of GDM, was associated 
with increased risk of clinical neonatal hypoglycaemia (83). Observational studies also 
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confirmed the relationship between GDM with the increased risk of neonatal 
hypoglycaemia. Shand and colleagues conducted a population-based study in Sydney, 
Australia, and they found that the rate of neonatal hypoglycaemia was increased in 
babies of GDM patients (19.1%) compared to their non-diabetic counterparts (1.6%) (OR 
15.07, 95%CI 14.38- 15.80) (147). In the United States, Langer and collaborators 
presented similar results, and showed that infants of GDM patients had increased risk 
of neonatal hypoglycaemia (6% vs. 2%, OR 2.98, 95%CI 1.84-4.84) (148). However, the 
rate of neonatal hypoglycaemia is hard to examine in the general population and might 
be underestimated.  
 Another cause of neonatal hypoglycaemia is maternal hyperglycaemia during 
labour, which results in persistent excessive secretion of fetal insulin 1 to 2 hours after 
birth. Balsells and colleagues found that the capillary blood glucose level of GDM 
patients during labour was associated with the development of neonatal hypoglycaemia 
(149). Moreover, previous studies demonstrated that higher maternal pre-gestational 
BMI, previous GDM history, higher fasting glucose level at diagnosis, and insulin 
treatment were all associated with increased risk of neonatal hypoglycaemia among 
babies of GDM mothers (149, 150). 
The clinical signs of neonatal hypoglycaemia are not specific; these signs 
include jitteriness, cyanosis, apnoeic episodes, tachypnoea, a weak and high pitched cry, 
hypotonia, poor feeding, eye rolling, pallor, hypothermia, sweating, temperature 
instability, and tachycardia. If the hypoglycaemia is prolonged, more severe signs could 
be noticed, including changes in level of consciousness (irritability, lethargy, stupor, and 
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coma), and seizures (151, 152). The literature confirmed that persistent low blood 
glucose level is associated with acute neurological dysfunction and presents a great risk 
for cerebral injury (153). The spectrum of cerebral injury includes: white matter injury 
(parenchymal haemorrhage and ischemic stroke), cortical neuronal injury, and 
sometimes changes in the basal ganglia (mostly the globus pallidus) and thalami. 
Posterior parietal and occipital lobes are affected more severely than other regions of 
the brain (153-155).  
Long term neurodevelopmental adverse sequelae following neonatal 
hypoglycaemia is still controversial (156); the other possible outcomes include milder 
motor,visual, learning and behavioural problems (157-161). Research also showed that 
neonatal hypoglycaemia in diabetic pregnancy was associated with worse neurological 
dysfunction: minimal brain deficits in attention, motor control, and perception, 
compared to children born to diabetic mothers, but without hypoglycaemia (162). 
The treatment strategies include prudent observation of a fetus’s clinical 
signs, regular blood glucose checking using a proper method, and feeding and/or 
intravenous glucose infusions (151, 152). 
 
1.4.1.5 Neonatal hyperbilirubinaemia  
Bilirubin is a metabolite resulting from the break-down of senescent or 
haemolysed red blood cells through the reticuloendothelial system. Biliverdin, released 
from degraded haem, is reduced to bilirubin by biliverdin reductase. This type of 
bilirubin (unconjugated bilirubin) is water-insoluble and needs to attach to albumin for 
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transportation via the blood to the liver. Then, in the liver, it is conjugated to glucuronic 
acid to become more water-soluble.  The conjugated bilirubin enters the small intestine 
and colon and is converted into different forms; most forms will be excreted outside the 
body through urine and faeces, while others enter the enterohepatic recirculation by 
reabsorption. Unconjugated bilirubin is highly soluble in lipid, which means it can cross 
the cell membranes including blood-brain barrier and is toxic to the developing neonatal 
brain (163, 164). 
High levels of bilirubin in the plasma causes yellow discolouration in elastin-
rich tissues, including sclera and skin. This phenomenon is known as jaundice. Neonatal 
jaundice is present in about 60% of term babies and 80% of preterm babies. It could be 
further divided into two categories, physiological jaundice and the more severe case of 
pathological jaundice (165). Increased production of bilirubin, deficiency of hepatic 
uptake, impaired conjugation of bilirubin, and increased enterohepatic circulation of 
bilirubin are the most common causes of neonatal pathologic jaundice (166). In the most 
serious cases of hyperbilirubinaemia, neonates could develop acute bilirubin 
encephalopathy (ABE) and kernicterus, due to neurotoxicity. Symptoms of ABE include 
lethargy, hypotonia and poor feeding. If this condition is not treated in this stage, it could 
lead to coma, seizures and, sometimes even death. Kernicterus is the chronic form of 
bilirubin encephalopathy, characterized by athetoid cerebral palsy, auditory dysfunction, 
dental-enamel dysplasia, paralysis of upward gaze and intellectual and other handicaps 
(167-169). 
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In the HAPO study, the researchers demonstrated that maternal 
hyperglycaemia was associated with increased risk of neonatal hyperbilirubinaemia, 
requiring phototherapy (83). Sayin and colleagues found that the rate of neonatal 
jaundice requiring treatment was higher in the GDM group compared to non-GDM 
group (17.7% vs. 6.3%, p< 0.001) (170). Similarly, Landon and colleagues indicated the 
rate of neonatal hyperbilirubinaemia (plasma values greater than 12 mg/dl) was higher 
in the untreated GDM group compared to the non-diabetic group (14% vs. 2%, OR 3.87, 
95%CI 2.64-5.67) (148). The underlying causes of this increased risk among infants of 
GDM patients include newborn polycythaemia due to fetal hypoxia, the resultant 
misbalance between increased fetal oxygen consumption that is caused by 
hyperglycaemia and hyperinsulinaemia, and reduced oxygen supply from the maternal 
side, that is due to increased maternal haemoglobin affinity of oxygen and reduced 
placental function, and also the relative immaturity of hepatic bilirubin conjugation and 
excretion in infants.  The higher numbers of broken-down red cells contribute to delivery 
of extra bilirubin to the immature glucuronosyltransferase enzyme system and results 
in increased serum unconjugated bilirubin concentration, with a rapid rate of rise 
followed by a later peak (171). Preterm birth and superficial head bruising due to birth 
trauma could also exacerbate the situation (172). 
The therapeutic options for hyperbilirubinaemia include phototherapy, 
immunoglobulins for isoimmune haemolytic disease (Rh and ABO haemolytic disease) 
and exchange transfusion (173). 
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1.4.1.6 Neonatal respiratory distress 
Respiratory distress (RD) is one of the most common neonatal complications 
after delivery, and its overall incidence rate is around 7%. Among these affected babies, 
preterm birth has the highest incidence, followed by post-term deliveries (174).  RD is 
defined as any sign of breathing difficulties in the neonates, including tachypnoea 
(RR >60/min) and tachycardia (HR>160/min), cyanosis, nasal flaring, grunting, apnoea/ 
dyspnoea, and chest wall recession (suprasternal, intercostal and subcostal). There are 
different pathogeneses of neonatal respiratory distress. The common causes of RD are 
transient tachypnoea of the newborn (TTN), respiratory distress syndrome (RDS), 
pneumonia, meconium aspiration syndrome (MAS) and primary or secondary 
pulmonary arterial hypertension (175, 176). 
TTN is now recognized as the main cause of RD in newborns. It is caused by 
inadequate lung fluid clearance at birth, resulting in excess lung liquid (177). It is 
generally a self-limiting disorder, and will present with grunting and mild signs of 
respiratory distress.  Usually the symptoms will disappear within 48 hours. However, 
some of the affected infants will develop an oxygen requirement and will necessitate 
admittance into the Neonatal unit for a few days (178). The risk factors of TTN include 
elective and emergency caesarean section, gestational age, birth weight (both low birth 
weight and high birth weight), maternal age and male sex (179, 180). 
A higher rate of TTN among infants of GDM patients has been reported. 
Persson and colleagues demonstrated that the rate of TTN was doubled among infants 
of GDM mothers (181, 182). Pinter and collaborators also indicated that fetuses of 
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diabetic rats had decreased fluid clearance in lung and a lack of thinning of the lung’s 
connective tissue, which might be the cause of TTN (183). Moreover, increased birth 
weight, increased rate of caesarean section and increased incidence of preterm birth 
are all potential explanations for elevated rates of TTN (83). However, other studies 
found that the rate of TTN was not different between infants of GDM mothers and 
infants of non-diabetic mothers (170, 184). This inconsistency might be due to the low 
prevalence of TTN among infants of GDM patients.  
RDS, also called hyaline membrane disease, is caused by a deficiency of 
surfactant (185). The type 2 pneumocytes start to produce surfactant around 24-25 
gestational weeks and reach adequate amount to support breathing after birth by 36-
37 weeks. The lack of surfactant causes widespread alveolar collapse and results in 
poorly compliant lungs (186). Normally, infants with RDS present respiratory distress 
within the first minutes or hours after birth, and most will require respiratory support 
with oxygen or mechanical ventilation (185). 
Babies of diabetic mothers are more likely to suffer from RDS due to two 
reasons, prematurity and abnormal surfactant production (181, 187, 188). GDM patients 
have higher incidence rates of preterm birth compared to the general population, which 
means their babies are at increased risk of developing straightforward surfactant-
deficient RDS (189, 190). Furthermore, high blood glucose is involved in several 
mechanisms that contribute to abnormal production of surfactant, including inhibited 
surfactant synthesis and secretion by type 2 cells, fewer type 2 pneumocytes/alveolar 
lining cells and fewer lamellar bodies/alveolar lining cells, blocked trafficking of lipids 
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from fibroblasts to type 2 cells, and decreased expression of mRNA for surfactant 
proteins B and C (191, 192). Thomas and collaborators found that infants of GDM 
patients had delayed onset of surfactant (phosphatidyl glycerol) compared to babies 
born to non-GDM women (37.3 ± 0.9 weeks vs. 35.9 ± 1.1 weeks, p<0.001) (193). 
Researchers have also indicated that maternal glucose control during pregnancy plays 
an important role in the rate of neonatal RDS; for patients who had well-controlled 
diabetes, their babies experienced similar lung maturation compared to their non-
diabetic counterparts. Babies born to mothers with poorly controlled diabetes showed 
a significant delay in the appearance of phosphatidyl glycerol (194, 195). 
Cardiomyopathy is another cause of RD in infants delivered by diabetic 
patients. The rate of cardiomyopathy is increased among babies of diabetic mothers 
with overt diabetes or GDM (196, 197).  Fetal hyperinsulinaemia, triggered by maternal 
hyperglycaemia, increases the synthesis and deposition of fat and glycogen in the 
myocardial cells and leads to an asymmetric septal enlargement in heart, characterized 
by increased left ventricular mass and contractility leading to obstruction in the left 
ventricular outflow tract (198, 199). The infants with cardiomyopathy are usually 
asymptomatic, but 5-10% of cases have respiratory distress or signs of cardiac 
dysfunction.  Normally, after two to three weeks of supportive care, symptomatic 
infants recover, and echocardiographic findings resolve within 6 to 12 months (200). 
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1.4.1.7 Other neonatal short term complications 
The increased risk of other neonatal complications, for example, 
polycythaemia, hypocalcaemia and hypomagnesaemia among infants of GDM patients 
has been documented, but the prevalence of these complications is relatively low.   
 
1) Fetal hypoxaemia, neonatal polycythaemia, and hyperviscosity  
Accumulated evidence indicates that diabetes increases the risk of fetal 
hypoxaemia during pregnancies (201). It happens more frequently when glucose levels 
are not well-controlled (202). The exact cause of fetal hypoxaemia is not fully 
understood. However, there are several potential explanations. Firstly, thickening of the 
basement membrane of the chorionic villi is more common in diabetic pregnancies, 
which increases the diffusion distance of oxygen between the mother side and the baby 
side. Secondly, uncontrolled diabetes could cause decreased uterine blood flow in the 
placental bed and result in decreased oxygen transfer to the foetus. Thirdly, in GDM 
patients who have vascular complications (mostly women with unknown pre-existing 
type 1 or type 2 diabetes prior to pregnancy), pathological changes can be found in the 
spiral arteries of the placental bed, which narrow the blood flow from the mother to the 
baby (203-205). Fetal hyperglycaemia and hyperinsulinaemia both contribute to the 
development of fetal hypoxaemia. Since glucose and insulin are anabolic resources and 
hormones respectively, they increase oxygen consumption with increased 
erythropoietin levels in fetal plasma (206, 207). Research has also confirmed the 
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relationship between the severity of fetal macrosomia and the risk of fetal chronic 
hypoxia (208). 
Chronic fetal hypoxaemia can lead to cord blood acidosis, low Apgar scores, 
reticulocytosis and, in the worst case, perinatal death (209). The best method to avoid 
fetal hypoxaemia is still under discussion. However, one commonly used method is 
intensive fetal monitors, including biophysical profile, doppler blood flow 
measurements and non-stress testing (210, 211). There are also guidelines that 
recommend ending pregnancy before term to avoid unpredictable perinatal death (212).   
Neonatal polycythaemia is defined by a venous haematocrit (hct) that 
exceeds normal values for gestational and postnatal age by two standard deviations 
(213). For a term infant, polycythaemia is diagnosed if the hct from a peripheral venous 
sample is greater than 65% or the haemoglobin in greater than 22 g/dl (214).   
The incidence of polycythaemia is 1.5-4% in the general population and the 
risk factors include fetal transfusions, intrauterine hypoxia and other rare fetal causes 
such as Beckwith Weidemann syndrome (214, 215). Infants of diabetic mother have 
higher risk, about 10% to 30%, of developing polycythaemia compared to babies of non-
diabetic mothers (216-218). The underlying pathogenesis of this higher incidence might 
be the increased erythropoietin concentration caused by chronic fetal hypoxemia (82). 
Hyperviscosity, normally caused by polycythaemia, is defined as a viscosity 
greater than 14.6 centipoise, at a shear rate of 11.5 reciprocal seconds. It can lead to 
different symptoms including intravascular aggregation, ischaemia, and infarction of 
vital organs (219). 
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2) Neonatal Hypocalcaemia 
In the human body, calcium exists in two places: skeleton (99%) and 
extracellular fluid (1%).  There are three different forms of calcium in the extracellular 
fluid: calcium bound to albumin (40%), calcium bound to anions like phosphorus, citrate, 
sulphate and lactate (10%) and free ionized calcium. Ionized calcium is a crucial element 
for many important biochemical processes, such as neuromuscular excitability, 
coagulation, cell membrane integrity and function, as well as cellular enzymatic and 
secretory activity; it is tightly regulated by parathyroid hormones and vitamin D levels. 
Elevated extracellular pH in cases such as acute respiratory alkalosis, could increase the 
binding of calcium to albumin, which decreases the concentration of ionized calcium 
without affecting the total serum calcium level (217, 218). 
In the third trimester, fetal serum calcium (SCa) is higher than the mother’s 
SCa, and is actively transferred from the maternal side to the fetal side. After birth, 
neonatal SCa starts to decrease and reaches a nadir of 7.5-8.5 mg/dl (1.9-2.1 mmol/l)  in 
healthy term babies in two days (220). However, PTH levels increase gradually in the 
first 48 hours of life and determine similar levels of SCa are seen in older children and 
adults by two weeks of age (221). 
Neonatal hypocalcaemia is defined as a total serum calcium level below 1.75 
mmol/l or ionized calcium less than 1 mmol/l in preterm babies. In term infants, the 
diagnostic criteria are total serum calcium below 2 mmol/l or ionized calcium less than 
1.2 mmol/l.  It can be divided into two categories: early onset neonatal hypocalcaemia 
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(ENH), that is relatively common and occurs within the first 3-4 days of life, and late 
onset neonatal hypocalcaemia (LNH), that is rare and usually presents at the end of the 
first week of life.  Prematurity, infants of diabetic mother, perinatal asphyxia, maternal 
hyperparathyroidism and intrauterine growth restriction are the common causes of 
EMH. The reasons for developing LNH include hypomagnesaemia, high phosphate load, 
hypoparathyroidism, vitamin D deficiency states, and iatrogenic cause.  
The clinical presentations of neonatal hypocalcaemia vary widely. Some cases 
are asymptomatic, others may present non-specific symptoms (apnoea, cyanosis, 
tachypnoea and vomiting). In some cases, neuromuscular symptoms (myoclonic jerks, 
jitteriness, exaggerated startle, tetany and seizures) and cardiac abnormalities 
(tachycardia, prolonged QT interval, decreased contractibility and heart failure) are also 
observed.  Calcium supplementation for at least 72 hours is the regular treatment for 
EMH, and usually will resolve hypocalcaemia in 48-72 hours without any significant 
sequelae. The therapy for LNH is longer and more complicated, based on the aetiology; 
in the most severe cases, babies with LNH may need lifelong treatment (221, 222). 
Diabetes increases the risk of hypocalcaemia in newborns; hypocalcaemia 
occurs in 10%-20% of babies of mothers with diabetes, including overt diabetes and 
GDM (223, 224). This may be related to the increased calcium demands of a macrosomic 
baby, as well as maternal hypomagnesaemia caused by magnesium depletion in diabetic 
mothers, combined with functional hypoparathyroidism in infants (225). The higher risk 
of birth asphyxia and prematurity might also contribute to the increased risk of 
hypocalcaemia in babies of diabetic mothers. Recent research demonstrated that 
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infants of GDM patients have specific calcium sensing receptor genotype that is 
associated with decreased calcium levels both at birth and on the 2nd day of life (226). 
Strict management of diabetes in pregnancy might reduce the risk of neonatal 
hypocalcaemia (227). 
 
3) Neonatal Hypomagnesaemia 
During pregnancy, maternal serum magnesium (Mg) levels decrease, 
combined with a 25% increase of renal Mg excretion. Diabetes will further exacerbate 
urinary loss of Mg, particularly the intracellular free magnesium level, which may cause 
neonatal hypomagnesaemia (228, 229). Little is known about fetal magnesium 
homeostasis. Animal studies show that the materno-fetal flux of magnesium is reduced 
in the presence of maternal diabetes mellitus (230). 
Neonatal hypomagnesaemia, defined as less than 0.02 mmol/l might have an 
increased rate among infants of diabetic mothers within the first three days after birth. 
Prematurity and pregnancy complicated with preeclampsia will increase the risk of 
developing hypomagnesaemia (231, 232). Neonatal hypomagnesaemia is usually 
transient and asymptomatic; however, there are also severe cases with different 
manifestations, including neuromuscular hyperexcitablility (e.g. tetany, convulsions), 
cardiovascular symptoms (e.g. changing in ECG, atrial and ventricular arrhythmias), and 
hypokalaemia (233, 234). It can also reduce both parathyroid hormone (PTH) secretion 
and PTH responsiveness. Thus, for neonates that have both hypomagnesaemia and 
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hypocalcaemia, the treatment for hypocalcaemia might not work until the 
hypomagnesaemia is corrected (85, 235). 
                   1.4.2 Maternal short term complications 
1.4.2.1 Hypertension disease induced by pregnancy 
Hypertension is a common maternal complication during pregnancy and is 
associated with increased maternal and neonatal mortalities and morbidities. They can 
generally be divided into four categories: 1) Chronic hypertension: hypertension that 
was present at <20 weeks gestation that does not progress to preeclampsia. 2) 
Gestational hypertension: a systolic blood pressure ≥ 140 mm Hg and/ or a diastolic 
blood pressure ≥ 90 mmHg on two occasions at least 4 hours apart after 20 weeks of 
gestation in a woman with previously normal blood pressure. 3) Preeclampsia: 
hypertension after 20 weeks of gestation associated with proteinuria of ≥ 300 mg per 24 
hours or ≥1+ dipstick. Preeclampsia is also diagnosed as hypertension in association with 
thrombocytopenia, impaired liver function, new development of renal insufficiency, 
pulmonary oedema or new-onset cerebral or visual disturbances, even in the absence 
of proteinuria. 4) Chronic hypertension with superimposed preeclampsia: chronic 
hypertension combined with the symptoms of preeclampsia that develop after 20 
gestational weeks (236-238). There are also more severe types of pregnancy-induced 
hypertension such as eclampsia (hypertensive patients with convulsions during 
pregnancy or in the first 10 days postpartum) and HELLP syndrome (a syndrome 
characterized by Haemolysis, Elevated Liver enzymes and a Low Platelet count). 
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However, their prevalence is quite low, around 0.27% and 0.8% among all the pregnant 
women, respectively (239, 240). 
Approximately 10% of women have gestational hypertension during 
pregnancy. For preeclampsia, the prevalence is around 2-8% depending on the studied 
population (241). Maternal adverse outcomes associated with hypertensive disorders 
include increased caesarean deliveries, abruptio placentae, renal failure, stroke, cardiac 
arrest, adult respiratory distress syndrome, coagulopathy and liver failure.  It also 
increases the risk of developing perinatal morbidities, including fetal growth restriction, 
prematurity, and respiratory distress syndrome after birth (242, 243). 
Gestational diabetes is associated with increased risk of pregnancy-induced 
hypertension including gestational hypertension and pre-eclampsia, even after 
adjustment for body mass index, age, ethnicity, parity and prenatal care (244-247). In 
the HAPO study, authors indicated that maternal hyperglycaemia was associated with 
increased risk of preeclampsia (83). In a large Australian population-based study, Shand 
and colleagues demonstrated that GDM patients had increased risk of gestational 
hypertension (6.9% vs. 4.2%, OR 1.74, 95%CI 1.64-1.85) and preeclampsia (6.7% vs. 4.4%, 
OR 1.63, 95%CI 1.53-1.74) (147).  Accumulated evidence indicates that this association, 
at least in part, could be due to insulin resistance (248-250). A secondary analysis of the 
HAPO study proved that higher fasting C-peptide, an acceptable measure of insulin 
sensitivity in pregnancy if patients have normal insulin secretory capacity, is an 
independent risk factor of preeclampsia, after being adjusted for BMI and fasting 
glucose (251).  
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The underlying mechanisms between insulin resistance and gestational 
hypertension are not fully understood. However, it is believed that insulin resistance 
could cause hypertension at cellular, circulatory and neurologic levels. In the 
sympathetic nervous system, insulin resistance stimulates the release of plasma 
norepinephrine and reduces the capacity of vasodilation. At the circulatory level, 
hyperinsulinaemia can cause hypertrophy of the vascular smooth muscle cells and 
vasoconstriction. Hyperinsulinaemia also has an effect on the cellular membrane pump, 
and can increase intercellular calcium and vascular tone (252).  
Independent of insulin resistance, hypertension could also be induced by 
functional abnormalities of the vascular endothelium that results from maternal 
hyperglycaemia. Hyperglycaemia increases the concentration of free radicals and 
advanced glycosylation endproducts, which reduce the availability of NO for 
vasodilation (253, 254). Placental abnormalities, such as plethora, chorangiosis, and a 
relatively immature villous structure, happen more frequently in diabetic mothers, and 
could lead to the release of different vasoactive and pro-inflammatory substances (α-
TNF, leptin, etc.), that are related to the development of gestational hypertension (255-
257). Finally, gestational diabetes could cause dyslipidaemia, characterized by increased 
oxidized low density lipoprotein (LDL) that can inactivate endothelial nitric oxide (NO) 
and cause vascular dysfunction (254, 258, 259). 
Several randomized controlled trials have found that strict treatment of GDM 
could reduce the risk of developing pregnancy-induced hypertension during pregnancy. 
The Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) found a 
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lower incidence of preeclampsia in the treated group compared to the routine-care 
group (12% vs. 18%, p=0.02)(260). Similarly, Landon and colleagues indicated that 
treatment reduced the risk of pregnancy-induced hypertension, both for gestational 
hypertension and preeclampsia, in GDM patients (8.6% vs. 13.6%, p=0.01) (261).  
 
1.4.2.2 Preterm Birth 
Preterm birth is defined as birth occurring before 37 weeks of completed 
gestation. An estimated 10% of all births worldwide are preterm, which means around 
41,000 infants are born before term each day (262). In a comprehensive systematic 
review, authors indicated that most countries have shown an increase in preterm birth 
rates over the last 20 years (263). In Australia, the risk of preterm birth increased from 
5.5% in 1991 to 7.5% in 2011: 0.8% pregnant women gave birth at 20-27 weeks, 0.7% at 
28-31 weeks, and 6.0% delivered at 32-36 weeks (264, 265).  
Preterm birth can be divided into two categories depending on the clinical 
presentation: spontaneous preterm birth (which contemplates either spontaneous 
onset of labour with intact membranes, or after preterm premature rupture of 
membranes - PROM), and medically-indicated preterm birth for maternal or fetal 
indications. This includes maternal preeclampsia, fetal distress, SGA, and placental 
abruption. It is estimated that around 2/3 of all preterm births are spontaneous (266). 
Preterm birth is associated with increased perinatal mortality, as well as 
short- and long-term morbidities. It is known that the risk of adverse consequences 
decline with increasing gestational age (267). In Australia, the rate of neonatal death 
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was 410 per 1000 births for infants born <28 weeks, but decreased exponentially to 30 
per 1000 birth for infants born at 28-31 weeks, and 4.7 per 1000 for infants born at 32-
36 weeks. However, even the lowest mortality rate of babies born preterm at 32-36 
weeks is still five times higher than mortality for infants born after 37 weeks (268). Other 
countries show similar trends (269). Compared to term-born babies, preterm born 
infants had increased risk of respiratory distress, infection, hypothermia, hypoglycaemia, 
hyperbilirubinaemia, hypoxic-ischaemic encephalopathy (HIE), intraventricular 
haemorrhage and feeding problems. Necrotizing enterocolitis and retinopathy have also 
been reported, although they are more common in the infants born extremely preterm 
(< 28 weeks) (267, 270, 271). Infants born preterm experience long-term complications, 
such as an increased risk of cerebral palsy, developmental coordination disorder, visual 
impairment, hearing impairment, cognitive impairment, and neurobehavioral disorders 
(272, 273). 
The HAPO study also confirmed that an increased risk of preterm delivery is 
associated with elevated 1h OGTT results (OR 1.18 95% CI 1.12-1.25), and 2h OGTT 
results (OR 1.16 CI 1.10-1.23) but not for the fasting OGTT result (OR 1.05 95%CI 0.99-
1.11) after being adjusted for confounders (83). Yang and colleagues found that patients 
who had impaired glucose tolerance during pregnancy with conventional obstetric care, 
had increased risk of preterm birth (OR 6.42 95%CI 1.46-28.34) (274). In a large 
population-based cohort study including 1,260,297 women with singleton pregnancies 
in Sweden, researchers demonstrated that GDM patients had a higher risk of preterm 
birth (8.6% vs. 5.0%, adjusted OR 1.71, 95% CI 1.58-1.86) (84).  
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It is important to note that these studies did not separate spontaneous 
preterm birth from medically-indicated preterm birth. The increased rate of preterm 
birth may be attributed to the higher risk of indicated preterm birth, caused by increased 
risk of preeclampsia in GDM patients. There were inconsistent results regarding the 
relationship between GDM and spontaneous preterm birth (sPTD). Jensen and co-
workers found that despite treatment, an increased risk of sPTD is associated with 
higher 2h OGTT results, either between 9.0-11.0 mmol/l (OR 2.0 95% CI 1.0-3.6) or ≥11.0 
(OR 5.1 95%CI 2.4-11.0) (275). Similar results were confirmed by Lao and colleagues 
(275). They demonstrated that the incidence of sPTD correlated significantly with 
increasing glucose intolerance in diet-treated GDM patients; the rate of sPTD increased 
from 5.5%, in patients whose 2h OGTT results were 5.9 mmol/l or less, to 10.3%, in 
patients whose 2h OGTT results were 11.0 mmol/l or greater (276). Conversely, Yogev 
and collaborators conducted a retrospective study, and concluded that the rate of sPTD 
was similar between GDM and non-GDM patients (10.7% vs. 11.7%, p=0.20). However, 
they indicated that sPTD patients in their research had a higher mean blood glucose 
result in the OGTT (114± 16 mml/l vs. 106± 14 mml/l, p= 0.001), and a lower proportion 
of patients with well-controlled glucose levels (35% vs. 54%, p= 0.004), when compared 
to GDM patients who had term birth. GDM patients who had sPTD were likely to have 
fewer prenatal visits, although the result was not statistically robust (6.2± 1.3 times vs. 
7.7 ± 2.2 times, p= 0.08). Moreover, the rate of insulin use was comparable between 
GDM patients who had preterm deliveries and GDM patients who had term birth (47% 
vs. 50%, p= 0.22) (277). Bar-Hava and colleagues also demonstrated that the incidence 
of sPTD among GDM patients was similar to the non-diabetic population (6.2% vs. 6.5%, 
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p= 0.82). They also stated that there was no statistical difference in the proportion of 
patients who had poor glycaemic control, defined as a mean blood glucose level higher 
than 6.1mmol/l, between GDM patients who had sPTD and GDM patients who had term 
birth through the entire treatment period (26.6% vs. 31.2%. p= 0.83), as well as the week 
preceding delivery (40% vs.17.9%, p=0.28). However, patients in this study generally had 
relatively good glucose control, based on their low mean blood glucose, which might 
explain the inconsistent results. Moreover, the sample size in this study was also 
relatively small (34 sPTD patients) (278).  
In conclusion, the overall rate of preterm birth is increased among GDM 
patients. It is still controversial whether GDM patients have an increased risk of 
spontaneous preterm birth. However, the rate of sPTD might be associated with the 
severity of glucose intolerance and glucose control during pregnancy.  
 
                   1.4.2.3 Rate of caesarean section (CS) 
Caesarean section is defined as the delivery of a baby through surgical incision 
in the abdomen and uterus. It is also known as an intervention used to reduce the risk 
of obstructed labour and the adverse complications associated with it, such as shoulder 
dystocia (279). Just like any surgical procedure, CS has its own side effects. For mothers, 
it is directly associated with several unpleasant outcomes, including wound infection and 
dehiscence, postpartum infection, postpartum haemorrhage, urinary and 
gastrointestinal injuries and deep venous thrombosis (280, 281). Furthermore, CS for a 
current pregnancy, increases the likelihood that CS will become necessary in subsequent 
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pregnancies, and increases the risk of malpresentation, placenta praevia, antepartum 
haemorrhage, placenta accreta, prolonged labour, uterine rupture, small for gestational 
age babies, and in the worst case scenario, unexplained stillbirth (282). There are also 
fetal risks related to CS. The incidence of transient tachypnoea of the newborn born was 
about three times higher among babies born to CS compared to those who went through 
vaginal birth (283).  The increased risk of respiratory distress syndrome was also reported 
among neonates after CS; however, having labour before CS lowers the risk of respiratory 
distress syndrome. The OR was 2.6 (95% CI 1.3 – 2.8) without labour and 1.9 (95%CI 2.2-
2.9) with labour (284, 285). Children born to CS may have a higher risk of developing 
allergies, asthma, type 1 diabetes and malignancies in the future (286). 
Evidence from different studies indicate that untreated GDM increases the 
risk of CS. Langer and colleagues demonstrated that the overall risk of CS increased 2-
fold for untreated GDM patients, compared to non-diabetic mothers, and the risk was 
further increased to 4-fold for GDM patients with LGA babies (148). Similar results were 
demonstrated by Naylor et al in the Tri-Toronto Hospital Gestational Diabetes Project. 
They found the rate of CS in the untreated GDM group was higher than in the 
normoglycaemic controls (29.6% vs. 20.2%, p=0.02) and this increase could be attributed 
to the increased rate of macrosomia (28.7% vs. 13.7%, p<0.001) (287). The most decisive 
evidence comes from the HAPO study; the authors found that after adjustments for 
maternal BMI and other confounders, elevated fasting glucose level (OR 1.11 95% CI 
1.06-1.15), 1-hour glucose level (OR 1.10 95%CI 1.06-1.15), 2-hour glucose level (OR 1.08 
95%CI 1.03- 1.12) were all related to increased risk of primary CS. Importantly, in the 
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HAPO study, the results of OGTT were blinded to both the care providers and the patients, 
which excluded the influence of subjective bias on decision making, as well as the 
patients themselves (81). 
However, the relationship between treated GDM and the rate of CS is still 
controversial. Landon and collaborators conducted a large randomized study to examine 
the effects of GDM treatments. They demonstrated that GDM treatment could reduce 
the risk of CS among GDM patients (26.9% vs. 33.8%, p=0.02) (261). However, in another 
study assessing the efficacy of GDM treatment, Crowther and colleagues found that the 
risk of elective CS was comparable between GDM patients who received intervention 
and GDM patients who had routine care (15% vs.12%, p= 0.33), as well as the rate of 
emergency CS (16% vs.20%, p= 0.31) (288). Moreover, Naylor et al demonstrated that 
although treatment of GDM normalized the babies’ birth weights, the rate of CS was still 
increased after adjustments for potential confounders (OR 2.1 95% CI 1.3-3.6) when 
compared to the normoglycaemic controls, and the risk was comparable to the 
untreated group (33% among treated GDM patients vs. 29.6% among un-treated GDM 
patients). The author concluded that the awareness of GDM may lower the threshold for 
surgical delivery (287). Similar results were found in a recent study; Gorgal et al 
demonstrated that patients treated for GDM have an increased risk of having non-
elective CS compared to glucose tolerant women after adjustments for maternal age, 
pre-pregnancy BMI, gestational weight gain, previous caesarean section, gestational age 
at delivery and birth weight (adjusted RR 1.52 CI 1.06- 2.16). Given the similar rates of 
fetal distress and failure to progress in both GDM patients and the control group, 
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researchers suggested that GDM might modify obstetrical practice and increase the risk 
of CS (289).  
In conclusion, the rate of CS is increased among untreated GDM patients. 
Whether the treatment of GDM could reduce the risk of CS was controversial. However, 
awareness of GDM might lower the threshold for CS.  
 
1.4.2.4 Other maternal complications during pregnancy 
There is increased risk of other maternal complications during pregnancy, for 
example, operative vaginal delivery and psychological problems. However, these 
complications have not been fully analysed and are less frequently reported in the 
literature. 
1) Operative vaginal delivery 
Operative vaginal delivery was defined as the application of forceps or 
vacuum extractors during the second stage of labour (290). The association between 
operative vaginal delivery (OVD) and GDM has not been comprehensively analysed. 
Kristina et al found a comparative risk of OVD between untreated GDM patients and 
non-diabetic women (19% v.s.19%, p> 0.05) (291). In another study that compared the 
outcomes of glucose-tolerant women with patients who had gestational impaired 
glucose tolerance (a fasting glucose level <6.7 mmol/l and a 2-h glucose level of the 
OGTT in the 9.0-11.0 mmol range) but were not treated, the risk of OVD was also similar 
between the two groups (7.5% vs. 7.9%, p>0.05) (184). Similar results were reported in 
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terms of the risk of OVD among GDM patients with treatment. Svare et al demonstrated 
a comparable rate of OVD between treated GDM patients with non-diabetic women (7% 
vs. 10%, p>0.05) (292). However, there are also contradictory results in the literature. In 
a recent large population-based cohort study conducted in Sweden, authors found that 
the rate of OVD was lower in the treated GDM group, compared to non-diabetic women 
(5.5% vs.6.6%, p<0.001) (84). Conversely, in an Australian population-based study, 
authors found that the risk of OVD was higher in the treated GDM group compared to 
non-diabetic women after adjustment for the high prevalence of macrosomia (28.7% vs. 
41.0%, OR 1.4, 95% CI 1.4-1.7) (293). 
Furthermore, GDM was associated with an increased risk of failure in OVD. 
Sameer et al conducted a population-based case control study to determine the risk 
factors of failed OVD. They demonstrated that, after controlling for macrosomia, GDM 
was still associated with an increased risk of failed OVD (OR 1.54 CI 1.13- 2.10) (294). 
 
2) Perineal injuries  
Perineal injuries are classified into degrees, depending on the anatomical 
structures involved, from first degree (injury to perineal skin only) to fourth degree 
(injury to perineum involving the anal sphincter complex and anal epithelium) (295). The 
relationship between GDM and perineal injuries is controversial. In a population study 
in Australia, the authors found that the risk of third and fourth degree perineal tears 
were higher among GDM patients compared to non-diabetic women (1.9% vs. 1.3%, OR 
1.43, 95%CI 1.24-1.65) (147). Similarly, in Saudi Arabia, researchers found an increased 
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risk of perineal lacerations in GDM patients compared to non-GDM women (18% vs. 
10.7%, p<0.001) (296).  
However, this association was not confirmed in other studies. Adams 
demonstrated comparable risk of rectal injury between women with unrecognized GDM 
and non-diabetic women (291). In the Toronto Tri-hospital Gestational Diabetes Project, 
researchers also demonstrated that there was no statistical difference in terms of the 
risk of perineal injuries between treated GDM patients and non-diabetic controls (287). 
 
3) Post-partum Haemorrhage 
Post-partum Haemorrhage is normally defined as maternal blood loss more 
than 500 ml within the 24 hours following childbirth (297). The relationship between 
GDM and post-partum haemorrhage has not been fully evaluated. According to a recent 
large population-based cohort study in Denmark, post-partum haemorrhage was similar 
between the GDM group and the non-GDM control population (298). In Australia, 
researchers demonstrated that the risk of post-partum haemorrhage was comparable 
between GDM patients and non-GDM women (6.3% vs. 6.0%, OR 1.06, 95%CI 0.99-1.13) 
(147).  
Similarly, the treatment of GDM did not reduce the risk of post-partum 
haemorrhage. Crowther el at found that the rate of post-partum haemorrhage (> 600 
ml) was comparable between the intervention GDM group and the routine-care GDM 
group (6% vs. 6%, p=0.86) (288).  There is no difference in the risk of post-partum 
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haemorrhage between GDM patients who were treated with metformin and patients 
who were treated with insulin (299). 
 
4) Psychological problems 
A diagnosis of GDM has a significant influence on women’s perception of 
health, pregnancy experience and may create psychological problems. Nolan et al 
interviewed women who had type 2 diabetes and GDM during pregnancy, and 
demonstrated three primary themes regarding their health concerns, including concern 
for the infants, concern for self and sensing a loss of personal control over their health 
(300). Rumbold and co-workers conducted a survey to evaluate the experience of 
pregnant women after being screened for GDM. They found that patients who had 
positive screen results had lower health perceptions (p< 0.005), were less likely to rate 
their health as “much better than one year ago” (p<0.005) and were more likely to only 
rate their health as “fair” compared to pregnant women who had negative results. 
However, no differences were found in levels of anxiety or depression between the two 
groups (301). An American study indicated that GDM diagnosis was associated with an 
increased level of anxiety and depression throughout pregnancy and six weeks 
postpartum (302). Interestingly, in a longitudinal prospective study, researchers found 
that the GDM group had significantly higher anxiety scores at the beginning of the 
treatment for GDM, but the scores became comparable to the non-diabetic group at 36 
weeks or 6 weeks postpartum (303). Researchers from the Australian Carbohydrate 
Intolerance Study in Pregnant Women (ACHOIS) also revealed that glucose intolerant 
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patients who underwent intensive intervention had lower rates of depression and 
improved health-related quality of life, compared to those who had routine obstetric 
care (304). 
The results regarding the patients’ experiences of treatment were 
inconsistent. Carolan and colleagues found that most GDM patients spoke of the 
challenge of implementing a complex regimen of blood testing and dietary manipulation 
within a very short time frame, while they were still in shock from the GDM diagnosis. 
Instead, GDM patients found treatment via the use of insulin an easier option, compared 
to dietary control alone. They were happy to start insulin treatment as they felt that it 
made their task more achievable (305). Conversely, Melinda and collaborators indicated 
that GDM patients treated with insulin were more likely to experience shock, fear or 
anxiety (306). 
 
1.5 Long term complications of GDM 
There is an increased risk of developing metabolic abnormalities, 
cardiovascular problems and other diseases among GDM patients and their offspring.  
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                   1.5.1 Neonatal long term complications 
1.5.1.1 Metabolic abnormalities: obesity, type 2 diabetes, and metabolic 
syndrome 
The association between maternal diabetes during pregnancy and increased 
risk of metabolic abnormalities in offspring has been demonstrated by a number of 
studies, using various methodologies. A study focused on the Pima Indians of the Arizona 
population, who had very high levels of obesity, type 2 diabetes and gestational diabetes, 
provided convincing evidence of the aforementioned link between maternal diabetes 
and metabolic abnormalities in offspring. Diabetic diseases during pregnancy include 
pre-existing type 1 and type 2 diabetes and gestational diabetes, and gestational 
diabetes accounts for the majority (about 88% gestational diabetes, 7% type 1 diabetes 
and 5% type 2 diabetes) (307). In this population, babies of diabetic mothers had a 
higher prevalence of obesity at 15 to 19 years of age, as compared to babies of pre-
diabetic and non-diabetic mothers, even for the babies who had normal birth weight 
(307, 308).  
In order to exclude genetic and postnatal maternal lifestyles influence, sibling 
studies were performed. Offspring of diabetic mothers showed higher mean BMI and 
risk of type 2 diabetes compared to their siblings born before their mothers were 
diagnosed with diabetes. Further, there was no association between paternal diabetes 
around the time of their partner’s pregnancy and the offspring’s BMI or the risk of 
diabetes (308). These results showed that in the Pima Indian population, the increased 
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risk of obesity and diabetes in the offspring of diabetic mothers was at least partially due 
to intrauterine exposure mechanisms.  
This association has also been confirmed by studies in other populations. In a 
large epidemiologic study including more than 280,000 Swedish males, the authors 
found an average 0.94 kg/m2 BMI higher in subjects whose mother had either GDM or 
overt diabetes during their pregnancy, compared to their brothers born before their 
mothers were diagnosed with diabetes (309). A recent study analysed the relationship 
between maternal GDM and female offspring adiposity. The results indicated that 
maternal GDM increased the risk of childhood adiposity in female offspring. Moreover, 
the risk of adiposity was also increased if the mother was overweight (310). 
Metabolic syndrome is defined as central obesity, plus any two of four 
additional factors: elevated triglyceride level, reduced HDL-cholesterol, 
hypertension/elevated blood pressure, or elevated fasting plasma glucose (311). In Pima 
Indians, a diagnosis of diabetes in the mother was strongly associated with elevated 
systolic blood pressure in the offspring (312). In another study in Denmark, researchers 
compared adult offspring of women with diet-treated GDM, women with type 1 
diabetes and offspring from the normal population, and found that the risk of metabolic 
syndrome increased 4-fold in the offspring of GDM mothers and 2.5-fold in the offspring 
of mothers who had type 1 diabetes. The offspring’s risk of the metabolic syndrome 
increased in parallel with increasing maternal fasting blood glucose and 2-h blood 
glucose (313). However, in an American study, researchers demonstrated that only the 
LGA offspring of diabetic mothers had an increased risk of metabolic syndrome in 
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childhood; this increased risk was not found in LGA offspring of non-GDM mothers, 
appropriate–for–gestational age (AGA) offspring of GDM mothers and AGA offspring of 
non-GDM mothers (314). 
Epigenetic modifications may explain the association between maternal 
diabetes during pregnancy, and increased risk of metabolic disease of the offspring in 
their later lives, since such modifications are generally assumed to moderate gene-
environment interactions (315). Among these modifications, DNA methylation of 
specific sequences is best understood. The affected genes include the leptin gene 
promoter (316), the adiponectin gene promoter (317),  mesoderm-specific transcript 
(MEST) (318) and others. Research also showed that reduced circulating cord blood 
endothelial colony-forming cell (ECFC) numbers and premature ECFC senescence may 
predispose infants born to diabetic mothers to develop endothelial dysfunction and 
hypertension (319). 
 
1.5.1.2 Cognitive ability  
Whether maternal pregnancy diabetes will adversely affect offspring 
cognitive development is still controversial. The offspring of diabetic mothers, not 
specific the type of maternal diabetes, were found to have higher rate of memory 
deficits (age 1) (320), higher rate of attention deficits, lower cognitive scores, lower gross 
and fine motor achievements at younger age (321), higher army rejection rates (322), 
higher risk of not completing compulsory schooling (age 16) (323), and lower IQ score 
(age 9)(324). Aberrant lipid metabolisms, such as third-trimester plasma β-
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hydroxybutyrate and free fatty acid in GDM mothers were found to be associated with 
poorer intellectual performance and psychomotor development in offspring (325). 
However, researchers in India failed to prove the association between 
maternal GDM and poorer cognitive ability in their offspring, when assessed for learning, 
reasoning, verbal ability, attention, and concentration (326).  Interestingly, in a Swedish 
sibling study, subjects whose mother had pregnancy diabetes had, an IQ that was lower 
on average than subjects whose mothers did not had diabetes in pregnancy (OR -1.36,95% 
CI -2.12, -0.60), in non-siblings. But in siblings, offspring exposed to maternal diabetes 
in pregnancy did not show a significant difference in IQ score compared to their non-
exposed siblings. This finding suggested that exposure to diabetic milieu could not fully 
explain the observed decrease in offspring cognitive abilities (327). 
 
1.5.1.3 Other complications 
Researchers found an increased risk of malignant neoplasm in children 
prenatally exposed to maternal type 2 diabetes, but found no relation to paternal 
diabetes. The authors suggested the risk of malignant neoplasm later in life may to some 
extent be programmed by a suboptimal intrauterine environment associated with 
maternal diabetes (328). Similarly, studies showed an increased risk of hospitalization 
for neoplasms in children (up to 10 years old) born to the mothers who had pre-existing 
diabetes, but no increased risk was observed for children of GDM mothers (329). 
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Researchers also indicated that children born to GDM mothers (OR 1.20 95% 
CI 1.11-1.28), and children born to the mothers who had pre-existing diabetes (OR 1.56 
95% CI 1.43-1.70) had an increased risk of being hospitalized for infections (329).  
In Pima Indians with type 2 diabetes, their offspring had a higher prevalence 
of elevated urinary albumin excretion (UAE) (58%), compared to the offspring of 
prediabetic mothers (i.e. not diabetic at the time of the pregnancy but whom developed 
diabetes after pregnancy) (43%), and also the offspring of non-diabetic mothers (40%). 
This result suggested that the diabetic intrauterine environment might be independent 
of other susceptibility factors that may lead to nephropathy (330). 
 
1.5.2 Maternal long term complications 
1.5.2.1 GDM recurrence 
The recurrence rate of GDM is high, and previous studies have found rates 
that ranged from 35% to 69%. In a retrospective Canadian study, authors found a 35.6% 
recurrence rate of GDM between 1980 and 1996. Infant birth weight in the index 
pregnancy and maternal pre-pregnancy weight before the subsequent pregnancy were 
predictive factors in multivariate regression analysis (331). An American study indicated 
that the risk of GDM in the second pregnancy among women with previous GDM was 
higher, compared to those without previous GDM (adjusted OR 13.2 95% CI 12.0 – 14.6). 
For the third pregnancy, the highest rate of recurrence was found for patients whose 
first and second pregnancies were all complicated with GDM (adjusted OR 25.9 95% CI 
17.4- 38.4), which means the magnitude of recurrence risk increased with the number 
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of prior episodes of GDM. Researchers also found that Hispanics and Asian/Pacific 
Islanders had a higher risk of GDM recurrence, compared to other ethnicities (332). In 
Australia, a recent study presented a similar rate of GDM recurrence (41.2%). Authors 
concluded that a maternal age over 35 years old, particular ethnicities (Middle 
East/North Africa and Asia), pregnancy hypertension, LGA in infants, preterm birth in 
the first pregnancy, longer inter-pregnancy period, and multiple pregnancies in the 
second pregnancy were all independent predictors of GDM recurrence (333). Higher 
rates of GDM recurrence was reported by Spong et al and Major et al, 68% and 69% 
respectively (334, 335). 
 
1.5.2.2 Type 2 diabetes  
GDM history can increase the risk of developing type 2 diabetes in the future. 
A comprehensive meta-analysis including 20 studies and 675 455 women (10 859 with 
type 2 diabetes) concluded that women with previous gestational diabetes had at least 
a seven-fold increased risk of developing type 2 diabetes in the future, compared to 
women without GDM history. The risk ratio was generally consistent after controlling 
for ethnicity, follow-up time, study design, BMI at index pregnancy, and follow-up BMI 
(336).  The elevated pre-pregnancy BMI, later GDM diagnosis and insulin requirement 
during pregnancy were all risk factors for the development of type 2 diabetes in the 
future (337). Further, Kim et al concluded in another systemic review that the 
cumulative incidence of type 2 diabetes increased markedly in the first 5 years after 
delivery and appeared to plateau after 10 years. Higher fasting glucose level during 
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pregnancy was the most common risk factor for the development of type 2 diabetes 
(338).  
All these risk factors potentially represent the magnitude of the insulin 
resistance, which is a hallmark of developing future diabetes (339). The association 
between GDM and type 2 diabetes has also been supported by genetic analysis. Some 
of the type 2 diabetes-associated genetic variants were also associated with GDM (340, 
341). 
 
1.5.2.3 Cardiometabolic abnormalities 
Women with previous GDM history had a higher risk of developing metabolic 
abnormalities, as well as cardiovascular problems. A recent large meta-analysis, 
including more than 5000 participants (2520 cases and 3312 control) confirmed that 
women with GDM history had almost 4-fold higher risk of developing metabolic 
syndrome (OR 3.96 95% CI 2.98 – 5.26). Interestingly, Caucasian women demonstrated 
a significantly higher chance of having metabolic syndrome after pregnancy complicated 
with GDM than Asian patients (Caucasian OR 4.54 95% CI 3.78 – 5.46; Asian OR 1.28 95% 
CI 0.64 – 2.56). Further, the author found that GDM patients with higher BMI were more 
likely to develop metabolic syndrome compared to the BMI matched group (higher BMI 
OR 5.39 95%CI 4.47 – 6.50; matched BMI OR 2.53 95% CI 1.88 – 3.41) (342).  
To examine the association between GDM history and future cardiovascular 
disease, a scoping review was performed, which included 11 studies until mid-2012. In 
the review, the author stated that previous GDM history is associated with an increase 
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in the risk of cardiovascular disease; however, this association disappeared after 
adjustments for subsequent diagnoses of diabetes (343). Recently, Fadl et al and 
colleagues conducted a large population-based case-control study in Sweden. They 
found that previous GDM history increased the risk of cardiovascular disease 1.5-fold 
(95% CI 1.07- 2.14) after being adjusted for common risk factors for cardiovascular 
disease, including chronic hypertension, smoking, BMI, education level, parity and 
ethnicity. However, a diabetes diagnosis after pregnancy presented an even higher risk 
for cardiovascular disease (OR 4.8 95% CI 3.23- 7.13). The association between GDM 
history and cardiovascular disease lost statistical significance after adjustments for 
postpartum diabetes, excepted for women who were overweight or obese (344). 
Inflammation that is associated with insulin resistance may be a potential link 
between GDM history and subsequent cardiometabolic disease (345). Research 
indicates that high levels of C-reactive protein (CRP) is the mark of cardiometabolic 
diseases (346, 347). Recently, osteoprotegerin (OPG), a soluble member of the tumour 
necrosis factor receptor superfamily that increases inflammation has been linked with 
both cardiovascular disease(348) and metabolic syndrome (349) and further confirmed 
the relationship between inflammation and cardiometabolic abnormalities.  Further, 
research found that small artery function was impaired at 2 years postpartum, in women 
with abnormal glucose levels during pregnancy (350).  
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1.6 GDM treatment 
1.6.1 Rationale for treatment  
As indicated in the HAPO study, higher maternal plasma glucose levels are 
associated with adverse maternal and neonatal complications such as pregnancy-
induced hypertension, macrosomia, and neonatal hypoglycaemia (83). In spite of an 
accumulation of evidence indicating that abnormal lipid profiles of GDM women may 
also play a role in causing these complications, there is still a lack of specific treatments 
for this pathological pathway. The current treatment strategies mainly tackle maternal 
hyperglycaemia through self-monitoring of glucose, diet and exercise, and, if needed, 
pharmaceutical treatment. Several large randomized clinical trials have confirmed the 
effectiveness of GDM treatment. The Australian Carbohydrate Intolerance Study in 
Pregnant Women (ACHOIS) trial was published in 2005. It included 1000 patients with 
mild glucose intolerance who were randomly assigned to receive dietary advice, blood 
glucose monitoring and insulin therapy if needed (the intervention group) or routine 
care in which mothers and their treating clinicians were blinded to the abnormal glucose 
tolerance. The researchers showed that patients in the intervention group had less 
serious perinatal complications with a significantly reduced occurrence of the composite 
outcome of perinatal death, shoulder dystocia, bone fracture, or nerve palsy (1% v.s. 4%, 
p= 0.01). However, patients in the intervention group also had higher rates of induced 
labour (39% v.s. 29%, p<0.001) and similar rates of CS (31% v.s. 32%, p= 0.73), and their 
infants were also more likely to be admitted into NICU (71% v.s. 61%, p=0.01) (260). 
Later, Landon and colleagues conducted another randomized clinical trial to compare 
the outcomes of patients with mild GDM who received routine prenatal care unaware 
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of the diagnosis (control group) with women who had dietary intervention, self-
monitoring of blood glucose, and insulin therapy (treatment group). They demonstrated 
that patients in the treatment group had reduced rates of pregnancy-induced 
hypertension (8.6% v.s. 13.6%, p= 0.01) and a lower rate of CS (26.9% v.s. 33.8%, p= 
0.02). The babies of mothers in the treatment group had lower mean birth weight 
(3302± 502g v.s. 3408± 589g, p<0.001), reduced fat mass (427± 198g v.s. 464±222g, 
p=0.003), lower risk of being LGA (7.1% v.s. 14.3%, p<0.001) and lower risk of being born 
macrosomic (5.9% v.s. 14.3%, p<0.001). However, the frequency of the composite 
adverse outcome that included stillbirth, neonatal death, hyperbilirubinaemia, 
hypoglycaemia, hyperinsulinaemia and birth trauma was comparable between the two 
groups (32.4% v.s. 37.0%,p=0.14) (351). In a recent systematic review, Hartling and 
colleagues concluded that treating gestational diabetes results in a lower incidence of 
preeclampsia, shoulder dystocia and macrosomia. However, there was still insufficient 
evidence to prove that treating GDM would reduce the risk of neonatal hypoglycaemia 
or future adverse metabolic outcomes. The only short-term harm regarding GDM 
treatment that was found was an increased demand for service (352). 
 
1.6.2 Self- glucose monitoring  
GDM patients can be made aware of whether the target glucose levels are 
being achieved or not, through self-measurement of blood glucose. Hawkins and 
collaborators compared the outcomes in diet-treated GDM patients who used personal 
glucose monitors, with those who underwent intermittent fasting glucose evaluation 
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during semi-weekly obstetrical visits. They found that patients in the self-BGL 
monitoring group had significantly fewer macrosomic and LGA infants, and also gained 
less weight (353, 354). These findings support the practice of self-monitoring of BGL for 
women with diet-treated gestational diabetes.  
DeVeciana and colleagues performed a randomized clinical trial to compare 
the outcomes between insulin-treated GDM patients who checked for pre-prandial BGL 
with those who were doing 1-hour post-prandial BGL monitoring. They showed that 
patients using post-prandial BGL measurements had greater HbA1c change (-3.0 ±2.2 
percent v.s. -0.6±1.6 percent, p<0.001); their infants had lower birth weight (3469±668g 
v.s. 3848±434 g, p=0.01), a lower rate of neonatal hypoglycaemia (3% v.s. 21%, p=0.05), 
less risk of being LGA (12% v.s. 36%,p=0.04) and were less frequently delivered by CS 
due to cephalopelvic disproportion (12% v.s. 36%,p=0.04) (355). This study confirmed 
that postprandial glucose levels are more important in terms of predicting neonatal 
adverse outcomes. Based on these findings, a self-monitored BGL regimen including four 
daily glucose checks, performed after fasting and either 1 or 2 hours after each meal was 
recommended (356). Weisz and collaborators conducted a prospective observational 
study and found that GDM patients using one hour postprandial glucose measurements 
had a lower need for insulin therapy (28% v.s. 40%, p<0.05) compared to patients using 
two hour postprandial glucose measurements. Furthermore, even though it was not 
statistically different, patients using one hour glucose measurements had fewer 
macrosomic infants (7.5% v.s. 10.6%), fewer LGA infants (7.4% v.s. 15.2%) and a lower 
rate of CS (24% v.s. 30%) (357). 
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Studies have shown that continuous glucose monitoring could even more 
accurately detect high postprandial blood glucose levels and nocturnal hypoglycaemic 
events, compared to self-monitoring of blood glucose in women with GDM (358). 
However, there is no established evidence regarding the cost-effectiveness of 
continuous glucose monitoring in GDM treatment.  
 
1.6.3 Target blood glucose levels  
Glucose control during diabetic pregnancy is a balancing act between 
hyperglycaemia and hypoglycaemia. Hyperglycaemia leads to LGA babies, but overly 
strict control of maternal glucose levels may initiate frequent maternal hypoglycaemic 
episodes and/or cause SGA babies. The available evidence suggests that mean plasma 
glucose levels around 5.8 mmol should avoid both of these adverse pregnancy outcomes 
(359). 
The optimal therapeutic target levels remain uncertain, due to the lack of 
randomized trials. There is substantial inconsistency regarding the target glucose levels 
in different international guidelines. The most popular target glucose levels are those 
endorsed by ADA, ACOG, Endocrine Society and ADIPS, which stipulates: fasting glucose 
level ≤ 5.3 mmol/l, 1-h postprandial glucose level ≤ 7.8 mmol/l, and 2-h postprandial 
glucose level ≤ 6.7 mmol/l (80, 356, 360, 361). These postprandial glucose levels were 
supported by Veciana and colleagues; they found that achieving these target 
postprandial glucose levels could reduce the risk of neonatal hypoglycaemia, 
macrosomia, and CS (355). Similarly, the fasting glucose target is supported by Landon 
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and collaborators. They found that by using this fasting glucose level as the target 
glucose level, patients had fewer adverse perinatal outcomes (261).  
However, a recent review that included 255 pregnant women with normal 
weight and glucose tolerance from 12 studies, spread over half a century, reported that 
the weighted average glucose values (± 1 SD) were as follows: a fasting glucose level of 
3.9± 0.4 mmol/l, 1-h postprandial equal to 6.0± 0.7 mmol/l, and 2-h postprandial equal 
to 5.5± 0.6 mmol/l. Based on these results, authors proposed that the target glucose 
level for GDM patients should be 4.5 mmol/l for the fasting level, 6.8 mmol/l for 1-h 
postprandial, and 6.1 mmol/l for 2-h postprandial, which is considerably lower than the 
current target glucose levels (362). Similarly, another comprehensive meta-analysis that 
aimed to evaluate the ideal glucose targets for GDM patients recommended a lower 
fasting glucose level for GDM treatment. This meta-analysis included 34 studies, 
enrolled 9433 women, and demonstrated that a fasting glucose target of < 5.0 mmol/l 
was most strongly associated with reduced risk of macrosomia (OR 0.53 95% 0.31-0.90) 
for GDM patients during the third trimester. However, the overall evidence is still 
relatively sparse, and is inconclusive in terms of selecting pre-prandial and postprandial 
targets for GDM treatment (363). A large, prospective randomized trial is needed to 
decide the optimal glucose targets for GDM patients.  
1.6.4 Medical nutrition therapy (MNT) 
MNT is the corner stone of GDM management. The ultimate goals of MNT are 
to allow appropriate weight gain based on the mother’s pre-pregnancy and prenatal 
weight, along with normoglycaemia, adequate fetal growth and absence of urine 
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ketones. An individualized nutritional counselling based on the pre-gestational BMI was 
recommended by the ADA (364). 
There is no definitive evidence that the optimal weight gain for women with 
gestational diabetes is different from that of healthy women; the same 
recommendations for weight gain during normal pregnancy from the Institute of 
Medicine have been endorsed for GDM patients by a number of guidelines. Additionally, 
the ADA discourages weight reduction during pregnancy, in order to avoid ketosis (365, 
366) (See Table 3). 
Table 3 -2009 Institute of Medicine Recommendations for Total Weight Gain and Rate 
of Weight Gain during Pregnancy, by Pre-pregnancy BMI. 
Pre-pregnancy BMI Total Weight Gain (kg) Rates of Weight Gain in 
Second and Third 
Trimester (kg/week) 
Underweight (<18.5 kg/m2) 12.5-18  0.51 (0.44-0.58)  
Normal Weight  
(18.5-24.9 kg/m2) 
11.5-16 0.42 (0.35-0.50) 
Overweight  
(25.0-29.9 kg/m2) 
7-11.5 0.28 (0.23-0.33) 
Obese  
(≥ 30.0 kg/m2) 
5-9 0.22 (0.17-0.27) 
BMI, Body mass index 
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Nutritional recommendations generally include a carbohydrate-controlled 
diet that is sufficient to maintain normoglycaemia and avoid ketosis. Calorie restriction 
is not warranted for underweight or normal-weight GDM patients, as long as fetal 
growth and weight gain targets are met. Overly strict calorie restriction might increase 
ketosis (367) and limited studies have indicated that ketonuria may be associated with 
impaired psychomotor development in the offspring (368, 369). However, the ADA 
suggested that obese women (BMI > 30kg/m2) might benefit from a 30 percent caloric 
restriction (approximately 25 kcal/kg/d), and still achieve the appropriate weight gain 
without ketosis and intrauterine growth retardation (370). 
The composition of the calories to be consumed is also a controversial topic. 
Jovanovic-Peterson and colleagues indicated that a low carbohydrate diet prescription, 
including 40% carbohydrate, 20% protein, and 40% fat that was calculated based on 
body weight was associated with a reduction in macrosomia incidence (371). It was 
reported that a low carbohydrate diet could decrease the need for insulin therapy, the 
incidence of having LGA infants and the rate of CS due to cephalopelvic disproportion 
(372). However, Moreno-Castilla and collaborators performed a randomized trial that 
assigned 152 GDM patients to either a 40 percent or 50 percent daily carbohydrate diet 
and found no difference in pregnancy outcomes (373). Moreover, Roman and colleagues 
found that a higher carbohydrate intake was associated with a decreased incidence of 
newborn macrosomia in GDM patients (374). Despite the inconsistencies in the 
literature, some authorities still recommend a low carbohydrate diet; carbohydrate 
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intake is limited to 35% -45%, and distributed in three small to moderately-sized meals, 
and two to four snacks (20, 375).  
Carbohydrate-rich foods with a low glycaemic index (GI) appear to be 
healthier. In a crossover study, researchers recruited 14 non-pregnant women without 
diabetes, to compare the post-prandial blood glucose levels after a 540 kcal meal 
containing foods from a low GI group and a high GI group. Each meal contained 17% 
protein, 28% fat and 55% carbohydrate, but were different in the GI value (54 v.s. 92). 
They indicated that women in the low GI group had a significantly lower average 
increase in blood sugar (p<0.001) and lower insulin response (p<0.001) (376). Similarly, 
a small crossover study including 5 GDM patients, which aimed to compare the 
outcomes of a low-fat, high- carbohydrate (unrefined) diet (70% carbohydrate, 10% fat, 
20% protein, and 70g fibre each day) with a low-carbohydrate and high-fat diet (35% 
carbohydrate, 45% fat, 20% protein, 70g fibre each day). The authors showed that 
patients who had the low-fat, high unrefined carbohydrate diet, had significant lower 
urinary glucose output (1.3± 1.1 mmol/l v.s. 2.6±3.0 mmol/l, p<0.05), lower fasting 
plasma cholesterol concentration (5.9±1.1 mmol/l v.s. 6.3 ± 1.1 mmol/l, p<0.01) and 
lower fasting free fatty acid level (590±270 µmol/l v.s. 690± 270 µmol/l, p<0.02) (377). 
Moreover, Moses and collaborators demonstrated that GDM patients who consumed a 
low GI diet required less insulin compared to those who had a high GI diet. They also 
found that 9 patients in the high GI group who needed insulin treatment could cease 
insulin use after switching to a low GI diet (378). 
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Maternal lipids including serum triglycerides (TGs), cholesterol, free fatty 
acids (FFAs) were shown to be strong predictors for fetal lipids and fetal growth in GDM 
patients, independent of glycaemic control (379). However, no organization currently 
recommends specific amounts and sources of fat consumption for GDM patients. 
Research indicated that mono-unsaturated fatty acids may be protective for patients 
with impaired glucose tolerance, whereas saturated fatty acid can increase glucose and 
insulin levels in women with GDM (380). A recent systematic review regarding strategies 
in the nutritional management of GDM patients demonstrated that a diet rich in ad 
libitum complex carbohydrates (using higher fibre and lower glycaemic index 
carbohydrates) and limited saturated fats might be optimal in normalizing glycaemia, 
preventing further insulin resistance and reducing excess fetal fat accretion. However, 
the evidence is far from conclusive; larger prospective and randomized trials are 
undoubtedly in need to identify optimal diets for GDM women (381). However, research 
has shown that insulin was necessary to reduce excess birth weight in the offspring of 
obese women with gestational diabetes, regardless of whether the appropriate glucose 
control was achieved (382). 
 
1.6.5 Exercise (physical activity) 
                   Up to 39% of women with GDM could not meet the target BGL only by diet 
treatment (383). Thus, physical activity, as a supplement to diet treatment, has been 
advocated since it can improve insulin sensitivity through increased muscle glucose 
uptake and glycogen synthesis (385, 386).  
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There is insufficient evidence to determine the most appropriate exercise 
regimen for GDM patients. Jovanovic-Peterson and colleagues indicated that a program 
that combined diet treatment and exercise was more likely to achieve normoglycaemia, 
and was also safe for the mother and her baby (384). Dye et al conducted a population-
based study in America and demonstrated that exercise was associated with reduced 
rates of GDM, specifically among women with a BMI greater than 33 kg/m2 (OR 1.9, 
95%CI 1.2-3.1) (385). Bung and colleagues performed a prospective randomized trial to 
evaluate the effectiveness and safety of exercise treatment among GDM women who 
require insulin treatment. Patients in the exercise group had a compliance rate higher 
than 90%. They found that in the absence of ominous fetal heart rate (FHR) changes or 
significant changes in uterine activity following the exercise sessions, regular physical 
activity seemed to be a safe therapeutic option for GDM patients (386). Brankston et al 
demonstrated that compared to a diet-alone group, overweight GDM patients (BMI >25 
kg/m2 ) in a diet-plus-exercise treatment group had lower rates of insulin use and a 
longer delay from GDM diagnosis to the initiation of insulin therapy (387). Based on 
these findings, in 2003, ACOG recommended 30 or more minutes of moderate exercise 
a day on most, if not all days of the week, for GDM patients without medical or obstetric 
complications (375, 388).  
However, there were also studies that demonstrated contradictory results. 
Stafne and colleagues indicated that there were no differences in insulin resistance and 
GDM prevalence, between pregnant women who followed a 12-week standard exercise 
program, and pregnant women who received standard antenatal care. Furthermore, 
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only 55% of women in the exercise group managed to follow the recommended exercise 
protocol. However, these participants had a relatively low average BMI, equal to 
24.8±3.2 kg/m2, which might explain the inconsistency between different studies (389). 
 
1.6.6 Insulin treatment  
Insulin treatment is considered standard therapy in women with GDM, when 
target glucose levels cannot be consistently achieved through nutrition treatment and 
exercise. GDM patients produce insulin endogenously, but cannot meet the increased 
insulin requirement to counter the diabetogenic placental hormones, to maintain 
euglycaemia. A variety of rapid and longer acting exogenous insulin preparations are 
available to supplement the mothers endogenous insulin, so as to reproduce the 
physiological insulin requirements as close as possible in order to accomplish tight 
glycaemic control (390).  
There is no consensus on the glucose levels that signals a necessity for insulin 
treatment. ACOG recommended that insulin should be administrated when fasting 
glucose levels are at 5.3 mmol/l or more, or if 1-h postprandial glucose levels exceed 
7.2- 7.8 mmol/l , or if 2-hour postprandial glucose levels reach or exceed 6.7 mmol/l 
(391). In Australia, prior to recent changes in guidelines (80), insulin replacement was 
indicated if blood glucose targets (a fasting glucose level < 5.5 mmol/l and 2-h 
postprandial glucose level < 7.0 mmol/l) were exceeded on two or more occasions 
within a 1 to 2 week interval, particularly in association with suspicion of macrosomia 
(392). In England, NICE recommends initiating insulin treatment after 1-2 weeks, if 
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lifestyle treatments are insufficient, or if fetal abdominal circumference measurements 
are above the 70th centile at the time of GDM diagnosis (393). 
Insulin treatment could be a combination of intermediate- or long-acting and 
short-and rapid-acting insulin and dose adjustments are based on glucose levels at 
particular times of the day. Regular human insulin and neutral protamine Hagedorn 
(NPH) were the commonly used insulin types. Regular human insulin has been used to 
control the postprandial glucose level. It firstly self-collaborates to form hexamers, and 
then dis-collaborates into the monomeric form that can be absorbed through the 
capillary wall after subcutaneous injection. The slow diffusion into circulation leads to a 
delayed peak action as well as a longer duration of action compared to endogenous 
insulin, which may result in increased risk of post-meal hyperglycaemia and pre-prandial 
hypoglycaemia. NPH is an intermediate-acting insulin, which is used to mimic basal 
insulin secretion. There are also some limitations regarding NPH. The effective duration 
of NPH is about 16-18 h, and thus a single dose is unable to provide basal insulin for a 
full day. Furthermore, night-time injections of NPH may result an un-physiological rise 
in insulin levels in the early morning and increases the risk of hypoglycaemia (394). 
Rapid-acting insulin analogues such as insulin Aspart and insulin Lispro, with less time to 
reach peak action, have been approved by the Food and Drug Administration for use 
during pregnancy.  Studies demonstrated comparable if not better treatment capacity 
and safety between rapid-acting insulin analogues and regular human insulin (395, 396). 
Long-acting insulin analogues including Glargine and Detemir, are also promising (397, 
398). However, a large prospective clinical trial for Glargine has not been performed.   
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A combination of intermediate- and short-acting insulin analogues is mostly 
used to achieve ideal glucose control. Insulin could be administered according to the 
patient’s pattern of glucose concentration during the day; if the fasting glucose is 
elevated, evening NPH insulin injections can be used. If postprandial glucose levels are 
elevated, regular human insulin or rapid-acting insulin analogues can be prescribed. If 
both pre and postprandial glucose levels are elevated, a regimen of four injections, 
including 3 pre-meal short-acting insulin injections and one night NPH insulin injection 
could be implemented (399). Although the basal-bolus regimen more closely mimics 
physiological insulin secretion, the regimen itself is complicated and difficult to follow. 
Research has shown that there is an inverse relationship between patient compliance 
with treatment and regimen complexity (400). Premixed insulin formulations are 
produced by including a rapid-acting insulin analogue for prandial coverage and its 
protaminated counterpart for basal coverage, in formulations that are available in 
different ratios (30/70, 25/75 and 50/50). These premixed formulations can reduce the 
number of insulin injections to twice a day. However, an open label, randomized trial 
which compared the level of glycaemic control and perinatal outcomes between 
diabetic patients (the majority of which are GDM patients) who received insulin four 
times daily (3 injections after meals and 1 injection before bed) with those who received 
insulin twice daily (1 injection before breakfast and 1 injection before dinner), shows 
that GDM patients who received the four-times-daily regimen had better glycaemic 
control and lower rates of overall neonatal morbidity than patients who received the 
twice-daily regimen (401).   
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1.6.7 Oral hypoglycaemic agents  
Traditionally, insulin therapy has been the gold standard for GDM treatment 
if lifestyle treatments were not enough, because a tight level of glucose control could be 
achieved without pharmacological treatment crossing the placental barrier. However, 
insulin therapy is also expensive and invasive. Oral hypoglycaemic agents are less 
invasive, and usually are a cheaper alternative. Oral hypoglycaemic agents also enhance 
the patients’ compliance to GDM treatment, while achieving similar perinatal outcomes 
(353).  
Metformin has its major effect on lowering blood glucose by reducing hepatic 
glucose production. It is also able to slow intestinal glucose absorption and may have 
some additional effect to decrease peripheral insulin resistance (402, 403). However, 
Metformin crosses the placental barrier such that the fetal concentration is at least half 
the maternal level. However, in animal studies, using rats and rabbits, metformin is 
shown to not be teratogenic at doses of up to 600 mg/kg a day, which is equivalent to 
2-6 times higher than the maximum recommended human dose (404). The Metformin 
in Gestational Diabetes (MiG) study was designed to evaluate the effectiveness and 
safety of metformin in the treatment of gestational diabetes. It randomly allocated 751 
GDM patients to open-label treatment with metformin (1000-2000 mg daily) and insulin 
treatment. There was no significant difference in the primary outcomes, which is a 
composite of neonatal complications including hypoglycaemia, respiratory distress, 
hyperbilirubinaemia needing phototherapy, birth trauma, low Apgar score and 
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prematurity. When these adverse outcomes were compared separately, the metformin-
treated group had a lower rate of hypoglycaemia but a higher number of preterm births. 
In the secondary outcomes, only maternal weight gain and treatment satisfaction were 
in favour of metformin. In the metformin group, 168 (46.3%) patients required insulin 
to achieve the ideal glucose level, but the median insulin dose required was lower than 
patients who were treated with insulin therapy only (405). Because of concerns that 
metformin crosses the placental barrier and may affect the babies’ metabolic function, 
the Offspring Follow-Up (TOFU) study was performed. This study aimed to compare the 
fat distribution of children born to women who participated in the MiG trial, at an age 
of 2 years old. The results demonstrated that the body fat percentage is comparable 
between the children of metformin-treated women and the children of insulin-treated 
women. Interestingly, children born to metformin-treated mothers had more fat being 
stored in subcutaneous sites. The authors suggested that a further follow-up is required 
to determine whether children exposed to metformin in the uterus will develop less 
visceral fat, or show any changes in insulin sensitivity (406). 
Glyburide (glibeclamide in Australia) is a second-generation sulfonylurea drug 
that lowers glucose levels by increasing insulin secretion. In vitro placental perfusion 
studies indicated that glyburide does not cross the placenta in significant amounts (407). 
In 2005, Langer and colleagues reported that glyburide concentrations in neonatal 
umbilical cord serum at the time of delivery were below the limit of assay detection 
(10ng/ml) (408). However, in 2009, Hebert and collaborators found that glyburide 
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concentrations in umbilical cord plasma were approximately 70% of the maternal 
plasma concentration, by using a more sensitive assay (409).  
Glyburide treatment might have comparable effects on maternal glucose 
control compared to insulin treatment. In a large clinical study, 404 GDM patients were 
randomly assigned to receive either insulin or glyburide treatment. The results indicated 
that there was no difference in the mean blood glucose measurement and HbA1c level. 
However, 18% of glyburide treated patients could not achieve the target glucose control, 
compared to 12% in the insulin-treated group, but patients in the glyburide group also 
had a significantly lower number of hypoglycaemia episodes (4% v.s. 20%, p= 0.03). The 
rates of preeclampsia and CS were comparable between the two groups (408). In 
addition, researchers demonstrated that glyburide treated GDM patients had less post-
diagnosis weight gain compared to the insulin treated women (410) 
Whether glyburide-treated GDM patients have comparable neonatal 
outcomes compared to insulin-treated patients is still controversial. London et al 
reported that babies born to glyburide-treated women had similar rates of LGA, 
macrosomia, hypoglycaemia, lung complications and NICU admission (408). Conversely, 
other studies reported an increased risk of neonatal hypoglycaemia, macrosomia, and 
NICU admission in infants of GDM patients who were treated with glyburide (411-413). 
A recent meta-analysis was performed to evaluate glyburide management in 
comparison with insulin. The authors indicated that glyburide is as effective and as well-
tolerated as insulin. However, the risk of neonatal hypoglycaemia, high fetal birth weight 
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and macrosomia was higher in the babies born to glyburide treated women. They also 
suggested that a large, long term follow-up study is needed (414).   
Like metformin, not all patients who received glyburide treatment achieved 
target glucose levels. Chmait and colleagues conducted a prospective observational 
study and reported a 19% failure rate in glyburide treated patients. The researchers also 
demonstrated that gestational age at the time of dietary treatment failure, and the 
mean fasting blood glucose level prior to initiating glyburide were the two most 
significant indicators of glyburide success (415). Based on these findings, the Endocrine 
Society recommended that glyburide could be used as an alternative to insulin therapy, 
in GDM patients who failed to achieve the target glucose level after one week of diet 
and exercise, except for those women who were diagnosed with GDM before 25 weeks 
gestation and had fasting plasma glucose levels > 6.1mmol/l (20). 
 
1.6.8 Obstetric issues regarding GDM treatment 
Obstetric surveillance is a key part in the treatment of GDM patients, and 
includes regular cardiotocography (CTG), ultrasound (the measurements of amniotic 
fluid volume, biophysical profile, and umbilical artery Doppler) and fetal movement 
counts. If the results of these tests are not reassuring, more aggressive options may be 
taken, such as a contraction stress test (OCT) or membrane rupture. There is no 
consensus regarding the value or timing of antepartum fetal testing. The ACOG 
recommends fetal surveillance in women with GDM, who display poor glycaemic control 
(375). 
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In spite of monitoring fetal vitality, ultrasound is useful for assessing fetal 
growth, and to provide information vital to the treatment plan. Kjos and collaborators 
have shown that adjusting the insulin level based on a combination of glucose testing 
results and fetal growth ultrasound, could identify pregnancies at low risk, and reduce 
the rate of CS, compared to glucose testing alone (416). Furthermore, ultrasound is also 
used for detection of fetal anomalies.  
The timing and method of deliveries for GDM patients is an important 
obstetric decision. Whether elective induction reduces the risk of shoulder dystocia 
compared to spontaneous labour remains controversial. Kjos and colleagues randomly 
grouped 200 diabetic pregnant women requiring insulin (187 of whom had GDM) at 38 
week of gestation into two groups, a group which had active induction of labour within 
5 days, and a group which had expectant management. They found that expectant 
management increased the gestational age at delivery by 1 week. Patients in the 
expectant management group had similar rates of CS (31% v.s. 25%), but had an 
increased risk of LGA (23% v.s. 10%) and shoulder dystocia (3% v.s. 0%). Based on these 
results, the authors recommended that induced delivery should be considered at 38 
weeks for women with insulin-requiring diabetes during pregnancy. However, this is the 
only randomized controlled trial that compared perinatal outcomes between elective 
induction and expectant management of labour. In a systematic review, including other 
retrospective information, Witkop and collaborators demonstrated that GDM patients 
who went through elective labour induction at term had a reduced rate of having 
macrosomic babies and related complications. However, they also concluded that there 
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was insufficient evidence to recommend induction of labour in GDM patients at 38 
weeks (417). 
It is also not conclusive whether elective CS should be performed on GDM 
patients to avoid obstructed delivery. Garabedian and co-workers conducted a 
systematic review and indicated that as many as 588 CS deliveries in GDM patients with 
an estimated fetal weight ≥ 4250g would be necessary to avoid one case of permanent 
brachial plexus palsy (418). In a retrospective study including more than 16000 pregnant 
women, Ron and colleagues found that elective CS for GDM patients who had an 
estimated fetal weight higher than 4500g had no significant effect on the incidence of 
brachial plexus injury (419). However, the ACOG still suggests that CS should be 
considered in women with GDM whose fetuses have a sonographically estimated weight 
≥ 4500g (375). 
 
1.7 Rationale for this research 
As discussed before, the perfect treatment strategy for GDM is still unknown 
and different institutions have their own treatment systems. In the ACT, Australia, GDM 
patients are categorized into two groups based on whether they can achieve the target 
glucose levels by diet and exercise within one week. Patients who can achieve target 
BGLs with lifestyle treatment only are stratified into a low-risk group and they are 
referred back for usual obstetric care provided by GPs and midwives without further 
appointment with the diabetes team. Alternatively, patients who cannot control their 
glucose level only by lifestyle treatment are stratified into a high-risk group and they 
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attend the Diabetes in Pregnancy Service Multidisciplinary Clinic (DIPS-MDC). During the 
appointment in the DIPS-MDC, high-risk patients are cared for by a team including 
endocrinologists, diabetes educators, dietitians, midwives and obstetricians; the 
majority of these patients require insulin treatment. More detailed information on this 
stratified treatment strategy for GDM patients in the ACT is provided in the research 
setting (Chapter two).  
 
1.7.1 High-risk group patients may have worse perinatal outcomes 
Patients in the high-risk group who are unable to maintain the target BGLs 
through lifestyle changes in one week are assumed to have worse glucose tolerance and, 
therefore, a more severe form of GDM associated with higher rates of other risk factors 
such as obesity and hypertension. Some will also have previously undiagnosed type 1 
and type 2 diabetes.  
This assumption is supported by a previous study that used a similar 
stratification criterion. Wong and collaborators performed a study to examine the 
factors of insulin initiation in GDM patients. Notably, they used the same diagnostic 
criteria of GDM as in this current study, and initiated insulin treatment based on whether 
patients could maintain the target BGL (fasting BGL < 5.3 mmol/l, and 2h BGL < 6.8 
mmol/l) after applying lifestyle changes for one week. Furthermore, this study was 
conducted in NSW, Australia, which means that the ethnic composition of their 
population is more likely to be similar to this study compared to the studies that have 
been conducted in other countries. Overall, the characteristics of the patients in their 
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insulin treated group are quite similar to the high-risk group patients seen in the ACT. 
The author indicated that, compared to the non-insulin treated patients, their insulin-
treated patients had a higher BMI (29.9 ± 7.3 kg/m2 vs. 26.5 ± 6.3 kg/m2, p<0.001), a 
higher rate of having GDM history (25.9% vs. 16.7%, p=0.006), and a higher fasting 
glucose level in the diagnostic OGTT test (5.57 ± 1.19 mmol/l vs. 5.05 ± 0.67 mmol/l, 
p<0.001). Patients in the insulin-treated group were most likely to be Anglo–European 
(30.8% vs. 23.8%) and least likely to be South-east Asian (17.8% vs. 28.4%) (420). 
Moreover, the majority of the high-risk group patients needed insulin 
treatment to achieve the targeted level of glucose control. And, previous studies also 
demonstrated that GDM patients who needed insulin treatment had worse OGTT results 
and higher pre-gestational BMI, and they were more likely to be Anglo-Celtic and less 
likely to be Asian (421, 422).  
Poor OGTT results, higher pre-gestational BMI and particular ethnicity have 
been shown to be associated with adverse perinatal outcomes. The HAPO study 
confirmed that increased levels of fasting glucose, 1-hour postprandial and 2-hour 
postprandial results in the OGTT test were associated with birth weight above the 90th 
percentile, cord-blood serum C-peptide level above the 90th percentile, primary CS and 
clinical neonatal hypoglycaemia (83). For pre-gestational BMI, Jensen and colleagues 
found that after excluding glucose intolerant patients, overweight (BMI 25.0-29.9) and 
obese (BMI > 30) pregnant women were associated with an increased risk of having 
hypertensive complications, CS, induction of labour and macrosomic babies when 
compared to pregnant women with normal weight (BMI 18.5-24.9) (423). This 
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relationship has also been confirmed by other studies (426, 427, 428). Ethnicity is also a 
factor that contributes to the differences in perinatal outcomes. In Australia, Wong and 
colleagues demonstrated that compared to South-East Asians, Anglo-European GDM 
patients had higher rates of CS (28.8% vs. 17.9%, p<0.01), and the babies of Anglo-
European mothers also had higher birth weight (3.38 ± 0.57 kg vs. 3.18± 0.50 kg, 
p<0.001), higher risk of macrosomia (10.8% vs. 3.9%, p<0.01), and higher risk of being 
LGA (12.2% vs. 3.9%, p<0.001) when treated with similar management pathways (424). 
Other studies also demonstrated that compared to Caucasian GDM patients, Asian 
women had lower rates of primary CS (aOR = 0.86, 95% CI 0.77-0.96) and lower rates of 
having macrosomic infants (aOR = 0.58, 95% CI 0.48-0.70) (425). 
In conclusion, patients in the high-risk group might have more risk factors that 
lead to worse perinatal outcomes, such as poor OGTT results and higher maternal BMI.  
 
1.7.2 Low-risk group patients may not necessarily have better outcomes  
However, there may be another side to the story. Firstly, the low-risk group 
of patients receive a lower level of antenatal care compared to the high-risk group; they 
do not have follow-up sessions with the diabetes team and they do not meet 
obstetricians as regularly. Previous studies have indicated that lower levels of antenatal 
care are associated with an increased risk of adverse outcomes. Cao and collaborators 
conducted a study and randomly categorised GDM patients into a group that received 
intensive treatment (including individualized diabetes education, dietary and exercise 
advice, intensive BGL monitoring, frequent clinic visits) and a group that received the 
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standard therapeutic regimen (including group education of diet and exercise, but no 
individualized appointment with a dietitian and diabetes educator and no special clinic 
visit). The diagnostic criteria of GDM and the criteria of insulin treatment initiation was 
the same between both groups. The authors found that patients in the standard 
treatment group had higher risk of preterm birth (8.3% vs. 2.4%, p=0.033), higher 
neonatal birth weight (3.45 ± 0.55 kg vs. 3.26 ± 0.53 kg, p<0.001) and higher NICU 
admission rates (33.3% vs. 21.3%, p= 0.036). Because the rate of insulin use between 
the two groups was comparable, the authors concluded that these suboptimal 
outcomes in the standard treatment groups could be solely attributed to the lower level 
of obstetric care (426). 
Secondly, insulin therapy has been shown to improve some perinatal 
outcomes. Coustan and colleagues conducted a small randomized trial with 61 GDM 
patients, to compare two treatment regimens (insulin plus diet treatment vs. diet 
treatment alone) in 1978. They found that patients treated with insulin had a lower risk 
of having heavy infants (birth weight higher than 3856g) (427). Similar results were 
found in later studies. Thompson and collaborators randomized 108 GDM patients into 
an insulin plus diet treatment group, or a group treated through diet alone, and 
compared the perinatal outcomes between the two groups. The authors demonstrated 
that the infants of insulin-treated mothers had significantly reduced mean birth weight 
(3170 ± 522g vs. 3584 ± 543g, p=0.002), macrosomia rate ( 5.9% vs. 26.5%, p= 0.048), 
and lower ponderal index (2.51 ± 0.39 g/cm3 vs. 2.69 ± 0.28 g/cm3, p= 0.03) (428). 
Buchanan and colleagues also found that the mean birth weight, the percentile of LGA 
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infants and neonatal skin-fold measurements were reduced in insulin-treated GDM 
patients when compared to the GDM patients who were treated with diet alone (429). 
In a systematic review, researchers concluded that a diet plus insulin treatment could 
reduce the risk of having macrosomic babies in GDM patients when compared to 
treatment with diet alone; the risk difference was -0.098 (95% CI -0.168 to -0.028) (430).  
Finally, the treatment efficacy of the low-risk group patients is largely 
dependent on their compliance with self-management of their lifestyle. Previous studies 
have shown that the compliance level to lifestyle treatments is generally not satisfactory. 
Cypryk and collaborators analysed the compliance of GDM patients to the 
recommended diets, and found that the compliance rate was only about 50% (430). 
Ruggiero and colleagues analysed the self-reported compliance with diabetes self-
management in pre-existing diabetic patients during pregnancy. They found that 
achieving compliance with dietary management was more difficult than achieving 
compliance with other management methods including insulin administration and 
glucose testing (431). Similarly, in GDM patients, Carolan et al reported that they 
considered insulin treatment as “an easy option” compared to diet treatment (305). Hui 
and collaborators conducted a case study to find the obstacles facing women with GDM 
to follow dietary advice. They found that 1) personal food preferences conflicted with 
dietary advice; 2) eating in different social environments where food intake is difficult 
to control; 3) lack of knowledge and skills in dietary management and lack of tailored 
dietary planning; and 4) limited time for dietary changes, were all barriers for adherence 
to diet treatment (432). Moreover, research demonstrated that patients treated with 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 101 
 
diet alone may obsessively reduce carbohydrate intake to avoid the initiation of insulin 
treatment. The fear of insulin outweighed the concern of eating unbalanced meals (432).   
In conclusion, patients in the low-risk group may not necessarily have better 
perinatal outcomes than the high-risk group due to the lower level of antenatal care, 
differences in treatment, and potentially lower compliance with lifestyle self-
management.  
  
1.8 Research hypothesis and aims 
1.8.1 Research hypothesis  
Based on the arguments mentioned above, the hypothesis of this research is 
that compared to patients in the high-risk group, who might have worse glucose 
tolerance and other risk factors causing adverse perinatal outcomes, patients in the low-
risk group might not necessarily have better outcomes due to a lower level of antenatal 
care provided, different treatments and uncertainties in compliance with lifestyle self-
management.  
1.8.2 Research aims 
Aim one: To test the accuracy of the current stratification system of GDM 
treatment in the ACT, Australia. By comparing demographic data, medical history, OGTT 
results, and other information from low-risk and high-risk patients, the accuracy of the 
stratification system will be determined by whether it successfully allocates patients 
with better OGTT results and fewer risk factors for adverse obstetric outcomes into the 
low-risk group.  
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Aim two: To access the outcome of the current management of GDM patients 
in the ACT, Australia, especially for low-risk group patients. The treatment strategy for 
the low-risk group will be considered satisfactory if (i) patients in the low-risk group have 
at least as good, if not better, perinatal outcomes compared to patients in the high-risk 
group, and (ii) the rate of perinatal adverse outcomes among both GDM treatment 
groups are not higher when compared to the background population in the ACT and 
other related studies. 
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CHAPTER TWO RESEARCH SETTING AND METHODOLOGY 
2.1 General information about the Australian Capital Territory (ACT) area 
This research includes patients who were diagnosed with gestational 
diabetes mellitus in the ACT and were referred to the ACT Health Diabetes Service for 
education and treatment from 1st January 2010 to 30th June 2014. The ACT Health 
Diabetes Service is primarily located in The Canberra Hospital with three outreach 
community centres, and is responsible for the care of patients with diabetes across the 
ACT. The total area of the ACT is 2358 km², including Canberra, nearby small towns, 
agricultural land and national parks. The ACT has a population that has increased from 
about 361,900 (2010) to 384,100 (2013). Its annual population growth rate is 1.8% (433). 
Within the ACT population in 2013, 28.6% were born in countries other than 
Australia. The largest immigrant populations were from North-West Europe (22.4%) 
followed by South-East Asia (11.9%) and Southern and Central Asia (10.8%). In the ACT, 
the majority of employed people work in professional (29.7%), clerical/administration 
(19.2%) and management (15.8%) occupations (434). 
The number of births was 5152 in 2010, 5121 in 2011, 5461 in 2012 and 5545 
in 2013. The mean age of mothers and fathers in 2013 was 31.6 years and 33.8 years, 
respectively, being the highest of all states and territories in Australia. From the 
Australian Health Survey 2011-2012, almost 63% of people living in the ACT were 
overweight or obese (BMI 25 kg/m2 or more), with the female rate being 54.7% (435). 
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2.2 Pregnancy related health care in ACT 
There are four hospitals that provide maternity services: two are public 
hospitals, The Canberra Hospital and The Calvary Hospital; while the other two are 
private hospitals, the Calvary Private Hospital and the Calvary John James Hospital. For 
women who choose the public health care system during pregnancy, their maternity 
health care is provided by their general practitioners (GPs) and midwives, unless they 
are identified as high-risk patients, for example if they have a poor obstetric history, a 
twin pregnancy or develop complications such as preeclampsia. The high-risk pregnant 
women are referred to the special antenatal clinics and are seen by obstetricians and 
other specialists as required. For women who choose the private health care system, 
their care is provided primarily by private obstetricians.  
Currently, there are three pathology companies in Canberra: ACT Pathology, 
Capital Pathology and Laverty Pathology. Patients are free to choose one company to 
complete their blood and other required tests. If the tests are performed at ACT 
Pathology, ACT health employees can assess their patients’ results through the Clinical 
Information System (CIS) on the ACT Government Intranet. Capital Pathology and 
Laverty Pathology have not incorporated their results into the CIS yet; instead, their 
results are posted and/or faxed to the treating clinicians.  
2.3 Diagnosis of GDM in the ACT 
Within the study period of this research (01/01/2010-30/06/2014), the 
diagnosis of GDM was done through a two-step procedure for the majority of women 
according to the old ADIPS guideline published in 1998 (79). Usually, for the first step, 
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all pregnant women without previously diagnosed diabetes, would take a screening test 
for GDM, called the glucose challenge test (GCT), which was performed between 26-28 
weeks of gestation. The GCT in the ACT involved the measurement of the maternal 
plasma glucose level one hour after the consumption of a 50g glucose load by the 
woman in the non-fasting status. If the result was greater or equal to 7.8 mmol/l, the 
patient would then undergo the second step of screening which was a 75g oral glucose 
tolerance test (OGTT) performed after overnight fasting. The diagnostic criteria for GDM 
based on the OGTT results were a fasting glucose level greater or equal to 5.5 mmol/l 
and/or a 2h glucose level greater or equal to 8.0 mmol/l. However, an early OGTT test, 
without prior GCT, was advocated at any stage during pregnancy if the clinical suspicion 
of GDM was high, such as obesity, previous GDM history and having a previous 
macrosomic baby. In this scenario, if the OGTT results were negative at an early 
gestational stage, this test would be repeated between 26 and 30 weeks of gestation 
(79). By applying this diagnostic strategy, the prevalence of GDM in the ACT increased 
from 49.9 per 1000 people in 2010 to 59.3 per 1000 people in 2011 (263, 441). 
GDM screening could be ordered by GPs, midwives or obstetricians. The 
pathology laboratories released the GCT and OGTT on the same day of testing. For public 
patients, midwives checked the results and informed the patients of their results within 
the week of testing. The midwives (and private clinicians) refer patients with diagnosed 
GDM to the ACT Health Diabetes Service for education regarding GDM to be provided 
by diabetes educators and dietitians. 
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2.4 Stratified care system for GDM in the ACT 
2.4.1 GDM education session (part one): 
After being referred to the ACT Health Diabetes Service, GDM patients 
receive a comprehensive two-part education session provided by a registered diabetes 
educator and a dietitian. This education session is performed in groups of 4-8 patients. 
In the first part, presented by the registered diabetes educator, they are provided with 
information about GDM including causes, potential complications and treatment 
options. Additionally, they are taught how to monitor their own blood glucose levels at 
home. They are asked to monitor blood glucose four times a day: fasting and 2h after 
each of the three main meals. They are also taught to carefully record all the blood 
glucose values in a glucose diary provided by the educators. During this session, the 
women with GDM also complete two forms, the first providing key baseline 
demographic and pregnancy data to the clinical team (GDM Pathway Form), the other 
is a form that registers the GDM diagnosis with the National Diabetes Services Scheme 
(NDSS), which allows women to access subsidised glucose monitoring strips. The most 
recommended glucose meter for GDM pregnancy in the ACT is the ACCU-CHEK Performa 
and ACCU-CHEK Performa Nano produced by Roche (Basel, Switzerland).  
Before 2013, the target blood glucose levels for GDM patients were fasting 
<5.5 mmol/l and 2-h < 7.0 mmol/l. After June 2013, the target blood glucose levels used 
by the ACT Health Diabetes in Pregnancy Service (ACTH-DIPS) were changed to fasting 
<5.3mmol/l and 2h < 6.8 mmol/l after consideration of the suggested tighter targets of 
the Australasian Diabetes In Pregnancy Society (ADIPS) and the results of two 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 107 
 
randomised controlled trials (RCT) conducted by Crowther and colleagues (ACHOIS) 
(288), and Landon and collaborators (261). Those two trials showed benefits of treating 
GDM using target levels close to these values chosen by the ACTH-DIPS. ADIPS has 
suggested tighter targets for the fasting blood glucose level of <5.1 mmol/l and the 2h 
blood glucose level of <6.7 mmol/l, but in the consensus guideline statement 
commented that further research was required before these targets could be fully 
endorsed (80). 
 
2.4.2 GDM education session (part two) 
After a 10-minute break, the dietitians provide the second part of the 
education session. During this session, information and advice regarding medical 
nutrition therapy (MNT) is provided. A wide range of topics are covered, for example the 
appropriate pregnancy rate of weight gain, food safety, adequate intake of macro- and 
micronutrients, and carbohydrate (CHO) counting. The recommended weight gain in 
pregnancy is based on the Institute of Medicine’s Guideline and is dependent on pre-
pregnancy BMI. A weight gain of 12-18 kg is recommended if the patients' pre-
pregnancy BMI is less than 18 kg/m2, gradually reducing to a 5-9 kg weight gain if the 
pre-pregnancy BMI is above 30 kg/m2 (436). Based on the Healthy Eating 
Recommendation of the National Health and Medical Research Council (NHMRC) (437), 
patients are encouraged to take appropriate serves from five core food groups: 
vegetables, fruit, grain foods, lean meat and milk. Patients are taught how to count CHO 
in exchanges (one CHO exchange is equal to 15 grams of carbohydrate) and to spread 
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out their CHO intake within 3 meals and 3 snacks, about 2-4 exchanges per main meal 
and 1-2 exchanges per snack. Further, low Glycaemic Index (GI) foods and low fat intake 
are recommended for their diets. GDM patients are also advised to take enough calcium, 
iron, folate and iodine, from normal food or from supplementation. The consumption of 
caffeine should be minimal and alcohol should be avoided. Food safety (e.g. food 
preparation and the avoidance of raw food) is re-emphasized during the education 
session. Additionally, GDM patients are asked to keep a food record for reviewing 
purposes.  
During the course of this study, an exercise physiologist started to attend 
some second part education sessions along with the dietician to provide advice 
regarding optimal exercise for achievement of glucose control. A 30-minute walk or 
equivalent moderate exercise every day was recommended.  
 
2.4.3 Patient review and stratification into low and high-risk pathways: 
Following the group education sessions (part 1 and 2), the GDM patients are 
requested to follow the lifestyle advice given as best they can and to start self-blood 
glucose monitoring at home to achieve the target blood glucose levels. All women with 
GDM (private and public health systems) are reviewed by a dietitian of the ACTH-DIPS 
within one week of the education sessions 
 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 109 
 
2.4.3.1 GDM patients managed within the private health system 
Patients who choose the private health system are reviewed by an ACTH-DIPS 
dietitian within one week of following the education sessions with the blood glucose 
record book to determine if lifestyle change alone is adequate to control their blood 
glucose. The women also receive individualised dietary advice in this session. The review 
results are communicated to the diabetes educators. If the patients can achieve ideal 
BGL control with diet and exercise changes only, their latest information regarding GDM 
treatment is sent to their obstetrician by diabetes educators and further reviews will be 
booked. If patients, however, are not maintaining target BGL levels, the diabetes 
educators will inform their private obstetricians and the obstetrician will refer these 
patients to a private endocrinologist for consideration for insulin treatment. They will 
then continue the antenatal care with the private obstetrician and endocrinologist, with 
assistance by the ACTH-DIPS diabetes nurse educators and dietitians, but they do not 
come to the ACTH-DIPS-MDC. However, these patients did not give birth in either The 
Canberra Hospital or The Calvary Hospital and their delivery information was not 
available. Thus, they were not included in this study.  
 
2.4.3.2 GDM patients managed within the public hospital system 
Patients who choose public hospital care are similarly reviewed one-to-one 
by an ACTH-DIPS dietitian within one week of the education sessions. They have their 
BGL record book reviewed and receive individualised dietary advice. Patients achieving 
their target BGL are referred back to their previously determined (usual) antenatal care 
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pathway.  Patients who have more than three abnormal glucose readings that cannot 
easily be explained by diet are referred on to the diabetes educators. Then, the diabetes 
educators inform the endocrinologist about the patient’s situation and an appointment 
is arranged for them to attend the Diabetes in Pregnancy Clinic in The Canberra Hospital. 
 
2.4.3.3 Low-risk group  
The low-risk group in this research is comprised of patients who can control 
their glucose level by diet and exercise alone. For these patients, dietitians send a letter 
to their GPs, midwives and obstetricians describing their GDM status and the 
management that has been initiated. These low-risk group patients continue within their 
usual obstetric care pathway from this time, which mean they will not meet the diabetes 
team again unless they have trouble in maintaining target BGLs and are referred back.  
The usual obstetric care pathway in The Canberra Hospital is shared care 
between GPs, midwives and obstetricians. After midwifery preadmission at 12-14 weeks, 
patients will meet their care providers about 8 times during their pregnancies. They will 
have two ultrasounds, one at 11-13 weeks for nuchal translucency checking and another 
morphology ultrasound at 18-20 weeks. They do not meet the obstetrician unless they 
have other risk factors, for example, gestational hypertension, placenta praevia or poor 
obstetric history. They are generally allowed to continue the pregnancies to 10 days 
beyond term if fetal monitoring is reassuring, and they are more likely to have 
spontaneous labour (79). 
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Some of the low-risk patients choose to deliver in the Calvary Hospital. The 
usual obstetric care pathway in The Calvary Hospital is almost the same as in The 
Canberra Hospital, except they have one scheduled appointment with the obstetrician 
at 36 weeks. Based on the BGL level, the obstetrician might arrange a growth scan 
ultrasound. However, the BGL levels are mostly self-reported. Like in The Canberra 
Hospital, care providers in the Calvary Hospital recommend that these patients continue 
their pregnancies up to 10 days beyond term at the latest, if no other risk factors are 
present.  
All patients in this group are asked to contact the ACTH-DIPS if they later have 
more than 3 elevated BSL readings in any 5-day period. Some of these patients initially 
allocated to be low-risk will then be re-stratified into the high-risk category. 
 
                   2.4.3.4 High-risk group  
The high-risk group in this research are patients who cannot maintain their 
target BGLs by lifestyle treatment only on review by the ACTH-DIPS one week after the 
education session. These patients are referred to Multidisciplinary Diabetes in 
pregnancy Clinic (DIPS-MDC), which is attended by endocrinologists, dietitians, diabetes 
educators, midwives, obstetricians and social workers. Therefore, the patients be seen 
by several members of a multidisciplinary team at one single visit. Most of high-risk 
patients who attend the DIPS-MDC start insulin treatment; however, a small number of 
them continue diet treatment. This treatment decision is based on the judgement of the 
endocrinologist after evaluating the whole information available to them on the 
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individual GDM patient. This includes information on the patient’s overall medical and 
obstetric history, BGL record, diet and exercise compliance, stress, and the patient’s 
attitude toward treatment options. Patients who continue diet treatment attend the 
MDC regularly. Some do achieve the target BGL with extra dietary advice and are then 
referred back to usual antenatal care. Others eventually start insulin treatment if their 
glucose levels cannot be adequately controlled even after several extra weeks of lifestyle 
change. For patients who initiate insulin therapy, they attend this clinic every two to 
four weeks. During these visits, endocrinologists check the patients’ glucose levels and 
adjust their insulin dosages accordingly. The oral glucose lowering agent metformin is 
rarely used, and if so, is most often added as an adjunct to insulin therapy. However, 
metformin is occasionally used alone in patients in whom insulin therapy is not an option. 
HbA1c, thyroid function, liver function, kidney function and vitamin D tests are also 
ordered by the endocrinologist. In terms of obstetric care, all these patients are able to 
meet with both obstetricians and midwives, instead of meeting with midwives alone. 
Further, patients who attend DIPS-MDC in the third trimester receive at least one 
growth scan ultrasound, most often at 36 weeks gestation. All the patients are required 
to count fetal movements at home. Fetal Non-stress Test (NST) is not routinely 
prescribed unless abnormal fetal movements or other risk factors are encountered. 
Patients who use insulin treatment, have suboptimal glucose control, or are suspected 
of having LGA babies, are more likely to end their pregnancies earlier at 38-39 weeks by 
induction of labour or elective CS in order to avoid macrosomia and obstructed labour.  
Yan Zhang, Mphil Thesis, 2015 
 
 Page 113 
 
2.4.3.5 Determination of the two different risk groups 
These are the main characteristics of each risk group: 
1) The decision to allocate patients to the low-risk or the high-risk group is 
made based on whether they attended the DIPS-MDC or not. Accordingly, patients who 
went to the DIPS-MDC one or more times and were then referred to the usual antenatal 
care pathway, remained in the high-risk group for the purposes of this study. Patients 
initially designated low-risk and managed in usual antenatal care, but were later 
referred to the DIPS-MDC for elevated BGLs, were also determined to be in the high-risk 
group 
2) The majority of the patients in the high-risk group start insulin treatment; 
however, a small proportion of them continue lifestyle treatment only. Conversely, 
patients in the low-risk group are all treated with diet and exercise.   
3) Compared to the patients in the high-risk group, patients in the low-risk 
group have a lower level of antenatal surveillance. They have less antenatal clinic visits, 
less ultrasounds and blood tests, and are less likely to meet specialists individually 
(obstetricians and endocrinologists, dietitians and diabetes educators) regardless of the 
final treatment (Flow Chart 2). 
Flow chart 2 -The public stratification system for GDM management in ACT Health 
Diabetes service. 
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Patients diagnosed with GDM (ADIPS, 1998):
1. 50g GCT   1h≥ 7.8 mmol/l
2. 75g OGTT    FPG≥ 5.5 mmol/l or/and 2h ≥8.0 mmol/l
Diabetes education sessions:
1. Provided by diabetes educators and dietitians
2. Provides information about GDM, advice regarding diet 
and exercise, and   teaches self-monitoring of blood glucose levels    
Home blood glucose monitoring:
1. During 1 week
2. Target glucose levels:  Fasting < 5.5 mmol/l
2h < 7.0 mmol/l  *
Review by dietitian after 1 week
Divide patients into two groups according to whether they can 
achieve the target blood glucose level by diet and exercise alone.
High Risk Group: **
Attend the Diabetes in Pregnancy 
Multidisciplinary Clinic in The 
Canberra Hospital
Most of them start insulin 
treatment
Higher level of antenatal care
Low Risk Group:
Usual antenatal care, by GPs and 
midwives
Continue self-monitoring of blood 
glucose levels
Healthy diet and exercise reinforced
*Target BGL changed from mid-2013 to: Fasting < 5.3 mmol/l, 2h < 
6.8 mmol/l. 
** Patients who were managed within both pathways (e.g. referred from 
the DIPS-MDC to complete pregnancy in the usual antenatal care 
pathway, or referred from usual antenatal care to the DIP-MDC) were 
determined to be in the high-risk group for the purpose of this study.  
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2.5 Methodology 
This research is a retrospective clinical review of maternal characteristics and 
the pregnancy outcomes of women diagnosed with GDM who have attended the ACTH-
DIPS. Maternal demographic and antenatal clinical information, as well as maternal and 
neonatal pregnancy outcome data were collected from the patient medical records. 
Then, descriptive and inferential statistical analyses were performed.  
 
2.5.1 Ethics approval:  
This research was a low-risk research project, as there was no direct contact 
with patients and de-identified data only has been used and reported. No consent form 
was needed. This research was conducted at The Canberra Hospital and the Calvary 
Hospital. Ethics approvals from the ethics committees of the two hospitals were granted 
before the start of this research.  The Ethics Reference Numbers for this research are 
ETHLR.12.302 for The Canberra Hospital and 28-2014 for the Calvary Hospital. The 
official approval letters are shown in Appendix 1 and Appendix 2.   
 
2.5.2 Subjects:  
2.5.2.1 Inclusion and exclusion criteria:  
The subjects of this research included patients who were diagnosed with 
GDM and referred to the ACT Health Diabetes Service for a GDM education session and 
risk stratification from 01/01/2010 to 30/06/2014. This research recruited patients who 
gave birth at The Canberra Hospital or the Calvary Hospital. If a patient had more than 
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one pregnancy during the research period, each pregnancy was counted as a different 
case. 
Patients who were diagnosed with diabetes before pregnancy were excluded 
because they did not come to the GDM education session. Similarly, GDM patients who 
were referred to the ACTH-DIPS-MDC directly without attending the education session 
and did not go through the stratification process were not involved in this study. 
Unfortunately, the number of patients with pre-existing diabetes and patients who had 
GDM but did not go through the stratification procedure was not available due to the 
data collection strategy: only patients who attended the education session were 
identified.  
Patients who delivered in private hospitals or hospitals outside of Canberra 
were excluded due to the lack of outcome information and heterogeneity of the 
treatment regimen. Multiple pregnancies were excluded from this research due to the 
added risk of complications compared to singleton pregnancies; Pregnancies that ended 
before the full 28 gestational weeks were also removed because GDM is usually 
diagnosed between 26-28 weeks. These patients would have had insufficient time to be 
categorized into either the low-risk or high-risk groups. 
 
2.5.2.2 Medical record searching 
GDM patients in the ACT who were referred to the ACTH-DIPS attended the 
GDM education session either in The Canberra Hospital or at the Gungahlin Community 
Health Centre and their attending records were stored in the ACT Patient Administration 
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System (ACTPAS) and Clinical Record Information System (CRIS) data bases, which were 
assessed for eligibility to the study. The GDM education session was ACTPAS coded for 
The Canberra Hospital as TGDMIG before Jan 2014, which was changed to CHGDGE after 
Jan 2014. The Gungahlin Community Health Centre sessions had the ACTPAS code 
GGDMIG. The records of all women who attended these sessions in the period of 
interest were reviewed and they were included in the study if they met the inclusion 
criteria and none of the exclusion criteria. Allocation to the low-risk or high-risk 
treatment groups for the purpose of this study was also determined by use of ACTPAS 
codes. The low-risk group patients were those who attended TGDMIG, CHGDGE or 
GGDMIG sessions alone. The DIPS-MDC at The Canberra Hospital was coded ANEND and 
ANTEND. So patients who attended one of the education sessions and were also coded 
as attending an ANEND or ANTEND clinics, were categorized to be in the high-risk group.  
  
2.5.3 Data Collection 
2.5.3.1 Electronic medical record systems: 
Four electronic medical record systems have been used in this study.  
        1) Clinical Record Information System (CRIS): 
CRIS contains the scanned copies of the patients’ original medical files, 
including the entire outpatient clinic and hospital admission records to The Canberra 
Hospital. It is maintained by the staff in the medical records department. The currently 
used version is 20.1.10.  
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2) Birthing Outcomes System (BOS) 
BOS has the antenatal, perinatal and postnatal information of patients who 
delivered in The Canberra hospital, as well as the newborns. The midwives are 
responsible for updating it every time patients come to the hospital and receive 
obstetric care. The current used version is BOS 6.02.01. 
3) ACT Pathology Clinical Integration System (CIS)  
CIS provides pathology results of patients who have their tests performed by 
ACT Pathology to authorized clinicians. It can be accessed through the ACT Health 
intranet https:// actpath/cis/cis.dll. 
4) BirthPac  
BirthPac is an obstetrics-reporting package used in the Calvary Hospital. Just 
like the BOS at The Canberra Hospital, it covers information of mothers, births and 
infants and is maintained by the midwives. The currently used version is 1.2.608. 
 
2.5.3.2 Pathological data collection: 
All the pathology data of patients who had their blood tests performed by 
ACT Pathology were collected from CIS by searching their Medical Record Numbers 
(MRNs). This information included GCT and OGTT results. For the high-risk group, 
outcomes of HbA1c, TSH and Vitamin D tests were also extracted. The GCT and OGTT 
results performed by pathology laboratories other than ACT Pathology were collected 
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from the medical records if they were noted by clinicians during clinic visits. 
Unfortunately, some GCT and OGTT results could not be found by all means available.  
 
2.5.3.3 Maternal demographic data collection: 
Maternal demographic information was collected from the ACT Health 
Gestational Diabetes Mellitus Clinical Pathway Form. Each newly diagnosed GDM 
patient is asked to complete this form, regardless of whether they planned to deliver in 
the ACT or not.  The demographic information is based on self-report, including age, pre-
pregnancy weight, height, gestation, parity, previous history of GDM, family history of 
diabetes, smoking status, consumption of alcohol and other medical illnesses including 
hypertension, hypothyroidism, hyperthyroidism, asthma, polycystic ovary syndrome 
(PCOS). The gestational week when a patient completed this form was used as the GDM 
diagnosed time. The gestational week was calculated based on the date of the last 
normal menstrual period often confirmed by an early week ultrasound, or by a dating 
ultrasound if the menstrual history was unreliable.  
Gestational week at first appointment and country of birth were collected 
from either the BOS Antenatal Assessment section if delivered at The Canberra Hospital 
or the Event Summary Form from the BirthPac system if delivered at the Calvary Hospital. 
Due to the nature of self-reporting, this part of the data is less reliable. 
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2.5.3.4 Outcome information collection at The Canberra Hospital 
1) Maternal complications:  
The diagnoses of maternal complications that related to GDM were collected 
from the Maternal Admission Summary Form in CRIS and the Antenatal Summary in BOS. 
In order to achieve the greatest accuracy, all the notes of ANEND and ANTEND clinics 
were reviewed. Maternal complications were also recorded if noted by the doctors 
during the clinic visits. 
These complications included gestational hypertension (GH), preeclampsia 
(PE). The diagnostic criteria of these complications at The Canberra Hospital were the 
same as outlined in the latest guideline from The Royal Australian and New Zealand 
College of Obstetricians and Gynaecologists (RANZCOG). GH was defined as new onset 
of hypertension (≥ 140 mmHg systolic or ≥ 90 mmHg diastolic) after 20 weeks gestation. 
PE was classified as newly developed hypertension after 20 weeks gestations combined 
with existence of at least one of the following new-onset conditions, including 
proteinuria (spot urine protein/creatinine ≥30 mg/mmol or ≥ 300 mg urinary 
protein/day or at least 1 g/L on urine dipstick testing), other maternal organ dysfunction 
and uteroplacental dysfunction (438).  
 
2) Delivery information: 
The intrapartum information was collected from the neonatal sections of BOS, 
as well as Birth Summary Forms, ACT Midwives Data Collection Forms and Discharge 
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Summary Forms from CRIS. This information included onset of delivery (spontaneous 
onset, induction and no labour), mode of delivery (spontaneous labour, induced labour, 
elective CS and emergency CS), method of birth (normal birth, forceps, vacuum and CS), 
reasons for elective CS and emergency CS, perineal status including sutured status, 
gestational week of delivery, after delivery bleeding, length of hospitalization (after 
delivery), presence of the meconium and shoulder dystocia. Shoulder dystocia was 
defined as a vaginal cephalic delivery that requires additional obstetric manoeuvres to 
deliver the fetus after the head has delivered and gentle traction has failed (439).  
 
                   3) Neonatal information: 
Neonatal information was collected from the same documents as delivery 
information. It included birth status (live and stillbirth), Apgar score, gender, birth 
weight, birth length and admission to Neonatal Intensive Care Unit (NICU) and/or Special 
Care Nursery (SCN). The diagnoses of neonatal hypoglycaemia, neonatal jaundice and 
neonatal respiratory distress were recorded if mentioned. 
Neonatal hypoglycaemia was defined as blood glucose level less than 2.6 
mmol/l. The diagnoses of neonatal jaundice were based on yellow colouration of the 
skin and the sclera caused by a raised level of bilirubin in the circulation. Respiratory 
distress was defined as having grunting, flaring or retractions and/or respiratory rate 
outside the normal range (40-60 times per minute) (440). 
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4) NICU and SCN admission information 
The Medical Record Numbers (MRNs) of infants who were admitted into NICU 
and SCN were extracted from the mothers’ medical records. By searching these MRNs, 
a new research group, infants in NICU (SCN) was generated. The information regarding 
diagnoses and treatments of these neonates were collected from the Department of 
Neonatology Centenary Hospital Discharge Summary Forms in CRIS. Also, the reason for 
admission, the length of hospitalization, main diagnoses and treatments were recorded 
from these records.  
Based on the local policy, infants with BGLs less than 1.5 mmol/l were 
admitted into the NICU immediately for intravenous infusion of 10% dextrose. If BGLs 
were in the range of 1.5-2.0 mmol/l, NICU or SCN admissions were considered for 
initiation of 2 hourly supplementary feeds. Jaundiced infants requiring peripheral IV 
fluids and closer monitoring were also admitted in to NICU/SCN. The decision between 
treatments with phototherapy or exchange transfusion was made based on the 
guideline for Serum Bilirubin (SRB) levels and outcomes of phototherapy (Appendix 3). 
For infants with respiratory distress, those requiring crib oxygen, up to 25% or low flow 
oxygen were admitted into SCN, while those who needed continuous positive airway 
pressure (CPAP) or high flow oxygen were nursed in the NICU. Mechanical ventilation 
was indicated for infants managed with CPAP treatment if one of the following situations 
occurred: significant respiratory distress, respiratory failure (pCO2 > 55mmHg) or 
progressive hypoxaemia [despite fraction of inspired oxygen (FiO2) up to 0.6].  
 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 123 
 
2.5.3.5 Outcome information collection at the Calvary Hospital 
1) Maternal Complications: 
The diagnoses of maternal complications related to GDM were collected from 
the Antenatal Notes sections in the BirthPac system. These complications include GH 
and PE.  
Based on the local policy of the Calvary hospital, GH was diagnosed as 
hypertension arising in pregnancy after 20 weeks gestation without any other feature of 
a multi-system disorder. The diagnostic criteria for preeclampsia were: hypertension 
arising after 20 weeks gestation and the new onset of one or more of the following 
situations: proteinuria, renal insufficiency, liver disease, neurological disturbances or 
haematological disturbances.  
 
2) Delivery information 
The Event Summary Form and the Discharge Summary Form in the BirthPac 
system provided the delivery details. This information included onset of delivery 
(spontaneous onset, induction and no labour), mode of delivery (spontaneous labour, 
induced labour, elective CS and emergency CS), method of birth (normal birth, forceps, 
vacuum and CS), reasons for elective CS and emergency CS, perineal status including 
sutured status, gestational week of delivery, after delivery bleeding, length of 
hospitalization (after delivery), presence of meconium and shoulder dystocia. 
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3) Neonatal information 
The Mother’s Infant section in the BirthPac system provides general 
information about the newborn. Data regarding birth status (live and stillbirth), Apgar 
score, gender, birth weight, birth length, admission to NICU and/or SCN, neonatal 
morbidities and treatments were collected. However, the detailed medical records of 
neonates admitted into the NICU or SCN were not available in the BirthPac system.  
Based on the local policies of the Calvary hospital, neonatal hypoglycaemia 
was diagnosed as a blood glucose level of 2.5 mmol/l or below. The neonates were 
admitted to SCN if their BGL was less than 2 mmol/l. Intravenous treatment with 10% 
Dextrose was indicated for BGLs of <1.6 mmol/l. Neonatal jaundice was diagnosed based 
on yellow discoloration of infants’ skin and sclera, caused by increased bilirubin level. 
Jaundiced infants requiring peripheral IV fluid therapy and closer monitoring were sent 
to the SCN. Treatment for jaundice was based on the SRB and was recorded in Neonatal 
Phototherapy Record charts. Respiratory distress was defined as having grunting, flaring 
or retractions and/or respiratory rate outside the normal range (40-60 times per minute). 
The infants requiring oxygen therapy were admitted to the SCN. Severe cases were 
transferred to the NICU at The Canberra Hospital (See table 4). 
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Table 4 -Data collection from the medical record system  
 For patients in the 
Canberra hospital 
For patients in the 
Calvary Hospital 
Maternal demographic data 
Age GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
weight GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
height GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
gestation GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
parity GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
GDM history GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
Family history 
of diabetes 
GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
smoking GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
alcohol GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
medical issues GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
gestational 
week when diagnosed 
with GDM 
GDM Clinical Pathway 
Form in CRIS 
GDM Clinical Pathway 
Form in CRIS 
Gestational 
week at first appointment 
Antenatal Assessment in 
BOS  
The Canberra Hospital 
Event Summary Form in 
BirthPac 
the Calvary Hospital 
Country of birth Antenatal Assessment in 
BOS  
The Canberra Hospital 
Event Summary Form in 
BirthPac 
the Calvary Hospital 
Maternal Pathology Data 
HbA1c CIS/Clinic-visit notes CIS/Clinic-visit notes 
TSH CIS/Clinic-visit notes CIS/Clinic-visit notes 
Vitamin D CIS/Clinic-visit notes CIS/Clinic-visit notes 
GCT CIS/Clinic-visit notes CIS/Clinic-visit notes 
OGTT CIS/Clinic-visit notes CIS/Clinic-visit notes 
Maternal Outcomes Information 
GH Maternal Admission 
Summary Form 
Antenatal Notes in 
BirthPac 
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ANEND and ANTEND 
Clinic Notes in CRIS/ 
Antenatal Summary in 
BOS 
PE Maternal Admission 
Summary Form 
ANEND and ANTEND 
Clinic Notes in CRIS/ 
Antenatal Summary in 
BOS 
Antenatal Notes in 
BirthPac 
onset of delivery Birth Summary Form/ 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Event Summary Form/ 
Discharge Summary Form 
in BirthPac 
mode of delivery Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Event Summary Form/ 
Discharge Summary Form 
in BirthPac 
method of birth Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Event Summary Form/ 
Discharge Summary Form 
in BirthPac 
reason for emergency CS 
and elective CS 
Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Event Summary Form/ 
Discharge Summary Form 
in BirthPac 
perineal status including 
sutured status 
Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Event Summary Form/ 
Discharge Summary Form 
in BirthPac 
gestational week of 
delivery 
Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Event Summary Form/ 
Discharge Summary Form 
in BirthPac 
after delivery bleeding Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Event Summary Form/ 
Discharge Summary Form 
in BirthPac 
length of hospitalization Birth Summary Form Event Summary Form/ 
Discharge Summary Form 
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ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
in BirthPac 
meconium stained liquor Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Event Summary Form/ 
Discharge Summary Form 
in BirthPac 
shoulder dystocia Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Event Summary Form/ 
Discharge Summary Form 
in BirthPac 
Neonatal Outcome Information 
Birth status Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Mother’s infants  
in BirthPac 
Apgar score Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Mother’s infants  
in BirthPac 
gender Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Mother’s infants  
in BirthPac 
birth weight Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Mother’s infants  
in BirthPac 
birth length Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Mother’s infants  
in BirthPac 
admission to NICU/SCN Birth Summary Form 
ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
Mother’s infants  
in BirthPac 
Diagnosis neonatal 
complications 
Birth Summary Form Mother’s infants  
in BirthPac 
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ACT Midwives Data 
Collection Form 
Discharge Form in CRIS/ 
Neonatal section in BOS 
NICU/SCN Admission Information 
reasons for admission Department of 
Neonatology Centenary 
Hospital Discharge 
Summary Form in CRIS 
Nil 
length of stay in 
NICU/SCN 
Department of 
Neonatology Centenary 
Hospital Discharge 
Summary Form in CRIS 
Nil 
main diagnosis and 
treatment 
Department of 
Neonatology Centenary 
Hospital Discharge 
Summary Form in CRIS 
Nil 
GDM, gestational diabetes mellitus; GCT, glucose challenge test OGTT oral 
glucose tolerance test;  
GH, gestational hypertension; PE, preeclampsia; NICU, neonatal intensive 
care unit; SCN, special care nurseries;  
CRIS, clinical record information system; BOS, birthing outcomes system; 
CIS, ACT pathology clinical integration system  
 
           
2.5.4 Data management 
2.5.4.1 Data security:  
Microsoft Office Excel 2007 was used to store and process data in this study. 
All data was stored in a password protected Excel file. Patients’ MRNs and the assigned 
case numbers were recorded in a lab notebook manually and locked in an assigned 
bookcase located in the office of the Department of Endocrinology and the ACT Diabetes 
Service in The Canberra Hospital (Building 6, Level 3).  
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2.5.4.2 Data settlement:  
For analysis purposes, the original data was managed as follows. BMI was 
calculated using the formula BMI=bodyweight (kg)/height2 (m2). Based on the countries 
of birth, patients were divided into the following ethnic groups: Anglo-European 
(Australian, New Zealander, American and European), South Asian (Indian, Pakistani, Sri 
Lankan, Nepalese, Bangladeshi and Bhutanese), South-East Asian (Chinese including 
from Hong Kong and Taiwan, Vietnamese, Thai, Cambodian, Filipino, Malaysian, 
Indonesian, Lao people, Burmese, Korean and Japanese), Pacific Islander (Samoan, 
Tongan, Papua New Guinean and Fijian), Middle-Eastern (Syrian, Iranian, Iraqi, Jordanian 
and Afghanistan), and others (424).   
The outcome information also needed to be redefined. Preterm birth was 
defined as patients delivering before 37 weeks and patients who gave birth after 42 
weeks were identified as post-term birth (441). Apgar scores at 5 min of age were 
classified into three ordinal groups: low (Apgar 0-3), intermediate (Apgar 4-6), and 
normal (Apgar 7-10). Low Apgar score is closely related to the occurrence of neonatal 
adverse outcomes (442). Macrosomia was defined as birth weight greater than or equal 
to 4000g (443), while low birth weight was defined when birth weight was less than 
2500g, both irrespective of the gestational age (444). Small for gestational age (SGA) 
refers to a birth weight below the 10th percentile of the general population after 
adjustment for gestational age and gender (445). Alternatively, large for gestational age 
(LGA) was defined as birth weight above the 90th percentile after adjustment for 
gestational age and gender. A centile calculator was used to calculate the customized 
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birth weight percentage, which was specifically designed for the Australian population. 
Except for gestational age and neonates’ gender, customized birth weight centile also 
adjusted for maternal height, weight, ethnicity and parity (90, 446). Ponderal index (PI), 
another measurement of body size, was also calculated for the neonates. PI yields valid 
results even for very short and very tall persons and that is the reason why it is 
commonly used in paediatrics. It is a ratio of body weight to length expressed as PI= 
weight (g)*100/length3 (cm3). According to some authorities, normal PI value is from 
2.32-2.85 g/cm3. Neonates with a PI greater than 2.85 are classified as obese, while 
those with a PI less than 2.32 are classified as thin (447).  
While the majority of the patients categorized into the high-risk group 
received insulin, some did not. For some data analyses, the high-risk group was 
separated into subgroups, those receiving insulin [high-risk insulin treated (HRI)] and 
those treated with diet only [high-risk diet treated (HRD)]. Patients in the HRD subgroup 
were mostly those referred by their midwives and GPs to the DIPS-MDC due to abnormal 
BGL. However, rather than starting insulin, the endocrinologists considered that there 
was a reasonable chance that extra attention to diet or approaches to manage stress 
could improve their glycaemic control. A few patients attended as HRD patients due to 
psychosocial issues and/or language difficulties. The HRD patients attending the DIPS-
MDC were reviewed by the full team, including endocrinologist and obstetrician. Those 
HRD patients who achieved target BGL following one or more visits to the DIPS-MDC 
were referred back to the usual antenatal care pathway, unless the treating clinicians 
had other antenatal concerns. These patients kept stayed within the category of HRD 
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for the purposes of this study. Those patients initially managed with diet in the DIPS-
MDC, but subsequently treated with insulin, were categorized in the HRI subgroup for 
the purposes of this study. 
Data reliability was evaluated based on two factors: accuracy of data 
recording and collection, and number of missing data. Information that was clearly 
recorded in the electronic medical record system and percentage of missing data is 
lower than 10% were deemed as data with good reliability.  Otherwise, the data 
reliability is intermediate if there is inconsistency in results from different medical 
record systems, or the percentage of the missing data is higher than 10%. The data 
reliability is classified as low when the percentage of the missing data is higher than 50%.  
 
2.5.5 Statistical methods  
2.5.5.1 Sample size calculation: 
The hypothesis of this research was that outcomes in the low-risk group may 
not be better than in the high-risk group due to a lower level of antenatal surveillance 
and different treatment composition. Since birth weight is one of the primary outcomes 
of GDM patients, a difference of 100 g in the mean birth weight, if adjusted for 
gestational age, between the two research groups, either heavier or lighter, was 
considered clinically significant. The variation of the study population was determined 
from using the results of the HAPO study, which is the largest clinical data set in GDM 
research, with almost 25,000 participants. The standard deviation of birth weight in the 
HAPO study was 529g (83). By applying the equation of sample size calculation, n= 
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(Zα/2+Zβ)2*2*σ2/d2 (α=confidence level, 1-β= power, σ= measurement variation, d= 
smallest meaningful difference to be detected), it is determined that at least 439 
patients are required in each group to detect a 100g difference in birth weight with a 
95% confidence level and a power of 80%. 
 
2.5.5.2 Statistical analysis 
Tabulation of data and statistical analysis were performed using SPSS-version 
21.0. Kolmogorov-Smirnov test was used to exam whether the continuous data follow a 
normal distribution. The means of the parametric variables were compared using 
Student’s t-test whereas non-parametric data were compared using Mann Whitney U 
Tests. Categorical data were analysed using Chi square (x2) tests and Fisher s´ exact tests 
-- for contingency tables with minimum expected frequencies of less than 5. Stepwise 
logistic regression was performed for variables that were significant in univariate 
analysis to control for confounders. Odds ratios (ORs) with a 95% confidence interval 
(CIs) were calculated for variables of interest. Confidence intervals excluding 1.0 were 
considered significant. All tests were two-tailed with p< 0.05 considered significant. 
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CHAPTER THREE RESULTS 
3.1 General information: 
From 01/01/2010 to 30/06/2014, 1428 patients were diagnosed with GDM and 
were referred to the ACT Health Diabetes Service for education sessions. Among these 
patients, 414 were excluded from this study because their deliveries occurred in 
hospitals other than The Canberra Hospital and the Calvary Hospital. Further, patients 
who had twin pregnancies (36 cases), triple pregnancy (1 case) and delivery before the 
28th gestational week (2 cases) were also removed from the study population. 
Consequently, 975 patients were included in this study, with 509 in the low-risk group 
and 466 in the high-risk group (Flowchart 3).  This number fulfilled the sample size 
requirement to detect a 100 g difference in birth weight, with 95% confidence level and 
power of 80%.  
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                                        Flowchart 3 -Study Population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1428 patients were diagnosed with GDM and 
attended the education session * 
414 patients had no delivery 
information 
1014 patients gave birth in either The Canberra 
Hospital or The Calvary Hospital 
36 twins 
1 triplet 
2 patients delivered before 28 weeks 
975 patients in the research group 
509 patients in the 
low-risk group 
466 patients in the 
high-risk group 
* This number does not include patients who received care from the 
DIP pregnancy service but did not attend the GDM education session 
and stratification procedures (e.g. women with pre-existing diabetes 
or late transfers from other hospitals). 
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3.2 Maternal demographic information  
3.2.1 Maternal age, BMI, gestational age at first appointment, gestational 
age at GDM diagnosis, number of gestations and parity 
GDM patients in the low-risk group were younger (31.7 ± 4.8 years-old 
compared to 32.6 ± 5.3 years-old, p= 0.009), and had a lower BMI (26.3 ± 6.7 kg/m2 v.s. 
29.3 ± 7.5 kg/m2, p< 0.001). Low-risk group patients also had later first appointments 
with their care providers (15.1 ± 6.6 gestational weeks v.s. 13.2 ± 7.3 weeks, p< 0.001), 
later diagnosis of GDM (28.3 ± 2.8 gestational weeks v.s. 26.6 ± 4.5 weeks, p< 0.001), 
and a lower percentage of patients diagnosed with GDM before 24 weeks of gestation 
(6.0% v.s.18.9%, p<0.001). Interestingly, of the 975 women making up this study cohort, 
only 47 had diabetes in pregnancy according to WHO criteria. Moreover, of these 26 
were stratified to the high risk group and 21 were stratified to the low risk groups (non-
significant; p=0.28). Patients within the low-risk group had fewer pregnancies (2.1 ± 1.3 
times v.s. 2.5 ± 1.8 times, p<0.001), as well as fewer births (0.73 ± 1.0 times v.s. 0.98 ± 
1.2 times, p< 0.001) (Table 5). 
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Table 5 -Maternal age, BMI, gestational age at first appointment, gestational age at GDM 
diagnosis, number of gestations and parity. 
 Low-risk group 
(n=509) 
High-risk group 
(n=466) 
p- value* 
Age (years-old) 31.7 ± 4.8 32.6 ± 5.3 0.009 
BMI (kg/m2) 26.3 ± 6.7 29.3 ± 7.5 <0.001 
Gestational age at first 
appointment (weeks) 
15.1 ± 6.6 13.2 ± 7.3 <0.001 
Gestational age at GDM 
diagnosis (weeks) 
28.3 ± 2.8 26.6 ± 4.5 <0.001 
Diagnosed with GDM before 
24 gestational weeks (%)** 
6.0% 18.9% <0.001 
Gravida (times) 2.1 ± 1.3 2.5 ± 1.8 <0.001 
Parity (times) 0.73 ± 1.0 0.98 ± 1.2 <0.001 
* Student’s t-test was used. 
** Chi-square test was used 
         Regarding data reliability, less than 10 % of the cases had missing data (Table 6).  
However, these data are self-reported, and the reliability is intermediate.  
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Table 6 –Prevalence of cases with missing data on maternal age, BMI, gestational age at 
first appointment, gestational at GDM diagnosis, number of gestations and parity. 
  
 
 
 
 Number of cases with missing data (%) 
Low-risk  High-risk 
Age 0 0 
BMI 0.8% 0 
Gestational age at first 
appointment 
0.8% 0.6% 
Gestational age at GDM 
diagnosis 
1.2% 0.2% 
Diagnosed with GDM before 
24 gestational weeks (%) 
1.2% 0.2% 
Gravida 0 0 
Parity 0 0 
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                   3.2.2 History of GDM, family history of diabetes 
The prevalence of previous history of GDM and of family history of diabetes 
were lower in the low-risk group, compared to the high-risk group patients, 13.2% v.s. 
23.2%, p< 0.001, and 55.4% v.s. 67.0%, p=0.001, respectively (Chart 2).  
                  Chart 2 -History of GDM and family history of diabetes. 
 
* 2*2 Chi-square (χ2) test was used. 
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Data reliability: less than 10 % of the cases had missing data regarding history 
of GDM and family history of diabetes (Table 7). Based on the nature of self-report 
information, the reliability of these data is intermediate.  
Table 7 –Prevalence of cases with missing data regarding GDM history and family history 
of diabetes. 
 Number of cases with missing data (%) 
Low-risk group High-risk group 
GDM History 0 0 
Family History of Diabetes 0.2% 0.2% 
 
 
 
 
 
 
 
 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 140 
 
3.2.3 Smoking status and alcohol consumption 
The two groups had comparable number of patients who continued smoking 
(10.1% v.s. 10.1%, p= 0.996), and consumed alcohol (5.4% v.s. 4.7%, p= 0.653) during 
pregnancy (Chart 3). 
          Chart 3 -Smoking status and alcohol consumption during pregnancy. 
 
* 2*2 Chi-square (χ2) test was used. 
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Data reliability: The prevalence of cases with missing data regarding smoking 
status and alcohol consumption was less than 10% (Table 8). Based on the nature of self-
reporting information, the reliability of these data are intermediate. 
             Table 8 -Missing data on smoking status and alcohol consumption. 
 Number of cases with missing data (%) 
Low-risk group High-risk group 
Smoking  4.7% 8.6% 
Alcohol Consumption 4.7% 8.6% 
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3.2.4 Maternal ethnicity 
Based on the country of birth, mothers in the low-risk group were mostly 
Anglo-European (56.3%) , followed by South-East Asian (19.4%),  South Asian (18.0%), 
Pacific Islander (1.6%), Middle-Eastern (1.2%) and other ethnicities (3.6%). In the high-
risk group, the majority of patients were Anglo-European (58.7%), followed by  South 
Asian (21.4%), South-East Asian (11.9%%), Middle-Eastern (1.7%) Pacific Islander (1.1%), 
and other ethnicities (5.2%). Only the proportion of South-East Asian patients was 
statistically different between two groups with more South-East Asians in the low-risk 
group (19.4% v.s. 11.9%, p=0.002) (Chart 4). 
                                             Chart 4 -Maternal Ethnicity 
 
* 2*2 Chi-square (x2) test was used 
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Yan Zhang, Mphil Thesis, 2015 
 
 Page 143 
 
Data reliability: There are 12 missing data in this section, 1.6% in the low-risk 
group and 0.9% in the high-risk group (Table 9). This ethnicity information is based on 
self-reporting. The patients’ ethnicity is defined by the country of birth. There might be 
patients who born in Australia or other countries, but from ethnic backgrounds with 
higher GDM risk than the general population (eg: Asian, Maori). So, the reliability is 
intermediate.  
                         Table 9 -Missing data on maternal ethnicity. 
 Number of cases with missing data (%) 
Low-risk group High-risk group 
Maternal ethnicity 1.6% 0.9% 
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 3.2.5 Maternal pre-existing complications 
GDM patients in the low-risk group had lower prevalence of hypothyroidism 
(4.5% v.s. 7.7%, p=0.036) and of essential hypertension (0.6% v.s. 3.4 %, p= 0.001). There 
were no differences between low- v.s. high-risk groups regarding the prevalence of 
hyperthyroidism (0.6% v.s. 0.9%, p=0.619), asthma (3.7% v.s. 4.7%, p=0.443), and PCOS 
(2.9% v.s. 3.6%, p=0.539) (Chart 5).  
                                    Chart 5 -Maternal pre-existing complications. 
 
* 2*2 Chi-square (x2) test was used in comparing hypothyroidism, asthma, 
PCOS. Fisher’s exact test was used to compare essential hypertension and 
hyperthyroidism.  
Data reliablity: There is no missing data regarding this part of information. 
Due to the nature of self-reporting data, the reliability is intermediate.  
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3.2.6 GCT and OGTT results 
Patients in the low-risk group had lower 1-h glucose levels in the GCT test (8.9 
± 1.1 mmol/l v.s. 9.2 ± 1.5 mmol/l, p= 0.003) and lower glucose levels while fasting, 
during the OGTT (4.9 ± 0.5mmol/l v.s. 5.0 ± 0.8 mmol/l, p< 0.001). Interestingly, both 
groups had similar glucose levels, both 1-h (9.6 ± 1.4 mmol/l v.s. 9.8 ± 1.4 mmol/l, 
p=0.137) and 2-h (9.0 ± 1.0 mmol/l v.s. 9.0 ± 1.0, p=0.388) at the OGTT (Table 10). 
                                     Table 10 -GCT and OGTT results. 
 Low-risk Group High-risk Group P Value 
GCT (mmol/l) 8.9 ± 1.1 9.2 ± 1.5 0.003 
OGTT 
Fasting(mmol/l) 
4.9 ± 0.5 5.0 ± 0.8 < 0.001 
OGTT 1H(mmol/l) 9.6 ± 1.4 9.8 ± 1.4 0.137 
OGTT 2H(mmol/l) 9.0 ± 1.0 9.0 ± 1.0 0.388 
* Student’s t-test was used.  
** GCT, Glucose Challenge Test; OGTT, Oral Glucose Tolerance Test 
 
                  Data reliability: more than 10% of the cases have missing GCT and OGTT data 
(Table 11). These data were collected from the CIS. By considering the relatively large 
number of missing data, the reliability is intermediate.  
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                       Table 11 -Missing data of GCT and OGTT results. 
 Number of cases with missing data (%) 
Low-risk group High-risk group 
GCT 29.1% 45.1% 
OGTT Fasting 10.4% 13.7% 
OGTT 1H 12.6% 29.2% 
OGTT 2H 12.6% 29.2% 
* GCT, Glucose Challenge Test; OGTT, Oral Glucose Tolerance Test 
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3.2.7 Summary of maternal information: 
Patients in the low-risk group were younger and leaner. They had lower 
gravida, lower parity, and less personal history of GDM and family history of diabetes. 
There were more South-East Asian women in the low-risk group. Both groups had similar 
prevalence of smoking and alcohol consumption during pregnancy. In terms of pre-
existing complications, patients in the low-risk group had lower prevalence of 
hypertension and hypothyroidism. Additionally, patients in the low-risk group had lower 
GCT and fasting glucose results of the OGTT. However, the 1-h and 2-h results of the 
OGTT were not statistically different between the two groups.  
 In conclusion, low-risk group patients had less risk factors for adverse 
perinatal outcomes, as well as lower GCT results and fasting glucose level of OGTT, which 
indicated that the stratification system for GDM in the ACT is effective at differentiating 
risk.  
 
 
 
 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 148 
 
3.3 Maternal outcomes 
3.3.1 Gestational hypertension (GH) and preeclampsia (PE) 
Patients in the low-risk group had lower prevalence of GH (3.9% v.s. 7.7%, 
p=0.011). They also have lower prevalence of PE, but it was not statistically different 
(2.2% v.s. 4.1%, p=0.084). However, the low-risk group patients had lower overall risk of 
developing pregnancy-induced hypertension, which includes GH and PE (6.1% v.s. 11.8%, 
p= 0.002) (Chart 6).  
                                 Chart 6 -Pregnancy-induced hypertension. 
 
* 2*2 Chi-square (x2) test was used. 
** GH, gestational hypertension; PE, preeclampsia 
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3.3.2 Gestational age, preterm birth and post-term birth 
Patients in the low-risk group delivered later than the high-risk group patients 
(39.0 weeks v.s. 38.7 weeks, p< 0.001). More patients delivered after 40 weeks of 
gestation in the low-risk group compared to the high-risk group (33.4% v.s. 8.6%, 
p<0.001). Of note, one patients in the high-risk group delivered at 42 weeks, which could 
be diagnosed as post-term birth.  
Interestingly, the prevalence of having preterm births was significantly higher 
in the low-risk group patients (9.8% v.s. 6.0%, p= 0.028). In the multi-variant regression 
model, the risk of preterm birth was still higher in the low-risk group (OR 1.897, 95%CI 
1.137 – 3.164, p= 0.014), even after controlling for age (OR 1.050, 95%CI 0.998-1.106, 
p= 0.062), parity (OR 0.713, 0.523-0.972, p= 0.032), smoking status (OR 0.994, 95%CI 
0.429-2.304, p= 0.988) and alcohol consumption (OR 1.664, 95%CI 0.661-4.187, p= 
0.279).  
Among the low-risk patients, 6.1% had preterm spontaneous onset of labour, 
while 1.0% had preterm induction of labour and 2.8% had preterm birth without labour. 
Alternatively, in the high-risk group patients, 2.6% had preterm spontaneous labour, 1.3% 
had preterm induction and 2.1% had preterm birth without labour. Low-risk patients 
had higher rates of spontaneous preterm labour compared to the high-risk group (6.1% 
v.s. 2.1%, p= 0.010), however, the rates of having induced preterm birth and preterm 
birth without labour were not statistically different, p value equal to 0.656 and 0.370, 
respectively (Chart 7). 
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                                                  Chart 7 -The onset of preterm birth. 
 
* 2*2 Chi-square (x2) test was used. 
Data reliability: There is no missing data in this part of information. The 
gestational age is precisely recorded in the medical forms. The reliability of this 
information is good.  
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                    3.3.3 Onset of birth, mode of delivery and methods of birth 
1) Onset of birth 
Patients in the low-risk group had a higher rate of spontaneous-onset labour 
(59.9% v.s. 27.0%, p< 0.001). The rate of induced onset of labour was lower in the low-
risk group (23.2% v.s. 50.6%, p< 0.001). Similarly, the rate of patients who did not 
undergo labour was lower in the low-risk group compared to the high-risk group (16.9% 
v.s. 22.3%, p= 0.033) (Chart 8). 
                                                     Chart 8 -Onset of labour. 
 
* 2*2 Chi-square (x2) test was used. 
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                   2) Mode of delivery 
Patients in the low-risk group had a higher rate of spontaneous deliveries 
(spontaneous onset of labour and vaginal delivery) (52.1% v.s. 21.9%, p<0.001), but a 
lower rate of induced deliveries (induced onset of labour and vaginal delivery) (17.1% 
v.s. 38.6%, p<0.001) and a lower rate of elective CS (14.1% v.s. 20.4%, p=0.010). 
Interestingly, patients in the low-risk group had a similar rate of emergency CS (16.7% 
v.s. 19.1%, p=0.328) (Chart 9). 
                                                 Chart 9 -Mode of delivery. 
 
* 2*2 Chi-square (x2) test was used.  
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3) Methods of birth 
In the low-risk group, patients had a higher rate of normal vaginal delivery 
(53.8% v.s. 45.9%, p= 0.014), and a lower rate of CS (30.8% v.s. 39.7%, p= 0.004). 
However, the prevalence of instrumental delivery was comparable between the two 
groups. In the low-risk group, 8.6% of the patients needed forceps during labour, 
compared to 8.4% of the patients in the high-risk group (p= 0.878). Vacuum extractors 
were used in 6.7% of the deliveries in the low-risk group, compared to 6.0% in the high-
risk group (p= 0.668) (Chart 10). 
                                               Chart 10 -Methods of birth. 
 
 * 2*2 Chi-square (x2) test was used. 
Data reliability: There is no missing data in this section. All data were 
accurately recorded in the medical form. The reliability is good. 
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3.3.4 Reasons for elective CS and emergency CS 
1) Reasons for elective CS 
Patients in the low-risk group compared to the high-risk group delivered by 
elective CS had comparable indications of repeated CS (54.2% vs. 60.0%, p= 0.450), 
malpresentation (15.3% vs. 14.7%, p= 0.922), intrauterine growth restriction (IUGR) (1.4% 
vs. 1.1%, p= 0.843), and unspecified reason (19.4% vs. 16.8%, p= 0.664). However, the 
low-risk group patients had more elective CSs because of placenta praevia (8.3% v.s. 
3.2%, p< 0.001) while there were more high-risk group patients who had elective CS 
because of LGA (4.2% v.s. 1.4%, p= 0.006) (Chart 11). 
                                           Chart 11 -Reasons for elective CS. 
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* 2*2 Chi-square (x2) test was used to compare the indications of repeated 
CS, malpresentation, and other reasons. Fisher’s exact test was used to compare 
indications of placenta praevia, LGA, and IUGR. 
** LGA, large for gestational age; IUGR, intrauterine growth restriction 
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        2) Reasons for emergency CS 
Among the reasons for performing emergency CS, the low-risk group had 
comparable rates of obstructed labour (27.4% vs. 38.2%, p= 0.147), fetal distress (38.1% 
vs. 37.1%, p= 1.000) and non-significant trends for reduced obstructed labour combined 
with fetal distress (7.1% vs.15.7%, p= 0.097), increased malpresentation (7.1% vs. 3.4%, 
p= 0.319), increased placenta abruption (7.1% vs. 1.1%, p= 0.058) and increased 
placental praevia (4.8% vs. 0.0%, p= 0.054) compared to the high-risk group (Chart 12). 
                                            Chart 12 -Reasons for emergency CS. 
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* 2*2 Chi-square (x2) test was used to compare obstrcted labour and fetal 
distress, obstructed labour combined with fetal distress, and unknown reasons. Fisher’s 
exact test was used to compare placental abruption, and placenta praevia. 
Data reliability: There is no missing data in this section. Some inconsistencies 
were found in the medical records regarding this part of information. The reliability is 
intermediate.  
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3.3.5 Perineal status and suture 
1) Perineal status 
Of the low-risk group patients who underwent vaginal delivery, 21.1% had 
intact perineum, 14.5% had first degree perineal laceration, 42.5% had second degree 
perineal laceration, 6.0% had third degree perineal laceration, 0% had forth degree 
perineal laceration, and 16% had lateral episiotomy. Among the high-risk group patients 
who did not have CS, 23.0% had intact perineum, 18.4% had first degree perineal 
laceration, 38.3% had second degree perineal laceration, 7.4% had third degree perineal 
laceration, 0.4% had forth degree perineal laceration and 12.4% had lateral episiotomy. 
There was no statistical difference regarding perineal status between the two groups 
(p=0.340) (Chart 13). 
                                                       Chart 13 -Perineal status. 
 
* Fisher’s exact test was used. 
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2) Perineum suture 
After vaginal delivery, perineum suturing was performed in 71.9% of patients 
in the low-risk group and 68.1% of patients in the high-risk group. There is no statistical 
difference regarding the suture status between the two groups (p=0.300).  
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Data reliability: Information about perineal status was unavailable for 0.2% of 
patient in the low-risk group. Information in this section was well recorded in the 
medical forms. The reliability is good (Table 12). 
                     Table 12 -Missing data of perineal status and sutured status. 
 Number of cases with missing data (%) 
Low-risk Group High-risk Group 
Perineal status 0.2% 0 
Sutured status 0 0 
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3.3.6 Delivery complications 
Patients in the low-risk group had rates of shoulder dystocia comparable to 
the patients in the high-risk group (1.6% v.s. 1.5%, p=0.930), as well as of meconium 
liquor (4.9% v.s. 3.0%, p=0.129) (Chart 14). 
Chart 14 -Delivery complications including shoulder dystocia and meconium 
liquor. 
 
* 2*2 Chi-square (x2) test was used. 
Data reliability: There is no missing data in this section. The information 
regarding delivery complications were precisely recorded in the medical forms. The 
reliability is good.  
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        3.3.7 Hospitalization and after delivery bleeding 
After delivery, patients in the low-risk group tended to leave the hospital 
earlier than the patients in the high-risk group, but this number did not achieve 
statistical significance (2.7 ± 1.9 days v.s. 3.0 ± 2.07 days, p= 0.052). These two groups 
had similar amounts of after-birth bleeding (422.8 ± 336.7 ml v.s. 444.4 ± 393.4 ml, p= 
0.358) (Table 13). 
      Table 13 -Information regarding after delivery hospital stay and after delivery 
bleeding. 
 Low-risk Group High-risk Group P value 
Hospital stay after 
delivery 
(days) 
2.7 ± 1.9 3.0 ± 2.07 0.052 
Bleeding after 
delivery  
(ml) 
422.8 ± 336.7 444.4 ± 393.4 0.358 
* Student’s t-test was used.           
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 Data reliability: Missing data in the section is less than 10%. Data regarding after 
delivery information is well documented in the medical forms. The reliability is good 
(Table 13). 
              Table 13 -Missing data of after delivery information. 
 Number of cases with missing data (%) 
Low-risk Group High-risk Group 
Hospital stay after delivery 
 
0.4% 0 
Bleeding after delivery  
 
0.2% 0.4% 
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3.3.8 Summary of maternal outcomes 
The most interesting finding of this audit was the significant higher rate of 
spontaneous preterm birth among low-risk group patients. However, the low-risk group 
patients had a lower rate of developing pregnancy induced-hypertension compared to 
the high-risk group.  
Due to the different delivery strategy between the two groups, the low-risk 
group patients were more likely to start their labour spontaneously, while the high-risk 
group patients had more induced labours. Regarding the rate of having CS, patients in 
the low-risk group had a lower rate of elective CS. The main reasons of elective CS for 
both groups were repeated CS, followed by malpresentation. However, patients in the 
high-risk group were more likely to experience elective CS due to the suspicion of having 
a LGA baby. The emergency CS rate was comparable between the two groups. The 
reasons for emergency CS were similar between both groups, including rates of 
obstructed labour and fetal distress. There was also a strong trend for shorter hospital 
stays in patients of the low-risk group, which might be attributed to the lower CS rate. 
In terms of delivery complications, the rates of shoulder dystocia were low in 
both groups and also were comparable with each other. Similarly, there was no 
difference regarding perineal status and the requirement for perineal suturing between 
the two groups, as well as blood loss after deliver.  
In conclusion, patients in the low-risk group had significantly increased risk of 
preterm birth even after adjusting for multiple confounders. Patients in the low-risk 
group had lower prevalence of pregnancy induced hypertension, lower rate of induced 
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labour and a lower rate of elective CS. However, the rate of emergency CS was 
comparable between the two groups, as was the rate of shoulder dystocia.  
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3.4 Neonatal Outcomes 
3.4.1 Birth status  
There were two cases of stillbirth among all 975 patients (0.2%), one in each 
group.  In the high-risk group, the mother was obese (BMI = 35.4 kg/m2) with a high GCT 
results (12.1 mmol/l). This baby was delivered at 37.6 weeks of gestation, with birth 
weight equal to 3,295 g. In the low-risk group, the mother had a normal BMI (19.5 kg/m2), 
but abnormal OGTT results (fasting = 4.3 mmol/l, 1h = 12.5 mmol/l and 2h = 13 mmol/l). 
The baby was delivered at 38.5 weeks of gestation, weighing 3,190 g. Based on their GCT 
and OGTT results, it is possible that both mothers who had stillbirth might have had 
diabetes prior to their pregnancies.  
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3.4.2 Apgar Score  
Patients in the low-risk group had Apgar scores at 1 minute (8.2 ± 1.5 v.s. 8.3 
± 1.6, p= 0.717) and at 5 minutes (8.9 ± 0.9 v.s. 8.8 ± 1.2, p= 0.158), comparable or similar 
to patients in the high-risk group. 
        1) Apgar scores at 1 minute 
         Apgar scores at 1 minute were divided into three groups: low Apgar score (0-3), 
intermediate Apgar score (4-6) and normal Apgar score (7-10). In the low-risk group, 3.1% 
of patients had a low score, 14.2% had an intermediate score and 82.7% had a normal 
Apgar score.  In the high-risk group, 3.3% had a low score, 13.7% had an intermediate 
score and 83.0% had a normal Apgar score. There was no statistical difference between 
the two groups regarding low Apgar score (p=0.947), intermediate Apgar score 
(p=0.853), and normal Apgar score (p=0.889) (Chart 15). 
               Chart 15 -proportion of three groups of Apgar score at 1 minute. 
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* R*C Chi-square (x2) test was used. 
                   2) Apgar score at 5 minutes 
Compared to the babies of high-risk mothers, those of low-risk women had 
similar rates of a low score at 5 minute (0.8% vs. 1.5%, p= 0.289), an intermediate score 
at 5 minute (1.4% vs. 2.8%, p= 0.174), and a normal Apgar score at 5 minute (97.8% vs. 
95.7%, p= 0.068) (Chart 16). 
                 Chart 16 -proportion of three groups of Apgar score at 5 minute. 
 
* 2*2 Chi-square (x2) test was used. 
Data reliability: There is no missing data in this section. The information of 
Apgar score was well documented in the medical forms. The reliability is good. 
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                   3.4.3 Birth weight  
1) Birth weight, length, and ponderal index 
Compared to babies of high-risk mothers, babies born to mothers in the low-
risk group had similar birth weight (3,257.7 ± 498.3 g v.s. 3,299.9 ± 503.6 g, p=0.189), 
birth length (49.0 ± 2.4 cm v.s. 49.0 ± 2.4 cm, p= 0.776), and ponderal Index (2.8 ± 0.3 
g/cm3 v.s. 2.8 ± 0.3 g/cm3, p=0.234) (Table 15). 
      Table 15 -Information regarding birth weight, birth length and Ponderal Index. 
 Low-risk Group High-risk Group P value 
Birth weight (g) 3,257.7 ± 498.3 3,299.9 ± 503.6 0.189 
Birth length (cm) 49.0 ± 2.4 49.0 ± 2.4 0.776 
Ponderal index 
(g/cm3) 
2.8 ± 0.3 2.8 ± 0.3 0.234 
* Student’s t-test was used. 
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                   2) Macrosomia, low birth weight, neonatal obese, neonatal underweight 
Mothers in the low-risk group had comparable prevalence of macrosomic 
babies (5.5% v.s. 7.1%, p=0.309) and low-birth-weight babies (6.7% v.s. 5.2%, p=0.313), 
compared to the mothers in the high-risk group. Babies of low-risk group mothers also 
had similar rate of being obese (33.5% v.s. 37.7%, p=0.179) and being underweight (3.6% 
v.s. 4.3%, p=0.533) based on the PI value, compared to the babies born from mothers in 
the high-risk group (Chart 17). 
Chart 17 -Information regarding macrosomia, low birth weight, neonatal 
obese, and neonatal underweight. 
 
* 2*2 Chi-square (x2) test was used. 
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3) Customized LGA and customized SGA 
The customized LGA (cLGA) and SGA (cSGA) rates were calculated by using 
the customised centile calculator for the Australian population, which controlled for 
maternal height, maternal weight, maternal ethnicity, parity, neonatal sex, and 
gestational age. Compared to the babies of the low-risk group patients, more infants of 
the high-risk group women tended to be cLGA (9.4% vs. 6.1% in the low-risk group, p= 
0.050), but had a comparable rate of being cSGA (13.1% v.s. 12.4% in the low-risk group, 
p=0.739) (Chart 18). 
                            Chart 18 -Prevalence of cLGA and cSGA babies. 
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Data reliability: Birth weight had no missing data. Information in this section 
is precisely recorded in the medical forms. The reliability is good (Table 16). 
 Table 16 -Missing data for birth weight, length, ponderal index, macrosomia, 
low birth weight, obesity, leanness, cLGA, cSGA. 
 Number of cases with missing data (%) 
Low-risk Group High-risk Group 
Birth weight 0 0 
Birth length 0.4% 0.9% 
Ponderal Index 0.4% 0.9% 
Macrosomia 0 0 
Low birth weight 0 0 
Obesity 0.4% 0.9% 
Leanness 0.4% 0.9% 
cLGA 0 0 
cSGA 0 0 
cLGA customized large for gestational age 
cSGA customized small for gestational age 
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3.4.4 Neonatal complications 
1) Bone fracture and nerve palsy 
There were two cases of bone fractures, all in babies born to high-risk 
patients. One case had a right humerus fracture and other case had a left humerus 
fracture. 
Two cases of nerve palsies occurred during the study period of time: a case 
of facial nerve palsy in the low-risk group, and a case of Erb’s palsy in the high-risk group.  
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2) Hypoglycaemia, jaundice, respiratory distress and NICU/SCN admission  
Babies of patients in the low-risk group had a similar prevalence of 
hypoglycaemia (6.1% v.s. 7.1%, p=0.532), jaundice (8.8% v.s. 10.7%, p=0.320), and 
respiratory distress (6.3% v.s. 6.0%, p=0.857) compared to babies of mothers in the high-
risk group. Interestingly, the rate of admission into NICU/SCN was significantly higher in 
babies of low-risk group patients (16.7% v.s. 10.9%, p=0.010) (Chart 19). 
   Chart 19 -Information regarding hypoglycaemia, jaundice, respiratory 
distress, NICU/SCN admission. 
 
* 2*2 Chi-square (x2) test was used. 
Data reliability: There are no missing data in this section. The neonatal 
complications were well recorded in the medical forms. The reliability is good.  
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3) Stay in the NICU/SCN and reasons for NICU/SCN admission 
Babies of low-risk mothers stayed in the NICU/SCN for the same amount of 
time as babies of high-risk women (7.12 ± 6.67 days v.s. 8.57 ± 7.34 days, p=0.258). 
Among babies of low-risk group mothers, 35.3% were admitted for 
prematurity, 20.0% for respiratory distress, 10.6% for hypoglycaemia, 5.9% for low 
Apgar score, 4.7% for prematurity combined with respiratory distress, 3.5% for 
congenital abnormality, 1.2% for jaundice, and 18.8% for unspecific reasons. 
Alternatively, among babies of high-risk group mothers, 27.5% were admitted due to 
prematurity, 19.6% due to respiratory distress, 17.6% due to low Apgar score, 5.9% due 
to hypoglycaemia, 3.9% due to prematurity combined with respiratory distress, 3.9% 
due to congenital abnormality, 2.0% due to jaundice, and 19.6% due to unknown 
reasons. Only low Apgar score was statistically different between two groups among all 
these reasons (5.9% v.s. 17.6%, p= 0.028) (Chart 20). 
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Chart 20 –Reasons for NICU/SCN admissions.               
 
* 2*2 Chi-square (x2) test was used.  
NICU, neonatal intensive care unit; SCN, special care nursery  
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Data reliability: There were no missing data regarding the NICU/SCN 
admission reasons. There were 5 cases with missing information in the low-risk group 
about the time that babies spent in the NICU/SCN. Information in this section is well 
recorded in the medical forms. The reliability is good (Table 17). 
Table 17 -Missing data of NICU/SCN staying time and admission reasons. 
 Number of cases with missing data (%) 
Low-risk Group High-risk Group 
Time stay in the NICU/SCN 1.0% 0 
Reasons for NICU/SCN 
admission 
0 0 
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3.4.5 Summary of the neonatal outcomes 
The rate of serious neonatal complications was low: only two cases of 
stillbirth, two cases of bone fractures and two cases of nerve palsy were recorded among 
975 babies born to GDM patients.  
Birth weight is an important indicator of the effect of GDM treatment. Mean 
birth weights were comparable between the two groups. However, after adjusting for 
confounding factors such as gestational age, gender, maternal weight, maternal height, 
parity and ethnicity, high-risk group mothers tended to have an increased prevalence of 
LGA babies (9.4% vs. 6.1%, p=0.05). Interestingly, when measuring the ponderal index 
of babies born to mothers with GDM, obesity rates were similarly high in both groups. 
Infants of these two groups had comparable rates of macrosomia, low birth weight, SGA, 
and leanness.  
In terms of neonatal complications, babies in these two groups had 
comparable rates of hypoglycaemia, jaundice, and respiratory distress. Babies of 
mothers in the low-risk group had a higher rate of NICU/SCN admission. The main reason 
for NICU/SCN admission was prematurity, followed by respiratory distress. However, 
babies of low-risk group patients were less likely to be admitted into NICU/SCN because 
of low Apgar score. The duration of the NICU/SCN stay was comparable between both 
groups. 
In conclusion, the rate of severe neonatal complications, including stillbirth, 
bone fracture and nerve palsy was low in both groups. The rate of neonatal 
hypoglycaemia, jaundice and respiratory distress was comparable between the two 
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groups. Interestingly, more babies in the high-risk group tended to be LGA, and neonatal 
obesity, assessed by the ponderal index, was observed in babies from both groups.  
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3.5 NICU admission information in The Canberra Hospital 
3.5.1 General Information  
The rate of NICU/SCN admission was significantly lower at The Canberra 
Hospital compared to the Calvary Hospital (12.5% vs. 20.1%, p= 0.010). This is most likely 
due to differences in NICU admission policy between The Canberra hospital and the 
Calvary Hospital. For this reason, only an analysis of babies admitted to NICU at The 
Canberra Hospital was performed.  
Among 786 babies born to mothers with GDM in The Canberra Hospital, 47 
(14.7%) babies born to low-risk group mothers were admitted into NICU, while 51 
(10.9%) babies born to high-risk group were admitted.  Interestingly, the admission rates 
were not statistically different between the two groups (p=0.119). The length of stay in 
NICU was also not significantly different between the two groups (8.5 ± 6.7 days v.s. 8.6 
± 8.3 days, p= 0.941) (Table 18). 
Table 18 -NICU admissions of neonates born in The Canberra Hospital. 
 Low-risk Group High-risk Group P value 
NICU Admission 14.7% 10.9% 0.119 
Stay in the NICU 
(days) 
8.5 ± 6.7 8.6 ± 8.3 0.941 
* 2*2 Chi-square (x2) test was used to compare the rate of NICU admission. Student’s t-
test was used to compare the number of days these babies spent in the NICU.  
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3.5.2 Neonatal Complications 
1) Neonatal Death:  
In The Canberra Hospital NICU, there was one neonatal death (1%) of a baby 
born to a mother in the low-risk group. This infant died on the first day after being 
admitted into NICU, and the reason of death was a severe diaphragmatic hernia. 
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2) Hypoglycaemia: 
In babies admitted to NICU, those born to low-risk mothers had similar 
prevalence of having hypoglycaemia compared to babies of high-risk group patients 
(36.2% vs. 51.0%, p= 0.140) (Chart 20). Furthermore, the degree of hypoglycaemia was 
comparable between the two groups as well (low-risk group 1.42 ± 0.64 mmol/l v.s. high-
risk group 1.65 ± 0.52 mmol/l, p= 0.296). In terms of treatment options for neonatal 
hypoglycaemia, there was no statistical difference in requirement for intravenous 
glucose infusion between the two groups (low-risk group 84.6% vs. high-risk group 
73.9%, p= 0.682) (Chart 21). 
 Chart 21 -Information regarding neonatal hypoglycaemia and its treatment 
in The Canberra Hospital NICU. 
 
* 2*2 Chi-square (x2) test was used 
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        3) Jaundice:  
In babies admitted to NICU, those born to low-risk mothers with GDM had 
similar prevalence of developing jaundice compared to babies of high-risk group 
mothers ( 48.9% v.s. 58.8%, p= 0.417). Similarly, of the NICU babies diagnosed with 
jaundice, those born from mothers of the low-risk GDM group had comparable rates of 
needing phototherapy to those babies of the high-risk GDM group (39.1% v.s. 43.3%,p= 
0.786) (Chart 22). 
     Chart 22 -Information regarding neonatal jaundice and its treatment in The 
Canberra Hospital NICU. 
 
* 2*2 Chi-square (x2) test was used 
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       4) Respiratory distress: 
(1) Rate and main causes of respiratory distress 
In babies admitted to NICU, those born to the low-risk GDM mothers had 
similar prevalence of having respiratory distress compared to babies of the high-risk 
GDM mothers (59.6% v.s. 51.0%, p=0.422). The three main causes of neonatal 
respiratory distress among babies of the GDM mothers who were admitted into NICU 
were transient tachypnoea of the newborn (TTN) (31.6%), hyaline membrane disease 
( HMD) (12.2%) and pneumothorax (3.1%).  Babies of the NICU admitted babies of the 
low-risk group patients had comparable rates of TTN ( 36.2% v.s. 27.5%, p= 0.391), HMD 
( 14.9% v.s. 9.8%, p= 0.543), and pneumothorax (2.1% v.s. 3.9%, p=1.000) compared to 
the babies of the NICU admitted babies of the high-risk group mother (Chart 23). 
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Chart 23 -Respiratory distress and causes in The Canberra Hospital NICU 
     
                   * 2*2 Chi-square (x2) test was used 
** TTN, Transient Tachypnoes of Newborn (TTN); HMD, Hyaline Membrane 
Disease. 
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        (2) Treatment of respiratory distress 
For those  NICU babies who had respiratory distress, those born to low-risk 
group women were more likely to be treated with oxygen alone, compared to babies 
born to high-risk group patients ( 17.9% v.s. 0.0%, p= 0.038). However, the uses of 
continuous positive airway pressure (CPAP) (60.7% v.s. 65.4%, p= 0.723), mechanical 
ventilation (10.7% v.s. 15.4%, p= 0.610), and expectant (observational only) treatment 
(10.7% vs. 19.2%, p= 0.378) were comparable between the two groups (Chart 24). 
  Chart 24 -The treatment options of respiratory distress in The Canberra 
Hospital NICU. 
     
                   * 2*2 Chi-square (x2) test was used 
** CPAP, Continuous Positive Airway Pressure 
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       5) Other main complications 
In babies admitted to NICU, those of the low-risk group GDM mothers had 
comparable prevalence of developing other metabolic abnormalities including 
hyponatremia, hypernatremia, hypocalcaemia, hypophosphataemia and metabolic 
acidosis, compared to the babies born of the high-risk group GDM mothers (14.9% v.s. 
15.7%, p= 1.000). 
Babies admitted to NICU born to the low-risk compared to the high-risk group 
of GDM patients had similar rates of hypoxic ischemic encephalopathy (HIE) (4.3% v.s. 
7.8%, p= 0.679) and coagulopathy (4.3% v.s. 7.8%, p= 0.679) (Chart 25). 
                  Chart 25 -Other main complications in The Canberra Hospital NICU 
 
* 2*2 Chi-square (x2) test was used 
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*** Metabolic abnormalities include hyponatremia, hypernatremia, 
hypocalcaemia, hypophosphataemia and metabolic acidsis, but exclude hypoglyaemia 
and jaundice. 
Data reliability: There is no missing data of this section. This kind of 
information was precisedly recorded in the medical forms. The reliability is good.  
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        3.5.3 Summary of NICU admission information 
After excluding babies who were delivered in the Calvary Hospital, the rate of 
NICU/SCN admission in The Canberra Hospital was comparable between the two groups. 
This suggests that the increased rate of NICU/SCN admission in the low-risk group overall 
(see section 3.4.4) might be attributed to the different strategy of NICU/SCN admission 
between The Canberra Hospital and the Calvary Hospital. Additionally, the length of 
NICU/SCN stay was comparable between the two groups.  
There was only one case of neonatal death due to serious malformation. The 
rates of hypoglycaemia were comparable between babies of mothers in both groups, as 
well as the degree of hypoglycaemia and the number of babies who needed intravenous 
glucose infusion for treatment. Similarly, the rate of jaundice and the need of 
phototherapy was comparable between the two groups. The three main causes of 
respiratory distress among babies who were admitted into NICU/SCN in The Canberra 
Hospital were TTN, HMD and pneumothoraces. There was no difference regarding the 
rates of TTN, HMD and pneumothoras between infants of the low-risk and the high-risk 
group mothers. However, more babies of the low-risk group mothers who had 
respiratory distress were treated with oxygen alone, which might indicate that these 
babies had less severe forms of resipartory distress. The babies of both groups also had 
similar prevalence of other complications including HIE, coagulopathy and other 
metabolic abnormalities.  
In conclusion, the infants of mothers who delivered in The Canberra Hospital 
requiring NICU admission from the low- and high-risk GDM groups had comparable rates 
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of several neonatal complications including hypoglycaemia, jaundice, and respiratory 
distress. However, respiratory distress in the infants of the low-risk group mothers might 
be less severe.  
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3.6 Subgroup analysis of high-risk group patients who continued diet treatment 
(HRD) 
High-risk patients were subdivided into two groups: patients who attended 
the diabetes clinics and started insulin treatment (HRI), and patients who attended the 
multidisciplinary clinic, did not start insulin treatment, and were advised to undergo 
dietary treatment (HRD). The level of antenatal obstetric care of the HRD patients was 
higher than the low-risk group patients, but lower than the HRI patients. There were 509 
patients in the low-risk group, 75 patients in the HRD group, and 391 patients in the HRI 
group.  
 
3.6.1 Maternal demographic information 
Patients in the HRI group were the oldest (32.8 ± 5.4 years-old), and had the 
highest BMI (29.7 ± 7.7 kg/m2), the most parity (1.0 ± 1.2 times), the highest rates of 
GDM history (25.1%) and family history of diabetes (68.7%), and the earliest diagnosis 
of GDM (26.5 ± 4.5 weeks) among the three groups. The HRI group had the highest 
percentage of patients who were Anglo-European (61.0%), but the lowest percentage 
of patients who were South-East Asian (8.8%). Regarding the level of glucose intolerance, 
the HRI group also had the highest GCT results (9.3 ± 1.6 mmol) and the highest fasting 
glucose levels in the OGTT (5.1±0.8 mmol/l).  
Maternal demographic data of patients in the HRD group were quite similar 
to those of patients in the low-risk group. These two groups had comparable age, BMI, 
parity, GDM history, family history of diabetes, and results of GCT and OGTT. However, 
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patients in the HRD group met care providers earlier (11.4 ± 5.6 weeks vs. 15.1 ± 6.6 
weeks, p< 0.001) and were diagnosed with GDM earlier (27.1 ± 4.0 weeks vs. 28.3 ± 2.8 
weeks, p=0.007), compared to the low-risk group patients. Moreover, more HRD 
patients were of South-East Asian ethnic background (28.0% vs. 19.4%). 
All three groups had comparable rates of smoking and alcohol consumption, 
as well as 1-h and 2-h OGTT results (Table 19 and Table 20). 
                Table 19 -Maternal demographic information for the three groups part I. 
 Low-
risk 
group 
HRD 
group * 
HRI 
group * 
P value 
** 
P value *** 
Low-
risk 
vs 
HRD  
Low-
risk 
vs 
HRI 
HRD 
vs 
HRI 
Age  
(years-old) 
31.7 ± 
4.8 
31.6 ± 
5.1 
32.8 ± 
5.4 
0.006 0.821 0.002 0.065 
BMI 
(kg/m2) 
26.3 ± 
6.7 
27.0 ± 
5.8 
29.7 ± 
7.7 
<0.001 0.392 <0.001 0.003 
Parity 
(times) 
0.7 ± 
1.0 
0.7 ± 
1.0 
1.0 ± 
1.2 
<0.001 0.844 <0.001 0.003 
Gestational 
age of first 
antenatal 
15.1 ± 
6.6 
11.4 ± 
6.0 
13.6 ± 
7.5 
<0.001 <0.001 0.002 0.014 
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visit 
(weeks) 
Gestational 
age when 
GDM was 
diagnosed 
(weeks)  
28.3 ± 
2.8 
27.1 ± 
4.0 
26.5 ± 
4.5 
<0.001 0.007 0.002 0.234 
GCT results 
(mmol/l) 
8.9 ±  
1.1 
8.5 ±  
0.7 
9.3 ±  
1.6 
<0.001 0.104 <0.001 <0.001 
Fasting 
OGTT 
results 
(mmol/l) 
4.5 ±  
0.5 
4.5 ± 
0.5 
5.1 ± 
0.8 
<0.001 0.864 <0.001 <0.001 
1-h OGTT 
results  
(mmol/l) 
9.6 ± 
1.4 
9.6 ± 
1.3 
9.8 ± 
1.4 
0.264 0.780 0.103 0.502 
2-h OGTT 
results  
(mmol/l) 
9.0 ± 
1.0 
8.9 ± 
0.7 
9.0 ± 
1.1 
0.394 0.174 0.674 0.290 
* HDR, High-risk group on diet treatment; HRI, High-risk group on insulin treatment; BMI, 
Body Mass Index; OGTT, Oral glucose tolerance test 
** One-way ANOVA    *** Post Hoc analysis 
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         Table 20 -Maternal demographic information for the three groups Part II. 
 Low-risk group  
 
HRD group 
* 
 
The HRI group 
* 
P value 
** 
GDM history 13.2% 13.3% 25.1% <0.001 
Family history 
of diabetes 
55.5% 58.7% 68.7% <0.001 
Smoking 10.1% 7.1% 10.7% 0.669 
Alcohol 
consumption 
5.4% 4.3% 4.8% 0.890 
Anglo-
European 
56.3% 46.7% 61.0% 0.055 
 
South-East 
Asian 
19.4% 28.0% 8.8% <0.001 
 
South Asian 18.0% 20.0% 21.7% 0.378 
* HDR, High-risk group on diet treatment; HRI, High-risk group on insulin treatment 
** Pearson Chi-square Test 
                               
 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 195 
 
Data reliability:  The data reliability regarding maternal demographic data is good. 
However, for the GCT and OGTT results, there were a few missing data, so the reliability 
is intermediate (Table 21).                                    
                Table 21 -Missing data in demographic data. 
 Low-risk Group HRD Group HRI Group 
Age 0 0 0 
BMI 0 0 0 
Parities 0 0 0 
GDM history 0.2% 0 0 
Family history of 
diabetes 
0 0 0.3% 
Anglo-European  0 0 0 
South- East Asian 0 0 0 
Gestational Age at 
first appointment 
0.8% 0 0.8% 
Gestational Age 
when diagnosed 
with GDM 
1.2% 0 0.3% 
GCT 29% 42.7% 45.5% 
Fasting OGTT 10.4% 5.3% 15.3% 
1-h OGTT 12.6% 8.0% 33.0% 
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2-h OGTT 12.6% 8.0% 33.2% 
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3.6.2 Results of HbA1c, TSH and Vitamin D 
Compared to the HRI group patients, patients in the HRD group had similar 
results regarding HbA1c (5.3 ± 0.4 % v.s. 5.4 ± 0.5 %, p= 0.196), TSH (1.3 ± 0.9 mU/L 
v.s.1.2 ± 0.8 mU/L, p= 0.447), and Vitamin D (57.9 ± 21.2 ng/ml v.s. 57.3 ± 21.0 ng/ml, 
p= 0.887) (Table 22). 
                     Table 22 -Results of HbA1c, TSH and Vitamin D. 
 HRD Group HRI Group P Value  
* 
HbA1c (%) 5.3 ± 0.4 5.4 ± 0.5 0.196 
TSH (mU/L) 1.3 ± 0.9 1.2 ± 0.8 0.447 
Vitamin D(ng/ml) 57.9 ± 21.2 57.3 ± 21.0 0.887 
* Student’s t-test was used 
** HDR, High-risk group on diet treatment; HRI, High-risk group on insulin 
treatment 
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Data reliability: Not all patients who attended the multidisciplinary clinic were 
required to be submitted to these tests, and some patients might have choosen to 
complete these test at a pathology laboratory other than ACT pathology, which caused 
a few missing data in this section (Table 23). This information was extracted from CIS 
and clinic notes. Due to the number of missing data, the reliability of this information is 
low.  
         Table 23 -Missing data of HbA1c tests, TSH tests, and Vitamin D levels. 
 HRD Group HRI Group 
HbA1c 53.3% 9.7% 
TSH 48.0% 14.8% 
Vitamin D 58.7% 29.7% 
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3.6.3 Maternal outcomes of the three groups  
Patients in the HRI group had the highest prevalence of PIH (7.9%) followed 
by the patients in the HRD group (6.7%); patients in the low-risk group patients had the 
lowest prevalence (3.9%). For preeclampsia, although not statistically different, there 
was a similar trend among the three groups.  
In terms of preterm delivery, patients in the low-risk group had the highest 
rate (10.6%) compared to the HRD patients (6.7%) and HRI patients (5.9%), and the 
difference is statistically significant (p= 0.034).  
For the onset of labour, the HRD group patients were most likely to deliver 
spontaneously (64.0%) compared to the low-risk group patients (59.9%) and the HRI 
patients (20.0%). Patients in the HRI group were most likely to be induced (55.9%). 
Patients in the HRI group had higher rates of having an elective CS (22.3 %) compared to 
the HRD patients (10.7%) and the low-risk group patients (14.1%). However, these three 
groups of patients had comparable rates of having emergency CS. Surprisingly, in terms 
of the method of birth, although not statistically different, patients in the HRD group 
had the highest rate of instrumental vaginal deliveries compared to the low-risk group 
patients and the HRI group patients (HRD 22.7% vs. low-risk group 12.8% and HRI 15.3%, 
p= 0.081). 
 Shoulder dystocia was a rare event in all three groups, 8 (1.6%) cases in the 
low-risk group, 2 (2.7%) in the HRD group, and 5 (1.3%) in HRI group and the risk was 
comparable between the three groups (Table 24). 
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             Table 24 -Maternal outcomes for the three groups. 
 Low-risk group HRD group HRI group P value 
** 
Gestational 
Hypertension 
3.9% 6.7% 7.9% 0.036 
Preeclampsia 2.2% 2.7% 4.3% 0.166 
Preterm  
Delivery 
10.6% 6.7% 5.9% 0.034 
Spontaneous 
onset of 
labour 
59.9% 64.0% 20.0% <0.001 
 
Induced onset 
of labour 
23.2% 22.7% 55.9% <0.001 
 
Elective CS 14.1% 10.7% 22.3% 0.002 
Emergency CS 16.7% 21.3% 18.7% 0.533 
Instrumental 
delivery 
12.8% 22.7% 15.3% 0.081 
Shoulder 
dystocia 
1.6% 2.7% 1.3% 0.668 
* HRD, High-risk group on diet treatment; HRI, High-risk group on insulin treatment 
** 2*3 Chi-square Test  
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 Data reliability: There was no missing data in this section. However, some of 
the results were not consistent between different medical record systems. Thus, the 
reliability is intermediate.  
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3.6.4 Neonatal outcomes of the three groups 
Babies in these three groups had comparable mean birth weight. HRI patients 
had the highest rate of customized LGA babies (10.5%) and, although not statistically 
different, the lowest rate of customized SGA babies (11.5%) among the three groups. In 
contrast, patients in the HRD group had the lowest rate of customized LGA babies (4.0%) 
and they tended to have the highest rate of customized SGA babies (21.3%). 
In considering ponderal index (PI), a measure of the degree of leanness or 
obesity of the infants, the rates of obese and thin babies were comparable among the 
three groups. Obesity as determined by PI, was observed in 33.5% of the low-risk group 
babies, 39.2% in the HDR babies, and 37.4% in HRI babies (p=0.377). Excessively lean 
babies were observed in 3.5% in low-risk babies, 2.7% in HRD babies, and 4.6% in HRI 
babies. 
The rates of GDM-related neonatal complications were comparable among 
infants born to the three groups of patients; these complications included 
hypoglycaemia, jaundice, and respiratory distress. However, the rate of NICU/SCN 
admission was highest in infants born to the low-risk group patients (16.7%) compared 
to the HRD group (10.7%) and HRI group (11.0%) (Table 25). 
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                             Table 25 -Neonatal outcomes of the three groups. 
 Low-risk group HRD  
group * 
HRI 
group * 
P value  
** 
Mean birth 
weight (g) 
3257.7± 498.3 3270.3± 481.8 3305.6± 508.0 0.362 
*** 
Customized 
LGA 
6.1% 4.0% 10.5% 0.023 
Customized  
SGA 
12.4% 21.3% 11.5% 0.061 
Obesity rate  
(determined 
by high PI) 
33.5% 39.2% 37.4% 0.377 
Leanness rate 
(determined 
by low PI) 
3.5% 2.7% 4.6% 0.602 
Hypoglycaemia 6.1% 4.0% 7.7% 0.664 
Jaundice 8.8% 10.7% 10.7% 0.610 
Respiratory  
distress 
6.3% 6.7% 5.9% 0.951 
NICU/SCN 
admission  
16.7% 10.7% 11.0% 0.035 
* HRD, High-risk group on diet treatment; HRI, High-risk group patients on insulin 
treatment; PI, ponderal index 
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** 2*3 Chi-square test was used 
*** One-way ANOVA was used and Post Hoc test showed no statistical difference  
 
Data reliability: There is no missing data in this section. The reliability is the same as 
mentioned above (good). 
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3.6.5 Summary of subgroup analysis of HRD group 
Patients in the HRD group who went to the multidisciplinary clinic but 
continued diet treatment only had outcomes more similar to those of the low-risk 
patients, in terms of maternal demographic and antenatal information (excluding time 
of appointment with care provider, time of diagnosis of GDM, and ethnicity). They were 
clearly different to the high-risk group patients with respect to these characteristics.  
Similarly, patients in the HRD group had similar prevalence of pregnancy-
related complications (pregnancy-induced hypertension, preterm delivery, and shoulder 
dystocia) compared to the low-risk group patients. The method of delivery was also 
comparable between the HRD group patients and the low-risk group patients. 
Interestingly, the rate of instrumental delivery, although not statistically different, was 
higher in the HRD group compared to both the low-risk group and the HRI group.  
Regarding neonatal outcomes, patients in the HRD group had the lowest rate 
of LGA babies and a strong trend towards having the highest rate of SGA babies among 
the three groups. However, the mean birth weight of infants and the rate of neonatal 
complications were comparable among the three groups. The difference of NICU/SCN 
admission could be attributed to the different NICU/SCN admission criteria of the two 
hospitals.  
In conclusion, patients in the HRD group were more similar to the low-risk 
group patients in terms of maternal information, except the early appointment with care 
providers, early diagnosis and ethnic background. Patients in the HRD group had 
potentially highest rate of instrumental delivery among the three groups. Interestingly, 
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patients in the HRD group had the lowest prevalence of LGA babies and possibly the 
highest prevalence of SGA babies among three groups.   
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CHAPTER FOUR DISCUSSION 
This research is a clinical audit to evaluate the current stratified treatment 
system for GDM in the ACT. According to this system, patients who are diagnosed with 
GDM are instructed to optimise their lifestyle and monitor their blood glucose level at 
home. After a one-week adjustment period, patients who are able to achieve the target 
glucose level only through diet and exercise are categorised into the low-risk group and 
receive usual antenatal care from midwives and GPs. Patients who have more than three 
BGL higher than the target level (which cannot be attributed to diet) are categorized into 
the high-risk group and are asked to attend the multidisciplinary clinic. These women 
are cared for by endocrinologists, obstetricians, diabetes educators, dietitians and 
midwives. Most patients in this category require insulin treatment to achieve the target 
BGL.  
Compared to patients in the high-risk group, patients in the low-risk group 
have lower levels of antenatal surveillance and most require fewer medical resources; 
they do not receive specialist clinical services, nor additional ultrasound scans and blood 
tests. However, the glucose control of the low-risk group patient is unknown due to the 
lack of information on compliance of this group to lifestyle modification and self-
monitoring of glucose levels.  
It has been shown that, after the new IADPSG diagnostic criteria were 
endorsed, the prevalence of GDM in different populations did not change or increased 
by 3-fold (448-450). In Australia, researchers demonstrated that GDM prevalence 
increased from 9.6% to 13.0% if the IADPSG criteria were used instead of the ADIPS 
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criteria used for the period of this study (451). This high prevalence of GDM will most 
likely increase the burden on the already limited medical resources in Australia. The 
appropriate distribution of medical resources will become a major issue in the near 
future.  It could be argued that the change in diagnostic criteria could increase the 
number of mild cases of GDM that could be managed within low-risk pathways. 
However, this may not be the case, as Duran and associates reported that GDM patients 
diagnosed by IADPSG criteria had comparable rates of insulin treatment compared to 
those diagnosed by Carpenter-Coustan (CC) criteria (450). Nevertheless, a safe 
mechanism to stratify women with lower risk GDM into less intensive management 
pathways, no matter what diagnostic criteria are used, should help with allocation of 
limited medical resources. Thus, it is crucial to conduct this study at this time.  
This research compared the demographic features and perinatal (fetal and 
maternal) outcomes between the low-risk group and the high-risk group patients. The 
purpose of this study was to test the effectiveness of the stratification system and to 
access and compare the perinatal outcomes in two differently treated groups, with 
comparison also to the background pregnancy outcome data of the ACT. Particular focus 
was on safety, and therefore, the outcomes of the low-risk GDM group.  
 
4.1 Discussion for aim one:  
The first aim of this study was to test whether the stratification system 
actually allocated patients with fewer risk factors for adverse outcomes to the low-risk 
group. The results indicate that the stratification system of GDM treatment in the ACT 
is effective. 
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                   4.1.1 Baseline demographic information 
Patients in the low-risk group had fewer risk factors associated with adverse 
pregnancy outcomes, including younger age, lower BMI, less parity, later gestational age 
of GDM diagnosis, less previous history of GDM, less family history of diabetes, and 
lower fasting OGTT results. There were more South-East Asian patients in the low-risk 
group than patients of other races.   
The severity of glucose intolerance is associated with adverse outcomes. In 
the HAPO study, elevated fasting glucose level in OGTT tests was proven to be associated 
with increased risk of birth weight in the >90th percentile, primary CS, cord-blood serum 
C peptide >90th percentile, shoulder dystocia, and preeclampsia (83). As confirmed in 
previous studies, an elevated fasting BGL was also a strong predictor of insulin use. 
McFarland et al. even suggested that GDM patients should start insulin treatment earlier 
if fasting glucose levels were above 95 mg/ml (5.3 mmol/l) (452). 
Similarly, pre-pregnancy obesity is a crucial risk factor for perinatal adverse 
outcomes. Pregnant women who are obese have increased risk of developing 
preeclampsia, and they are more likely to deliver a baby by induction and CS (453, 454). 
Moreover, they have increased risk of having a macrosomic baby (455). Researchers 
analysed the independent effects of maternal obesity and gestational diabetes on 
pregnancy outcomes, and found that obesity alone increased the risk of CS delivery (OR 
2.16 95%CI 1.74-2.67), and increased the rate of macrosomic babies (OR 1.46 95%CI 
0.94-2.27). Furthermore, it was found that the combination of GDM and obesity further 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 210 
 
increased the risk of CS delivery (OR 2.26 95%CI 1.65-3.11) and delivering macrosomic 
babies (OR 3.45 95%CI 2.05-5.81) compared to GDM and obesity alone (456). 
The ethnicity of the patient also influences perinatal outcomes. In an 
Australian study, authors found that GDM patients of South-East Asian ethnicity had 
lower average birth weight (3.08 ± 0.58kg vs.3.38 ± 0.58 kg) and lower rates of CS (17.9% 
vs. 28.8%) compared to women of Anglo-European ethnicity (424). Similar results were 
found in the USA. Sridhar and colleagues indicated that Asian women with GDM were 
less likely to have LGA babies compared to Caucasian patients (457). Esakoff and 
colleagues also demonstrated that among GDM patients, Asians had lower odds ratios 
for primary CS (adjusted OR 0.86 95%CI 0.77-0.96) and lower odds ratios for birth 
weight >4000g (adjusted OR 0.58 95%CI 0.48-0.70) compared to other ethnicities (425).   
The high risk group had later diagnosis of GDM (28.3 ± 2.8 weeks v.s. 26.6 ± 
4.5 weeks, p< 0.001), as well as a lower percentage of patients diagnosed with GDM 
before 24 weeks of gestation (6.0% v.s.18.9%, p<0.001). This difference might be caused 
by the local diagnostic policy. In the ACT, during the time of this study, patients who had 
a higher BMI, a previous GDM history, and/or a previous macrosomic baby did not 
require a GCT prior to an early OGTT. Considering that the low risk group women had 
less of these risk factors for GDM, they were less likely to be screened early. The wider 
range of timing of screening in the high risk group is the reason for the higher SD for the 
gestational age at diagnosis parameter for this group. 
Unexpected, despite greater risk factors for GDM and earlier diagnosis of 
GDM in the high risk group, the number of women meeting diagnostic criteria for WHO 
diabetes in pregnancy was not higher in the high risk group. Of note, previous 
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researchers have shown higher rates of adverse perinatal outcomes for women 
diagnosed with early GDM (458). Similarly, advanced maternal age, family history of 
diabetes, higher parity, and previous GDM history have all been shown to be associated 
with multiple adverse perinatal outcomes, including increased risks for gestational 
hypertension, CS deliveries and LGA babies (459).  
Maternal smoking and alcohol consumption are associated with increased 
risk of adverse perinatal outcomes, including low birth weight, preterm birth, placental 
abruption, and stillbirth (460-462). In this study, the rates of maternal smoking and 
alcohol consumption were comparable between the low-risk and high-risk groups, 
which is expected as the stratification was only based on whether patients could achieve 
target glucose levels solely through diet and exercise, within one week, rather than any 
criteria based on smoking or alcohol consumption.  
These results are consistent with other similarly designed studies. There is no 
previous study that tested the efficacy of the stratification system used for GDM patients 
in the ACT. However, Wong and colleagues did conduct a study in New South Wales 
Australia, and found several risk factors for GDM patients who needed insulin treatment 
during pregnancy. As mentioned in section 1.7.1, there are several similarities between 
that study and this one, such as the diagnostic criteria, ethnic background of patients, 
dietary recommendations, GDM education, and more importantly, the stratification 
criteria (patients who exceeded target BGL on two or more occasions within 1 week 
were started on insulin treatment). In other words, the characteristics of insulin treated 
patients in the study by Wong et al. were comparable to the women in the high-risk 
group of this study; they also demonstrated that patients in the insulin-treated group 
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had higher BMI, higher fasting glucose level on OGTT, diagnosis of GDM at earlier age 
and were more likely to have previous GDM history (420).  
The majority of the patients in the high-risk group needed insulin treatment 
(84%). Although these results are not directly comparable, our results were consistent 
with previous studies that analyzed the risk factors of insulin initiation among GDM 
patients. Advanced maternal age, higher BMI, a higher rate of family history of diabetes, 
higher rate of previous GDM history, and worse OGTT results all contributed to the 
increased risk of insulin use. Similarly, other studies also indicated that GDM patients 
who needed insulin treatment were less likely to be South–East Asian (421, 463, 464). 
Interestingly, patients in the low-risk group had comparable values of the 1-
h and 2-h OGTT results compared to the high-risk group patients, which might be due to 
the large number of 1-h and 2-h results unavailable in this study, especially in the high-
risk group (12.6% in the low-risk group and 29.2% in the high-risk group). The potential 
explanations include: 1) patients who had previous GDM (more in the high-risk group) 
or other risk factors do not need to undergo a GCT, and are submitted to OGTT directly.  
2) Patients who have abnormal fasting glucose levels are diagnosed with GDM prior to 
receiving a glucose load, which is then not given, such that the 1h or 2h tests, likely to 
be higher in these patients, are not performed. High-risk group patients had higher 
fasting glucose levels compared to the low-risk patients. And it is assumed that more 
patients in the high-risk group were diagnosed with GDM on elevated fasting glucose 
alone. 3) Some patients complete their GCT and OGTT in a pathology lab other than ACT 
Pathology and their results were not always recorded by their doctors in the clinic notes.  
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In the HAPO study, higher 1-h and 2-h glucose levels of the OGTT were related 
to unfavourable outcomes (83). However, in terms of the requirement of insulin 
treatment, some researchers found that there was no statistical difference in the 1-h 
and 2-h OGTT results between patients who needed insulin treatment and who did not 
need it (420, 463), while others showed different findings; Pertot and colleagues found 
that higher 1-h OGTT results were associated with increased risk of insulin treatment 
(421). González-Quintero and colleagues suggested that, compared to 1-h and 2-h OGTT 
results, 3-h BGLs of the OGTT test might have greater predictive value for the initiation 
of insulin treatment (463).  
 
4.1.2 Maternal pre-existing conditions 
Patients in the low-risk group had lower rates of pre-existing hypertension 
and hypothyroidism, but comparable rates of asthma, hyperthyroidism and PCOS. 
 
4.1.2.1 Pre-existing hypertension 
Patients in the high-risk compared to low-risk group had higher rates of pre-
existing hypertension (3.4% vs. 0.6%), a complication that is associated with adverse 
perinatal outcomes. A recent meta-analysis encompassing 55 eligible studies and 
795,221 patients demonstrated that pregnant women with chronic hypertension have 
an increased frequency of adverse perinatal outcomes, including superimposed 
preeclampsia (RR 7.7, 95%CI 5.7-10.1), CS (RR 1.3, 95%CI 1.1-1.5), pre-term birth (RR 2.7, 
95%CI 1.9-3.6), low birth weight (RR 2.7, 95%CI 1.9-2.8), NICU admission (RR 3.2, 95%CI 
2.2-4.4), and perinatal death (RR 4.2, 95%CI 2.7-6.5) (465). Anyaegbunan and colleagues 
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performed a study to compare pregnancy outcomes between GDM patients with 
chronic hypertension and GDM patients without hypertension. They found that infants 
of hypertensive GDM patients had higher birth weight, higher frequency of being LGA, 
and higher rates of induced delivery. There was no difference regarding the average 
blood glucose and frequency of SGA deliveries between the two groups (466).  
 Patients who have essential hypertension are also more likely to be obese 
and have advanced age, which were consistent with the characteristics of high-risk 
group patients (467). Moreover, essential hypertension is associated with increased 
insulin resistance that is independent of age, BMI, sex and waist-hip ratio, which may 
indicate patients in the high-risk group had higher levels of insulin resistance compared 
to the low-risk group patients (468).  
 
4.1.2.2 Hypothyroidism 
Patients in the high-risk group had a greater rate of hypothyroidism 
compared to the patients in the low-risk group. Hypothyroidism is known to be a risk 
factor for several adverse perinatal outcomes, including pregnancy-induced 
hypertension, intrauterine growth restriction, pre-term delivery and increased risk of CS 
(469-471). However, researchers demonstrated that instead of the severity of the 
disease itself, the treatment of hypothyroidism during pregnancy was the main factor 
that influenced perinatal outcomes. By receiving adequate treatment, patients with 
hypothyroidism were not at any increased risk for perinatal morbidity (472, 473). 
 The higher rate of hypothyroidism in the high-risk group patients might be 
attributed to undiagnosed type 1 diabetes, a higher rate of GDM history and a higher 
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rate of family history of diabetes among high-risk group patients. Firstly, the association 
between hypothyroidism and type 1 diabetes has been confirmed in the literature. Up 
to 30% of female patients with type 1 diabetes develop hypothyroidism (474, 475), 
particularly those with positive thyroid peroxidase antibodies (TPOAb) (476). It is 
possible that there could be undetected early type 1 diabetes patients who need insulin 
treatment in the high-risk group. Secondly, Vitacolonna and colleagues conducted a 
prospective study to analyse the association between hypothyroidism and GDM. They 
found that thyroid function and prevalence of thyroid disorders during pregnancy was 
not associated with the rate of GDM. However, they indicated a significant increase in 
thyroid autoimmunity in women with GDM history and hypothesized that 
hyperglycaemia in previous pregnancy could trigger thyroid autoimmune disorders 
through upregulating major histocompatibility complex (MHC) class I expression and 
increasing thyroid antigen presentation (477). Thirdly, researchers also found that 
having a family history of diabetes mellitus was associated with the increased risk of 
being TPOAb positive (478). All these factors could contribute to the higher rate of 
hypothyroidism among the high-risk group patients. 
 
4.1.2.3 Other pre-existing maternal conditions 
Maternal hyperthyroidism is associated with increased risk of preeclampsia, 
preterm birth, induced labour and ICU admission (479). Similarly, the pregnancies of 
asthmatic women are also associated with increased risk of fetal death, preterm labour, 
pregnancy induced hypertension, and CS (480). However, it is not surprising that the 
rates of maternal hyperthyroidism and asthma were comparable between the low-risk 
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group and the high-risk group, because the stratification was based on the patients’ 
glucose control within one week by diet and exercise, which is not influenced by 
maternal hyperthyroidism and asthma.  
PCOS is associated with elevated insulin resistance and worse glucose 
intolerance (481, 482). Moreover, recent meta-analysis concluded that women with 
PCOS had a greater risk of being overweight and obese (483). Patients in the high-risk 
group had higher fasting glucose level and higher maternal BMI, which lead to the 
assumption that high-risk patients might have an increased rate of PCOS. However, the 
rate of PCOS was comparable between two groups (3.6% vs. 2.9%, p= 0.539). This result 
might be attributed to the small number of patients who had PCOS in this study or due 
to poor recording of this condition in the clinic notes. 
 
4.1.3 Conclusion for aim one 
The stratification system for the GDM patients that is currently applied in the 
ACT is effective. It allocated patients with fewer risk factors for adverse pregnancy 
outcomes to the low-risk group. The low-risk group patients had less advanced age, 
lower BMI, lower parity, later gestational age at diagnosis of GDM, lower rate of GDM 
history, lower rate of family diabetes, lower rate of pre-existing maternal conditions 
(essential hypertension and hypothyroidism), and a lower fasting glucose level in the 
OGTT. Additionally, more South-East Asian patients were allocated to the low-risk group, 
which is also related to the lower rate of adverse perinatal outcomes.  
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4.2 Discussion for aim two: 
The second aim of this research was to compare the maternal and neonatal 
outcomes between the two groups, and to test the effectiveness of the stratified 
treatment pathways of GDM in the ACT, especially with regards to the safety of the 
treatment pathway of the low-risk group.   
The results indicated that patients in the low-risk group had a lower rate of 
pregnancy-induced hypertension and were less likely to be submitted to delivery 
interventions. The rate of shoulder dystocia was low and comparable between the two 
groups. However, the low-risk group patients had significantly higher risk of 
spontaneous preterm delivery, which is of concern. In terms of neonatal outcomes, 
babies of the low-risk group patients had comparable rates of being macrosomic and 
having low birth weight. Although not statistically significant, there was a strong trend 
for low-risk patients to have fewer LGA babies, while the rates of SGA were similar 
among the patients of both groups. The PI, which is a better measure of leanness or 
obesity than birth weight, was comparable between the two groups; however, the PI 
results were relatively high in both groups. There was no difference between the two 
groups in terms of neonatal complications. The rate of NICU/SCN admission was higher 
in the low-risk group, which might be due to the difference in admission policy between 
the two hospitals, The Canberra Hospital and the Calvary Hospital.  
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4.2.1 Maternal outcomes: 
4.2.1.1 Pregnancy induced hypertension (PIH) 
Patients in this study, both in the low-risk and high-risk groups, had higher 
rates of PIH compared to the general population in the ACT (low-risk 6.1%, high-risk 
11.8%, general population 5.7%) (484).  The association between PIH and GDM has long 
been confirmed. A secondary analysis of the Calcium for Preeclampsia Prevention 
multicentre trial demonstrated that the adjusted relative risk of developing PIH among 
GDM patients compared with glucose tolerant women was 1.54 (95% CI 1.28-2.11) (485).  
In the HAPO study, maternal hyperglycaemia was significantly associated with increased 
risk of preeclampsia. However, the rate of gestational hypertension was not collected in 
the HAPO study (83). 
The low-risk group patients had a lower rate of gestational hypertension and 
potentially a lower rate of preeclampsia compared to the high-risk patients (6.1% vs. 
11.8%), which could be attributed to lower fasting glucose levels, lower pre-gestational 
BMI, and lower maternal age compared to the high-risk patients. As seen in the HAPO 
study, an increased fasting glucose level was associated with a higher risk of 
preeclampsia. Thus, the higher fasting glucose level of the high-risk group patients might 
partially explain the increased rate of PIH compared to low-risk group women. Higher 
BMI and advanced maternal age are also associated with increased risk of PIH among 
both diabetic and non-diabetic women, independent of glucose levels (486, 487). These 
results are consistent with the observations of this study, that patients in the high-risk 
group had higher pre-gestational BMI and advanced maternal age. Insulin resistance is 
believed to be the underlying connection between GDM and PIH (488, 489). 
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However, the lower rate of PIH in the low-risk group could also be explained 
by the lower level of medical surveillance. The blood pressure of the high-risk group 
patients was checked by the care providers every time when they came to the diabetes 
clinic, which may have increased the detection rate of PIH.  In a subgroup analysis, HRD 
patients who presented comparable pre-gestational BMI, maternal age and OGTT 
results as the low-risk group patients but received a higher level of perinatal care and 
had an increased rate of PIH (9.4% vs. 6.1%), which appears to support this inference. 
However, the rate of PIH in the HRI group was higher than the HRD group (12.2% vs. 
9.4%) suggesting more a real increase in the high-risk group.  
 
4.2.1.2 Preterm delivery 
The most interesting finding in this research is that patients in the low-risk 
group had a significantly higher rate of preterm delivery (9.8% vs. 6.0%, p= 0.028), 
particularly for the rate of spontaneous preterm delivery (5.9% vs. 2.6%, p=0.011) 
compared to the high-risk group. The rate of preterm delivery among the general 
population in the ACT was 8.4% in 2011 and 8.3% in 2012 (264, 484), which is lower than 
the rate in low-risk group by comparison.  
The exact reason for the increased risk of preterm delivery in the low-risk 
group is unknown, although there are several potential explanations. Firstly, compared 
to the high-risk group, the low-risk group patients had a lower level of perinatal care. 
Cao and colleagues performed a randomized study to analyse the outcomes of intensive 
treatment compared to standard treatment, among GDM patients. Both the intensive 
and the standard treatment group used the same target glucose levels and criteria of 
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insulin initiation. However, patients in the intensive treatment group received 
individualized diabetes education, lifestyle intervention and special clinic follow-ups 
instead of group-based diabetes education, which was used in the standard group. The 
difference in the level of antenatal care between the two groups in their research was 
similar to the difference in this study. The authors demonstrated that intensive 
treatment significantly reduced the risk of preterm birth (2.4% vs. 8.3%, p= 0.033). It is 
noteworthy that because of the comparable rate of insulin treatment, the authors 
concluded that the increased rate of preterm delivery was purely attributed to the lower 
level of antenatal care (426). The underlying mechanism that links intensive treatment 
and reduced risk of preterm birth could be better glucose control.  Although the patients’ 
glucose levels during pregnancy were not available in this study, the high-risk group 
patients may have had better glucose control due to the more intensive treatment (490). 
Glucose control has been reported to be closely associated with the rate of spontaneous 
preterm birth in GDM patients. Yogev and colleagues demonstrated that higher mean 
blood glucose (p=0.001) and lower rates of diabetes being well controlled (p= 0.004) 
were all significantly related to an increased risk of spontaneous preterm birth (277). 
Secondly, the extra ultrasound and blood tests for high-risk patients could 
reduce the risk of preterm birth. The extra ultrasound tests during the third trimester 
might detect cervical incompetence and polyhydramnios, both of which are common 
risk factors of preterm delivery. Timely treatment of patients in the high-risk group may 
have lowered the incidence of preterm birth (491). The high-risk group patients also had 
checks of their full blood counts, thyroid function and Vitamin D level, which may have 
led to the diagnosis of thyroid dysfunction, anaemia, and vitamin D deficiency. Previous 
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studies indicated that overt and subclinical hypothyroidism is associated with increased 
risk of preterm birth, and found that the risk could be reduced by providing adequate 
treatment (492). Although the patients in the high-risk group had a higher rate of pre-
existing hypothyroidism, this complication might be better controlled due to the more 
frequent clinic visits compared to the low-risk group patients. Similarly, maternal 
anaemia during pregnancy also increased the risk of preterm birth (493). The 
relationship between vitamin D deficiency and preterm birth is complicated. Vitamin D 
deficiency may increase a specific type of preterm birth (inflammation associated 
spontaneous preterm delivery) in a selective population (non-white population) (494). 
If patients in the high-risk group had undiagnosed hypothyroidism, anaemia or vitamin 
D deficiency, they would likely be detected and treated accordingly, while these 
complications would remain undetected in low-risk group patients and consequently, 
lead to the increased risk of preterm birth. However, this is only speculation at this point, 
as future studies would be required to prove these assertions. 
Thirdly, lower BMI in the low-risk group compared to the high-risk group 
might contribute to the increased rate of preterm delivery. In a sub-analysis of the HAPO 
study, authors found that preterm delivery was less frequent with higher maternal BMI 
after being adjusted for several confounders and glucose levels. However, the type of 
preterm birth is not clearly distinguished in that study (495). Parker and colleagues 
conducted a cohort study and demonstrated that pre-pregnancy obesity is associated 
with higher risk of medically-induced preterm birth, but not spontaneous preterm 
delivery (496). Another meta-analysis concluded that the relationship between maternal 
BMI and preterm birth is complicated. The researchers found that overweight (BMI 25-
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29.9 kg/m2) and obese I (BMI 30-34.9 kg/m2) women had a reduced risk for spontaneous 
preterm birth, although obese II (BMI 35-40 kg/m2) and obese III (BMI >40 kg/m2) 
women had increased risk of preterm birth (497). Overall, the relationship between 
maternal BMI and preterm delivery is not conclusive.   
Finally, gestational weight gain (GWG) may also have played a role in 
increasing the risk of preterm birth in the low-risk group. In a large meta-analysis, the 
authors indicated that mothers with higher total GWG had lower risk of all types of 
preterm delivery among pregnant women (498). This study is unable to collect 
information regarding GWG, because it was not often recorded in the medical files. 
However, a majority of the patients (84%) in the high-risk group needed insulin 
treatment to achieve the target BGL, and previous studies in the literature suggested 
that insulin treatment was associated with increased GWG (499). Therefore, the low-
risk group patients might have had lower GWG compared to the high-risk patients and 
consequently, had a higher risk of spontaneous preterm delivery. 
There may be other relevant factors that contribute to the increased risk of 
preterm birth in the low-risk group patients, other than those mentioned above. Future 
studies are needed to discover the exact reason, and to develop a suitable strategy to 
reduce the preterm birth rate in the low-risk group.  
 
4.2.1.3 Induction rate and elective CS rate 
High-risk patients had higher rates of induced labours and elective CS 
compared to low-risk patients, which might be due to the elective delivery strategy for 
high-risk patients who need insulin treatment. In the ACT, high-risk patients who are 
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treated with insulin are likely to be induced between the 38th to 39th weeks of gestation. 
Additionally, if there is serious suspicion that the baby is LGA, these patients are offered 
an elective CS to deliver the babies. Diet-treated GDM patients are normally allowed to 
continue pregnancy until the spontaneous onset of labour. However, the rate of 
emergency CS was comparable between the two groups. 
As mentioned in the introduction part, there is no consensus in terms of 
delivery time and method for GDM patients due to a lack of conclusive evidence. The 
ADA (20), the ACOG (500) in America, the NICE 2008 (501), the NICE 2013 (502) in the 
United Kingdom, and ADIPS (392) in Australia all have different recommendations. The 
advised timing of delivery for GDM patients without other complications varies from 38 
completed weeks to 10 days beyond term. 
Regarding the criteria for offering elective CS, ACOG suggested that it should 
be an option for GDM patients who have an estimated fetal weight ≥ 4500g (375). 
However, the ADA concluded that the role of fetal weight estimation in determining the 
route of delivery is unknown due to the lack of sufficient data (500). 
The main benefit of elective delivery is to avoid stillbirth in later pregnancy 
and to reduce the risk of fetal macrosomia and shoulder dystocia. However, elective 
delivery may also be associated with both maternal and neonatal complications, such as 
the increased risk of emergency CS due to the failure of induction and increased 
incidence of neonatal respiratory distress and NICU admission (502). There was only one 
randomized controlled trial that compared the outcomes between active induction and 
expectant management in diabetic pregnant women who needed insulin treatment 
(mostly GDM patients). The authors found that the rate of CS was comparable between 
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the two groups, and the babies of the patients in the active induction group had lower 
mean birth weight and a decreased rate of being LGA. There was also no difference 
regarding the rate of neonatal respiratory distress including TTN and RDS between the 
active-induced group and the expectant-treated group (503). Similarly, in this study, 
high-risk patients had comparable rates of emergency CS compared to low-risk patients, 
and also had similar rates of neonatal respiratory distress (both TTN and RDS) and 
NICU/SCN admission when using the same admission criteria.   
In this study, high-risk group patients had higher BMI and higher fasting 
glucose levels during the OGTT compared to the low-risk group patients, which may have 
led to an increased risk of having macrosomic babies and, consequently, shoulder 
dystocia. By applying the current elective delivery strategy, that is, early induction and 
elective CS for LGA babies, patients in the high-risk group had an acceptable rate of 
having macrosomic babies (7.1% vs. 5.5%, p= 0.309), as well as a low and comparable 
rate of shoulder dystocia, compared to the low-risk patients (1.5% vs. 1.6%, p=0.930). It 
is assumed that if the expectant delivery strategy had not been used in the high-risk 
group, more cases of macrosomia and shoulder dystocia would have occurred.  
The currently elective delivery management employed in the ACT, including 
earlier induction and elective CS, appears to be satisfactory. It did not increase the rate 
of related adverse perinatal outcomes (the increased rate of emergency CS and neonatal 
respiratory distress), while the rates of shoulder dystocia and LGA babies were 
acceptable in the high-risk group patients. However, conclusive evidence of the delivery 
timing and method for GDM patients in still lacking. 
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4.2.2 Neonatal outcomes 
4.2.2.1 Stillbirth 
The number of stillbirths is quite low in this study. Only two cases occurred, 
with one in each group, among 975 deliveries (0.2%), which is even lower than the 
stillbirth rate in the general population (0.7% in Australia, 2011) (264). GDM is suggested 
to not be an independent risk factor for stillbirth (504). In both stillbirth cases, the two 
mothers might have had pre-existing diabetes, based on their GCT and OGTT results. 
This is consistent with the previous literature showing that pre-existing diabetes is 
associated with a higher risk of stillbirth (504, 505). The IADPSG consensus statement 
on the diagnosis of hyperglycaemic disorders in pregnancy advocates universal testing 
of pre-existing diabetes in populations with a high prevalence of type 2 diabetes during 
the early stage of pregnancy (506). This result also emphasized the importance of 
identifying overt diabetes in the early stage of pregnancy, and a recommendation from 
this research could be that any women diagnosed with WHO diabetes in pregnancy 
should always be managed within high-risk multidisciplinary teams.  
 
4.2.2.2 Rate of customized LGA 
The mean birth weight as well as the rate of macrosomia (5.5% vs. 7.1%, p= 
0.309) was comparable for both the high-risk and low-risk groups. The rate of 
macrosomic babies in both groups was low compared to the general population in the 
ACT 2012 (11.8%).  However, it might not represent the real fetal growth due to 
differences in gestational age and maternal demographic information. In this study, a 
customized birth weight percentile calculator that controls for maternal age, maternal 
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height, maternal weight, parity, and ethnicity, which are all important factors that might 
influence the rate of LGA and SGA in babies, was used. This calculator, obtained from 
the www.gestation.net website, uses the method of Gardosi and Francis, which was 
specifically designed for the Australian population (507). By using the customised 
calculator, babies defined as LGA and SGA were more closely associated with perinatal 
complications than LGA and SGA babies categorized by the standard population-based 
chart (508). In the current study, when the customised calculator was used, we observed 
a strong trend towards high-risk group patients having more LGA babies, when 
compared to the rate of LGA babies in the low-risk group (9.4% vs. 6.1%, p= 0.050).  
The LGA rate in this study was reasonable compared to other studies. The 
rate of LGA was 9.5% in the HAPO study, which might represent the rate of LGA in the 
general population, due to the large number of participants and the exclusion of the 
mothers with significant glucose intolerance (83). There were two large randomized 
controlled trials aimed to demonstrate the influence of GDM treatment. Landon and 
colleagues found that the rate of LGA in their treated group was 7.1 %, while the rate of 
LGA was 13.0% among the treated group in another study conducted by Crowther and 
colleagues (260, 261). Although the LGA rates in this study could not be directly 
compared to previous studies, due to the differences in demographic characteristics of 
the patients, study design, diagnostic criteria and treatment strategy, we found 
comparable rates of LGA to those studies.  
The potentially higher rate of LGA in the high-risk group could be explained 
by several factors. Firstly, the high-risk group patients had higher fasting glucose levels 
compared to patients in the low-risk group, which might contribute to the greater rate 
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of LGA babies. As confirmed in the HAPO study, the fasting, 1-h and 2-h OGTT results 
were all significantly related to the increased rate of LGA (83).  
Secondly, this difference in the rate of LGA between groups could also be 
explained by the higher BMI of patients in the high-risk group. In a sub-analysis of the 
HAPO study, researchers demonstrated that higher BMI was associated with an 
increased risk of LGA (adjusted OR 3.31, 95%CI 2.68-4.10), independent of the patients’ 
glucose levels in the OGTT (509). This association was also supported by other studies 
(510, 511). Although the customized LGA calculation already controlled for maternal 
height and weight, these two factors were adjusted separately, unlike BMI, which 
combines both factors. Sjaarda and colleagues indicated that after excluding the 
adjustment of maternal weight from the customized calculator, more LGA babies were 
diagnosed by the modified percentile calculator, which was associated with greater 
rates of shoulder dystocia, NICU admission and neonatal respiratory complications. The 
authors suggested that the mathematic method for maternal weight adjustment in the 
customized calculator could be further improved (512).  Therefore, the influence of 
elevated maternal BMI in the high-risk group may still be a potential cause of higher 
rates of LGA babies in this group. 
Thirdly, the other possible explanation for the increased rate of LGA babies in 
the high-risk group is higher gestational weight gain. Lee and colleagues conducted a 
study to analyse the relationship between gestational weight gain, pre-pregnancy BMI 
and GDM with the risk of LGA. They found that compared to higher BMI and GDM status, 
excessive gestational weight gain (≥ 15 kg) was a more important risk factor (513). 
Similarly, Kim and colleagues performed a study to assess this association in a multi-
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ethnic population. They indicated that for all ethnic groups, GDM contributed the least 
(2.0-8.0%), whereas excessive gestational weight gain contributed the most (33.3%-
37.7%) to LGA rates (514). Insulin treatment was suggested to be associated with 
increased weight gain (499, 515). The majority of high-risk patients needed insulin 
treatment, which could have resulted in higher gestational weight gain, which on the 
one hand could contribute to the increased rate of LGA, but on the other hand by 
lowering BGL should reduce rates of LGA.  
The results of this study are consistent with the previous literature. Barnes 
and colleagues conducted an epidemiologic study to evaluate the customised predictors 
of LGA and SGA babies in GDM patients. This study used the same diagnostic criteria of 
GDM, had similar target glucose levels and used the same LGA and SGA calculator. 
Moreover, it took place in New South Wales Australia, which has a similar ethnic 
background compared to the population in this study. The authors found that higher 
gestational weight gain, higher pre-gestational BMI and insulin treatment were all risk 
factors of having LGA babies diagnosed under the customised calculation (515). 
 
4.2.2.3 Neonatal obesity rate assessed by ponderal index in both groups 
In addition to birth weight, birth length is another important anthropometric 
measurement in neonates. In the ponderal index (PI), the neonatal weight and length 
are inter-related [PI (g/cm3)= weight (g)*100/length (cm) 3], and PI is an alternative 
measurement in newborns, because the measurement more accurately accounts for 
variances in height (short or tall) (516). Fetal development could be asymmetrical or 
symmetrical according to PI. In symmetrical neonates, an appropriate relationship 
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between fetal weight and length is presented by a normal PI. However, asymmetrical 
neonates with a high PI have relatively greater weight than length, which is taken as a 
measure of neonatal obesity (517). Previously, PI values higher than 2.85 g/cm3 were 
used to define neonatal obesity, while PI values less than 2.32 was used to defined 
neonatal thinness (148, 447). In this research, the mean PI value, the rate of neonatal 
obesity and the rate of neonatal thinness were comparable between the low-risk group 
and high-risk group. However, the rate of obese babies was relatively high in both groups 
(33.5% in the low-risk group and 37.7% in the high-risk group) when compared to 
previous studies that showed that the neonatal obesity rate among non-diabetic women 
ranged from 13% to 16.5% (148, 518).  However, it is possible that the assessment of 
neonatal obesity for Australian babies is overestimated by a PI of >2.85 g/cm3, as is 
indicated in the study of Roje et al, who showed the 90th centile for PI at birth for 
neonates born in Croatia in the 39th week was higher at 3.03 g/cm3 (517). 
Previous research demonstrated that an increased PI value is associated with 
higher mean glucose value and increased High Blood Glucose Index (HBGI) (a measure 
of the frequency and extent of high blood glucose in continuous glucose monitoring). 
The parameters account for the frequency and amplitude of hyperglycaemic events 
during the second trimester, but not the third trimester (519). This relationship between 
glucose levels and glycaemic variability in the second trimester might explain why babies 
of GDM patients in this research had high obesity rates. Since GDM treatment is typically 
administered after GDM diagnosis, which occurs around 28 weeks, the treatment may 
be too late to reduce the PI value. Also, the current parameters used to predict fetal 
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growth, such as fasting glucose and postprandial glucose levels may not be sufficiently 
accurate as they do not dictate glucose excursions.  
Maternal obesity also is a potential contributor to the elevated rate of 
neonatal obesity. Hill and colleagues indicated that even babies born to patients with 
well-controlled GDM had increased PI values, compared to babies born to non-diabetic 
mothers. However, after adjustments for maternal age, parity and fat mass, this 
difference disappeared (520). Similarly, Black and colleagues conducted a study aimed 
to analyse the relationship between maternal pre-pregnancy obesity, gestational weight 
gain, GDM status and fetal overgrowth. They demonstrated that maternal obesity, 
regardless of GDM status, was associated with increased neonatal PI values (455). The 
GDM patients in this research, both the low-risk and high-risk groups, had higher BMI 
than the general population in Australia in 2011 (low-risk group 26.3 kg/m2 and high-risk 
group 29.3 kg/m2 vs. 25.9 kg/m2 general pregnancy women) (264), which might explain 
the higher rate of neonatal obesity. Similarly, although not reaching statistical difference, 
the rate of obesity is lower among infants born to the low-risk mothers who had lower 
BMI compared to the infants of high-risk mothers (33.5% vs 37.7%). 
Interestingly, researchers found that there was no difference between 
disproportionate LGA babies (D-LGA) (PI > 90th percentile) and proportionate LGA babies 
(P-LGA) (PI ≤90th percentile) among GDM patients, in terms of severe neonatal 
complications including low Apgar score (<4 in 5 minutes), birth trauma (Erb’s palsy and 
fractured clavicle), hypoglycaemia, acute respiratory distress (RDS, TTN, and meconium 
aspiration), and hyperbilirubinaemia requiring treatment with phototherapy or 
exchange transfusion. However, the risk of CS was highest among D-LGA babies of 
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diabetic mothers (41.3%) compared to P-LGA babies of diabetic mothers (31.8%), D-LGA 
babies of non-diabetic mothers (24.2%), and P-LGA babies of non-diabetic mothers 
(18.1%) (521). Those findings are consistent with the outcomes of this study. There was 
no difference between the infants born to high-risk patients and infants born to low-risk 
mothers in terms of neonatal complications (discussed below). However, the increased 
rate of neonatal obesity might have contributed to the higher emergency CS rate, both 
the low-risk patients and the high-risk patients, compared to the general population in 
the ACT (low-risk group 16.7% and high-risk groups 19.1% vs. ACT general population 
14.9%) (264).  
 
                   4.2.2.4 Neonatal complications 
The babies of low-risk patients had comparable rates of hypoglycaemia, 
hyperbilirubinaemia, and respiratory distress compared to the babies of high-risk 
patients. It is not possible to perform direct comparison regarding rates of neonatal 
complications between the current study and others, due to the different study 
populations, small numbers of cases of these complications, and varied diagnostic 
criteria for both GDM and neonatal complications.  
The HAPO study demonstrated that the rate of clinical neonatal 
hypoglycaemia and the rate of hyperbilirubinaemia (treatment required) was 2.1% and 
8.3%, respectively, in their study population. Compared to the HAPO study population, 
patients in our study had a higher rate of neonatal hypoglycaemia (low-risk group 6.3% 
and high-risk group 7.9%) and a higher rate of neonatal hyperbilirubinaemia (low-risk 
group 9.4% and high-risk group 10.9%). However, patients in this study were all GDM 
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patients and had worse glucose intolerance compared to participants in the HAPO study. 
The higher rate of maternal hyperglycaemia was associated with the increased risk of 
neonatal hypoglycaemia and hyperbilirubinaemia. Additionally, the diagnostic criteria of 
hypoglycaemia and hyperbilirubinaemia were stricter in the HAPO study, which might 
be why the risks of hypoglycaemia and hyperbilirubinaemia in this study were 
apparently higher (83).  
Two milestone studies aimed at examining the effectiveness of GDM 
treatment have both indicated that GDM treatment might not reduce the rate of 
neonatal complications significantly. The Australian Carbohydrate Intolerance Study in 
Pregnant Women (ACHOIS) demonstrated lack of difference between the intervention 
group (under glucose monitoring, diet and insulin treatment) and the standard-care 
group, regarding risk of jaundice requiring phototherapy (9% vs. 9%, p=0.72), 
hypoglycaemia requiring IV therapy (7% vs. 5%, p= 0.16) and respiratory distress 
syndrome (5% vs.4%, p= 0.15) (260). Landon and colleagues also showed comparable 
rates of hypoglycaemia (16.3% vs. 15.4%, p= 0.75), hyperbilirubinaemia (9.6% vs. 12.9%, 
p= 0.12), and respiratory distress (1.9% vs. 2.9%, p=0.33) between their treated group 
and routine-care group (351).  
Moreover, randomized controlled studies have also suggested that the type 
of GDM treatment and the level of antenatal care (which are the two major differences 
between the low-risk group and high-risk group patients in this study) did not affect the 
rate of neonatal complications significantly. Buchanan and colleagues conducted a RCT 
that aimed to compare the outcomes between diet treatment and insulin treatment in 
GDM patients, and they demonstrated that the rate of hypoglycaemia was similar 
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between the two differently treated groups (14% vs, 18%, p>0.05) (429). Similarly, 
another study has also indicated that the rate of hypoglycaemia (12.6% vs 14.9%, 
p=0.556), hyperbilirubinaemia (42.1% vs. 32.9%, p=0.118) and respiratory distress (8.7% 
vs. 10.9%, p=0.528) was comparable between patients who received intensive antenatal 
care and patients who had standard levels of antenatal care (426).  
Overall, GDM treatment did not significantly reduce the rate of neonatal 
complications, and there was also no difference between different treatment strategies 
in terms of the rate of neonatal complications. The comparable rates of neonatal 
hypoglycaemia, hyperbilirubinaemia and respiratory distress between the low-risk and 
high-risk group patients are consistent with these previous findings.  
The higher rate of NICU/SCN admission in the low-risk group could be 
attributed to the different NICU/SCN admission strategies in the two hospitals. The rate 
of NICU/SCN admission rate was 16.7% in the low-risk group and 10.9% in the high-risk 
group (p= 0.010). However, if patients delivered at the Calvary Hospital were excluded, 
the admission rate was comparable between the high-risk and low-risk groups (14.7% 
vs. 10.9%, p=0.119); babies born in the Calvary Hospital were more likely to be admitted 
into NICU/SCN compared to babies born in The Canberra Hospital. The rate of NICU/SCN 
admission rate in this study appears to be acceptable when compared to the admission 
rate of the general ACT population (14.7%) (484).  
A smaller proportion of the babies from the low-risk group admitted into 
NICU/SCN were due to low Apgar scores, compared to the high-risk group (5.9% vs. 
17.6%, p=0.028). Patients in the high-risk group had a higher rate of CS and pregnancy-
induced hypertension; both conditions have been shown to be associated with 
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increased risk of low neonatal Apgar scores (522). The rate of preterm birth, which is 
also an important risk factor, did not have a remarkable influence on the rate of low 
neonatal Apgar scores due to the relatively small number of preterm births (523).  
The infants who were admitted into NICU had comparable rates of 
hypoglycaemia, hyperbilirubinaemia and respiratory distress between the two groups, 
as well as neonatal complications such as hypoxic ischemic encephalopathy and 
coagulopathy. Furthermore, babies of both groups had similar rates of needing 
intravenous glucose infusion treatment for hypoglycaemia and phototherapy for 
hyperbilirubinaemia. Interestingly, in spite of the comparable rates of needing CPAP and 
mechanical ventilation for respiratory distress, the low-risk group patients were more 
likely to be treated with oxygen alone. The difference in the treatment of respiratory 
distress might have been due to the lower rate of low Apgar scores in the babies of the 
low-risk group patients. It might also indicate that babies in the low-risk group had a 
lower incidence of severe respiratory distress.  
                   4.2.4 Analysis of patients in the high-risk group who continued diet 
treatment alone (HRD) 
This research also identified a subgroup of patients (HRD group) who 
belonged to the high-risk group (entering the multidisciplinary clinic) but continued diet 
treatment to the end of the pregnancy. Patients in the HRD group had characteristics 
that were generally more similar to those of low-risk patients in terms of maternal age, 
BMI, gestation, parity, GDM history, family history of diabetes, and GCT and OGTT 
results (both fasting and 2-h results). However, HRD patients had earlier appointments 
with care providers during pregnancy, and were diagnosed with GDM at earlier stages, 
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when compared to low-risk women. Additionally, the percentage of patients with South-
East Asian backgrounds was highest in the HRD group (HRD group 28% vs. low-risk group 
19.1% and HRI group 8.7%).  
The earlier appointment with care providers and the earlier diagnosis of GDM 
among HRD patients could indicate that they have more risk factors related to the 
development of GDM and other complications, or have higher GCT results that could 
lead to the omission of OGTT. However, the similar maternal demographic information 
and comparable GCT results between the HRD and low-risk group patients did not 
support this assumption. Another explanation for this phenomenon is that patients in 
the HRD group might be more compliant with medical advice during pregnancy, which 
also indicates that these patients might pay more attention to their health and take 
greater care of themselves. The earlier diagnosis of GDM might have influenced the 
treatment decision made by the endocrinologist. The specialists might give patients 
more time to adapt to the lifestyle treatment if patients had earlier GDM diagnosis, 
instead of starting insulin treatment immediately because of the limited treatment time. 
The ethnic difference was also consistent with the previous literature. Wong and 
colleagues indicated that South-East Asian patients had the lowest rate of insulin 
treatment compared to GDM patients from other ethnicities (South-East Asian 37.2%, 
South Asian 55%, and Anglo-European 56.7%, p<0.001) (424).  
In terms of perinatal outcomes, the patients in the HRD group had similar 
rates of spontaneous delivery, induced labours, and CS as low-risk patients. They had 
middling rates of pregnancy-induced hypertension and preterm delivery amongst the 
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three groups. Further, the rate of neonatal complications was similar among the three 
groups.  
The patients in the HRD group had the lowest rate of LGA babies among the 
three groups (HRD 4.0% vs. low-risk group 6.1% and HRI 10.5%, p= 0.023). Paradoxically, 
their rate of assisted vaginal delivery was the highest and approached statistical 
significance (HRD 22.7% vs. low-risk group 15.3% and HRI 12.8%, p=0.081). A possible 
explanation for this phenomenon could be that there were more South-East Asian 
patients in the HRD group, whom are more likely to experience instrumental delivery 
compared to other ethnicities (524, 525). The exact cause of the increased risk of 
instrumental delivery among South-East Asian patients who had lower rate of having 
LGA babies compared to other ethnicities (424) is unknown. However, researchers 
found that there was a strong trend towards shorter mean perineal length in normal 
Asian pregnant women when measured in the first stage of labour, compared to 
Caucasian women (3.6±0.09 cm vs. 3.7±0.09, p=0.06), which might be the cause of the 
increased rate of instrumental delivery in the Asian population (526).  
Even after adjustments for maternal weight, maternal height and ethnicity, 
the HRD group still had the highest rate of having SGA babies, approaching statistical 
significance (HRD 22.7% vs. low-risk group 15.3% and HRI 12.8%, p=0.061). One possible 
reason for the increased rate of SGA babies in the HRD group could be insufficient 
gestational weight gain. The maternal weight gain during pregnancy has been shown to 
be inversely associated with increased risk of having SGA babies in GDM patients (515). 
It is likely that some of the HRD patients were advised that insulin treatment would be 
necessary if their glucose levels did not improve quickly, which might have led to HRD 
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patients excessively restricting their food intake to avoid the use of insulin. On the other 
hand, some of the HRD patients may have been asked to attend the multidisciplinary 
clinic due to concerns of the health professionals that they were too restrictive on food 
intake. Furthermore, as discussed before, patients in the HRD group are more likely to 
stick to the medical advice and pay more attentions to their health, which might also 
result in unnecessary food restriction. Insufficient food intake could have led to reduced 
maternal weigh gain during pregnancy, and subsequently caused the highest rate of SGA 
babies.  
 
4.2.5 Conclusion for aim two: 
Patients in the low-risk group had comparable rates of stillbirth, macrosomia, 
shoulder dystocia, as well as a lower rate of pregnancy induced hypertension, LGA, and 
CS, which indicates that the treatment pathway of the low-risk group is promising.  
However, the higher rate of preterm delivery in the low-risk group is concerning, such 
that further assessment and optimisation of the low risk pathway is necessary.  
As discussed before, it is also reasonable to continue elective delivery in the 
high-risk group patients who need insulin treatment until more conclusive evidence is 
available. That approach most likely leads to more acceptable rates of macrosomic 
babies and shoulder dystocia. Furthermore, the elevated rate of neonatal obesity 
observed as assessed by ponderal index in both groups needs further analysis, including 
analysis of cut-points for the Austalian population. Finally, the high rate of SGA babies 
among HRD patients also needs to be addressed.   
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4. 3 Advantages and limitations  
4.3.1 Advantages: 
1) This is the first clinical audit that evaluates the effectiveness of the current 
GDM care system used in the ACT, Australia, which has collected data from the two 
largest public hospitals in the region, i.e. The Canberra Hospital and the Calvary Hospital.  
2) To the best of our knowledge, this is the first study that compares the 
perinatal outcomes in the low-risk group and the high-risk group, categorized according 
to whether the patients attended the multidisciplinary diabetes clinic. This information 
could further complete the knowledge map regarding GDM treatment.  
3) This is a relatively large study. It included 975 patients diagnosed with GDM 
from 01/01/2010 to 30/06/2014. The number of patients fulfilled the requirements of 
sample size to detect a 100g difference in neonatal birth weight between the two groups. 
4) A special group of patients who needed to attend the multidisciplinary 
clinic but managed to control their glucose level only through lifestyle treatment was 
identified in this research. These patients had the lowest risk of having LGA babies, but 
the highest risk of having SGA babies, which may indicate that these patients may have 
over-restricted their food intake to avoid insulin treatment.  
5) The original medical records and electronic information systems were 
accessed. All important information was double checked, which increased the accuracy 
of the results.  
6) This research was able to provide detailed information regarding reasons 
for elective CS and emergency CS, NICU admission information, and treatments for 
neonatal complications. 
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                    4.3.2 Limitations and future studies  
1) This is a retrospective study, which can only identify the association 
between treatment and outcomes, but not the causal relationship. Because of the 
retrospective design, the information regarding the control of the glucose level, 
gestational weight gain, and the compliance of lifestyle management that are all crucial 
contributors to perinatal outcomes was not available. A future prospective study is 
needed, especially for identifying the cause of increased pre-term delivery in low-risk 
patients. 
2) Due to the retrospective nature of the study, it was not possible to identify 
clearly the women that were initially designated as low risk, but were later referred to 
the DIP-MDC. For this reason, all of these women were assessed as being in the high-
risk group. This did not allow an “intention to treat” analysis of the initial designation of 
risk.  
3) This study did not include the information of GDM patients who delivered 
in private hospitals because of the limited study time and resources. However, it will be 
interesting to compare the demographic data and perinatal outcomes of private hospital 
patients with patients treated in public hospitals. This would be expected to provide a 
more comprehensive perspective in terms of the GDM treatment system in the ACT.  
4) There is no control group of untreated GDM patients in this study. However, 
the main aim of this study was to compare the outcomes between the low-risk and the 
high-risk group patients. The maternal and neonatal information of the background 
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population in Australian and from other relevant researches was included in this study 
to create a more complete picture.  
4.3.3 Suggestions for the improvement of the current treatment system 
1) The exact reason for the increased risk of preterm birth in the low-risk 
group patients is unknown. However, previous research indicated that increasing the 
level of antenatal care could reduce the risk of preterm delivery (426). Thus, an 
additional appointment with a diabetes educator or dietitian could be beneficial to 
further document glycaemic control, adequacy of nutrition and potential need for 
insulin therapy. The patients’ glucose control and gestational weight gain, which are 
both factors that are related to the risk of preterm birth need to be closely monitored 
during an additional appointment (277, 498). Regarding obstetric surveillance, the meta-
analysis did not demonstrate sufficient evidence to endorse a specialised antenatal clinic 
for the prevention of preterm birth (527), however, there is no harm in providing 
improved education for low-risk group patients, especially about the signs of preterm 
labour. Whether it is necessary to have extra ultrasound for cervical assessment and 
blood tests for detection of maternal anaemia, thyroid dysfunction and vitamin D 
deficiency is still unknown. Further research and cost-effectiveness analyses are 
required.  
2) Pre-gestational obesity is associated with several perinatal adverse 
outcomes, such as increased rates of pregnancy induced hypertension and greater risk 
of having neonatal overgrowth (528). In a recent systematic review of the risks 
associated with obesity in pregnancy, the authors suggested that women with obesity 
need support to lose weight before pregnancy, to reduce the rate of adverse perinatal 
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outcomes (529).  A special clinic for overweight and obese women who plan to have a 
baby in the near future might be advisable. Information about the influence of obesity 
on perinatal outcomes and individualized plans for weight loss should be provided.  
3) Patients in the HRD group had the highest risk of having SGA babies, which 
might be due to the excessive food restriction. Instead of being referred back to normal 
antenatal care, they might need follow-up sessions with a dietitian. The importance of 
adequate food intake should be re-emphasized and weight gain should be assessed 
during these sessions. Further attention should be paid to determining the timing and 
delivery method of the HRD group patients to avoid unnecessary instrumental delivery.  
4) The patients’ ethnicities in this study were broadly classified according to 
the self-reported country of birth that does not always accurately reflect ethnicity. It 
would be helpful if future data collection included a field for self-reported ethnicity, as 
well as country of birth.  
  
4.4 Final Conclusion:  
The stratification system of GDM patients in ACT is effective, as it allocates 
patients who have fewer risk factors and lower fasting glucose levels in the OGTT that 
are related to the adverse pregnancy outcomes into the low-risk group. The treatment 
pathway of low-risk group GDM patients, although associated with some less adverse 
outcomes such as pregnancy-induced hypertension, delivery interventions and cLGA 
neonates, several neonatal outcomes were not less. Furthermore, some neonatal 
outcomes were higher than in the ACT background population. For these reasons, the 
low risk pathway has merit, but further assessment and optimisation are required. One 
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optimisation could be the exclusion of women with WHO diabetes in pregnancy from 
the low risk group, as one women in the low risk group with WHO diabetes in pregnancy 
had a stillbirth. In particular, the increased rate of spontaneous pre-term birth warrants 
attention. The earlier delivery strategy for the high-risk patients should be continued. 
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Appendix 2 Ethical approval letter from the Calvary Hospital 
 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 247 
 
 
 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 248 
 
Appendix 3 Indicators for Initiating Phototherapy 
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Appendix 4 The number of patients who presented as percentage in the results (part 
one) 
 Conditions  
 
Low-risk group High-risk group 
Maternal  
baseline  
demographic  
information 
(low-risk group  
n= 509, 
 high-risk group 
n= 466 
History of GDM 67 (13.2%) 108 (23.2%) 
Family history of 
diabetes 
282 (55.4%) 312 (67.0%) 
Smoking 49 (10.1%) 43 (10.1%) 
Alcohol consumption 26 (5.4%) 20 (4.7%) 
Anglo-European 282 (56.3%) 271 (58.7%) 
South-East Asian 97 (19.4%) 55 (11.9%) 
South Asian 90 (18%) 99 (21.4%) 
Pacific Islander 8 (1.6%) 5 (1.1%) 
Middle-Eastern 6 (1.2%) 8 (1.7%) 
Other ethnicity 18 (3.6%) 24 (5.2%) 
Essential hypertension 3 (0.6%) 16 (3.4%) 
Hypothyroidism 23 (4.5%) 36 (7.7) 
Hyperthyroidism 3 (0.6%) 4 (0.9%) 
Asthma 19 (3.7%) 22 (4.7%) 
PCOS 15 (2.9%) 17 (3.6%) 
Maternal  
outcomes 
Gestational 
hypertension 
36 (3.9%) 20 (7.7%) 
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(low-risk group  
n= 509, 
 high-risk group 
n= 466) 
Preeclampsia 11 (2.2%) 19 (4.1%) 
Pregnancy induced 
hypertension 
47 (6.1%) 39 (11.8%) 
Preterm birth 50 (9.8%) 28 (6.0%) 
Spontaneous preterm 
birth  
31 (60.2%) 12 (43.3%) 
Induced preterm birth 5 (10.2%) 6 (21.7%) 
Preterm birth without 
labour 
14 (29.6%) 10 (35%) 
Spontaneous onset of 
labour 
305 (59.9%) 126 (27%) 
Induced onset of 
labour 
118 (23.2%) 236 (23.2%) 
Onset of no labour 86 (19.6%) 104 (22.3%) 
Spontaneous mode of 
delivery 
265 (52.1%) 102 (21.9%) 
Induced mode of 
delivery 
87 (17.1%) 180 (38.6%) 
Maternal  
outcomes 
(low-risk group  
n= 509, 
Elective CS mode of 
delivery 
72 (14.1%) 95 (20.4%) 
Emergency CS mode of 
delivery 
85 (16.7%) 89 (19.1%) 
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 high-risk group 
n= 466) 
Normal vaginal 
delivery 
274 (53.8%) 214 (45.9%) 
Forceps 44 (8.6%) 39 (8.4%) 
Vacuum extractors 34 (6.7%) 28 (6.0%) 
Delivered by CS 157 (45.9%) 185 (54.1%) 
Reasons for the elective CS 
Repeated CS 39 (54.2%) 57 (60.0%) 
Malpresentation 11 (15.3%) 14 (14.7%) 
IUGR 1 (1.4%) 1 (1.1%) 
Placenta praevia 6 (8.3%) 3 (3.2%) 
LGA 1 (1.4%) 4 (4.2%) 
Un-specific reasons 14 (19.4%) 16 (16.8%) 
Reasons for the emergency CS 
Obstructed labour 23 (27.4%) 34 (38.2%) 
Fetal distress 32 (38.1%) 33 (37.1%) 
Obstructed labour 
combined with fetal 
distress 
6 (7.1%) 14 (15.7%) 
Malpresentation 6 (7.1%) 3 (3.4%) 
Placental abruption 6 (7.1%) 1 (1.1%) 
Placental praevia 4 (4.8%) 0 (0.0%) 
Un-specific reasons 8 (8.4%) 4 (4.5%) 
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Perineal status 
Intact 74 (21.1%) 64 (23%) 
First degree laceration 51 (14.5%) 55 (18.4%) 
Second degree 
laceration 
149 (42.5%) 107 (38.2%) 
Third degree 
laceration 
21 (6%) 21 (7.4%) 
Forth degree 
laceration 
0 (0%) 1 (0.4%) 
Lateral episiotomy 56 (16%) 35 (12.4%) 
Perineum suture 253 (71.9%) 190 (68.1) 
Shoulder dystocia 8 (1.6%) 7 (1.5%) 
Meconium liquor 25 (4.9%) 14 (3.0%) 
Neonatal 
outcomes 
(low-risk group  
n= 509, 
 high-risk group 
n= 466) 
Apgar score for 1 minute 
Low Apgar score (0-3) 16 (3.1%) 15 (3.3%) 
Intermediate Apgar 
score (4-6) 
72 (14.2%) 64 (13.7%) 
Normal Apgar score (7-
10) 
421 (82.7%) 387 (83.0%) 
Apgar score for 5 minutes 
Low Apgar score (0-3) 4 (0.8%) 7 (1.5%) 
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Intermediate Apgar 
score 
(4-6) 
7 (1.4%) 13 (2.8%) 
Normal Apgar score (7-
10) 
498 (97.8%) 446 (95.7%) 
Macrosomia 28 (5.5%) 33 (7.1%) 
Low birth weight 34 (6.7%) 24 (5.2%) 
Being obesity 170 (33.5%) 174 (37.7%) 
Being underweight 18 (3.6%) 20 (4.3%) 
Customized LGA 31 (6.1%) 44 (9.4%) 
Customized SGA 63 (12.4%) 61 (13.1%) 
Hypoglycaemia 31 (6.1%) 33 (7.1%) 
Jaundice 45 (8.8%) 50 (10.7%) 
Respiratory distress 32 (6.3%) 28 (6.0%) 
NICU/SCN admission 85 (16.7%) 51 (10.9%) 
NICU/SCN admission reasons 
Prematurity 30 (35.3%) 14 (27.5%) 
Respiratory distress 17 (20.0%) 10 (19.6%) 
Hypoglycaemia 9 (10.6%) 3 (5.9%) 
Low Apgar score 5 (5.9%) 9 (17.6%) 
Yan Zhang, Mphil Thesis, 2015 
 
 Page 254 
 
Prematurity combined 
with respiratory 
distress 
4 (4.7%) 2 (3.9%) 
Congenital 
abnormality 
3 (3.5%) 2 (3.9%) 
Jaundice 1 (1.2%) 1 (2.0%) 
Un-specific reason 16 (18.8%) 0 (19.6%) 
Information for 
infants in 
NICU/SCN in The 
Canberra 
Hospital 
(low-risk  
n= 47,  
 high-risk 
n= 51) 
NICU/SCN admission 
rate 
47 (14.7%) 51 (10.9%) 
Hypoglycaemia 17 (36.2%) 26 (51.0%) 
Hypoglycaemia need 
infusion 
14 (84.6%) 19 (73.9%) 
Jaundice 23 (48.9%) 30 (58.8%) 
Jaundice need 
phototherapy 
9 (39.1%) 13 (43.3%) 
Respiratory distress 28 (59.6%) 26 (51.0%) 
Transient tachypnoes  17 (36.2%) 14 (27.5%) 
Hyaline membrane 
disease 
7 (14.9%) 5 (9.8%) 
Pneumothorax 1 (2.1%) 2 (3.9%) 
Treatment for neonatal respiratory distress 
Oxygen 5 (17.9%) 0 (0.0%) 
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Continuous positive 
airway pressure 
17 (60.7%) 17 (65.4%) 
Mechanical ventilation 3 (10.7%) 4 (15.4%) 
Un-specific treatment 3 (10.7%) 5 (19.2%) 
Other metabolic 
abnormality 
7 (14.9%) 8 (15.7%) 
Hypoxic ischemic 
encephalopathy 
2 (4.3%) 4 (7.8%) 
Coagulopathy 2 (4.3%) 4 (7.8%) 
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Appendix 5 The number of patients who presented as percentage in the results (part 
two) 
 Conditions Low-risk group 
(n= 509) 
HRD group 
(n= 75) 
HRI group 
(n= 391) 
Maternal 
demographic 
information 
GDM history 67 (13.2%) 10 (13.3%) 98 (25.1%) 
Family history of 
diabetes 
282 (55.5%) 44 (58.7%) 268 (68.7%) 
Smoking 49 (10.1%) 5 (7.1%) 38 (10.7%) 
Alcohol 
consumption 
26 (5.4%) 3 (4.3%) 17 (4.8%) 
Anglo-European 282 (56.3%) 35 (46.7%) 236 (61.0%) 
South-East Asian 97 (19.4%) 21 (28.0%) 34 (8.8%) 
South Asian 90 (18.0%) 15 (20.0%) 84 (21.7%) 
Maternal  
outcomes 
information 
Gestational 
hypertension 
20 (3.9%) 5 (6.7%) 31 (7.9%) 
Preeclampsia 11 (2.2%) 2 (2.7%) 17 (4.3%) 
Preterm delivery 54 (10.6%) 5 (6.7%) 23 (5.9%) 
Spontaneous 
onset of labour 
305 (59.9%) 48 (64.0%) 78 (20.0%) 
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Induced onset of 
labour 
118 (23.2%) 17 (22.7%) 218 (55.9%) 
Elective CS 72 (14.1%) 8 (10.7%) 87 (22.3%) 
Emergency CS 85 (16.7%) 16 (21.3%) 73 (18.7%) 
Instrumental 
delivery 
78 (12.8%) 17 (22.7%) 50 (15.3%) 
Shoulder dystocia 8 (1.6%) 2 (2.7%) 5 (1.3%) 
Neonatal 
outcome 
information 
Customized LGA 31 (6.1%) 3 (4.0%) 41 (10.5%) 
Customized SGA 63 (12.4%) 16 (21.3%) 45 (11.5%) 
Obesity 170 (33.5%) 29 (39.2%) 145 (37.4%) 
Leanness 18 (3.5%) 2 (2.7%) 18 (4.6%) 
Hypoglycaemia 31 (6.1%) 3 (4.0%) 30 (7.7%) 
Jaundice 45 (8.8%) 8 (10.7%) 42 (10.7%) 
Respiratory 
distress 
32 (6.3%) 5 (6.7%) 23 (5.9%) 
NICU/SCN 
admission 
85 (16.7%) 8 (10.7%) 43 (11.0%) 
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Appendix 6 List of flowchart, tables and charts 
 
1. Flowchart 
Flowchart 1 -IADPSG diagnostic procedures of GDM 
Flowchart 2 –The public stratification system for GDM management in ACT health 
Diabetes service 
Flowchart 3 - Study Population 
 
2. Table 
 
Table 1 -Recommendations for screening procedures and diagnostic criteria for GDM 
Table 2 -Screening and diagnosis of GDM in this research 
Table 3 -Institute of Medicine Recommendations for total weight gain and rate of 
weight gain during pregnancy, by pre-pregnancy BMI  
Table 4 -Data collection from the medical record system 
Table 5 -Maternal age, BMI, gestational age at first appointment, gestational age when 
GDM was diagnosed, number of gestations and parity 
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Table 6 -Prevalence of cases with missing data on maternal age, BMI, gestational age 
at first appointment, gestational at when GDM was diagnosed, number of gestations 
and parity. 
Table 7 -Prevalence of cases with missing data regarding GDM history and Family 
History of Diabetes 
Table 8 -Missing data on smoking status and alcohol consumption 
Table 9 -Missing data on maternal ethnicity. 
Table 10 -GCT and OGTT results. 
Table 11 -Missing data of GCT and OGTT results. 
Table 12 -Missing data of perineal status and sutured status. 
Table 13 -Information regarding after delivery hospital staying and after delivery 
bleeding 
Table 14 -Missing data of after delivery information 
Table 15 -Information regarding birth weight, birth length and Ponderal Index. 
Table 16 -Missing data for birth weight, length, PI, macrosomia, low birth weight, 
obesity, leanness, LGA, SGA). 
Table 17 -Missing data of NICU/SCN staying time and admission reasons. 
Table 18 -NICU admissions of neonates born in The Canberra Hospital. 
Table 19 -Maternal demographic information for three groups part I. 
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Table 20 -Maternal demographic information for three groups Part II. 
Table 21 -Missing data in demographic data. 
Table 22 -Results of HbA1c, TSH and Vitamin D. 
Table 23 -Missing data of HbA1c tests, TSH tests, and Vitamin D levels. 
Table 24 -Maternal outcomes for three groups. 
Table 25 -Neonatal outcomes of three groups. 
 
3. Chart 
Chart 1 -maternal glucose concentration associated with adverse perinatal outcomes  
Chart 2 -History of GDM and family history of diabetes 
Chart 3 -Smoking status and alcohol consumption during pregnancy. 
Chart 4 -Maternal Ethnicity 
Chart 5 -Maternal pre-existing complications. 
Chart 6 -Pregnancy-induced hypertension 
Chart 7 -The onset of preterm birth 
Chart 8 -0nset of labour. 
Chart 9 -Mode of delivery 
Chart 10 -Methods of birth. 
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Chart 11 -Reasons for elective CS 
Chart 12 -Reasons for emergency CS. 
Chart 13 -Perineal statuses. 
Chart 14 -Delivery complications including shoulder dystocia and meconium liquor 
Chart 15 -proportions of three groups of Apgar score at 1 minute 
Chart 16 -proportion of three groups of Apgar score at 5 minute. 
Chart 17 -Information regarding macrosomia, low birth weight, neonatal obese, and 
neonatal underweight.  
Chart 18 -Prevalence of cLGA and cSGA babies. 
Chart 19 -Information regarding hypoglycaemia, jaundice, respiratory distress, 
NICU/SCN admission 
Chart 20 -Reasons for NICU/SCN admissions. 
Chart 21 -Information regarding neonatal hypoglycaemia and treatment. 
Chart 22 -Information regarding neonatal jaundice and treatment. 
Chart 23 -Respiratory distress and causes. 
Chart 24 -The treatment options of respiratory distress. 
Chart 25 -Other main complications. 
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